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Abstract 
Coronary heart disease is responsible for around 2 million deaths across 
Europe each year. This is largely caused by atherosclerosis, a chronic 
inflammatory disease of the vasculature characterized by development of 
plaque in the arterial wall. Advanced plaques may become unstable, carrying 
a risk of rupture or erosion and manifest as acute myocardial infarction. In 
patients with type 1 and type 2 myocardial infarction, mortality rates remain 
high; up to 15% and 25%, respectively.  Although risk stratification tools like 
the Global Registry of Acute Coronary Events (GRACE) 2.0 score can robustly 
predict outcome in these patients, new therapies targeting the unstable plaque 
are still needed to address this global epidemic.  
Long non-coding RNAs (lncRNAs) are an emergent class of molecules with 
diverse functional roles, widely expressed in human physiology and disease. 
Although some lncRNAs have already been identified in cardiovascular 
disease, their potential as novel targets in the prevention of atherosclerosis 
remains unknown. The aim of this project was to discover important lncRNAs 
in unstable plaque and gain insight into their functional relevance.  
Analysis of RNA sequencing previously performed on stable and unstable 
atherosclerotic plaque identified a panel of 47 differentially regulated lncRNAs. 
I focused on LINC01272, a lncRNA upregulated in unstable plaque previously 
detected in inflammatory bowel disease, and ultimately renamed it PELATON 
(plaque enriched lncRNA in atherosclerotic and inflammatory bowel 
macrophage regulation). PELATON is highly monocyte- and macrophage-
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specific across vascular cell types, and almost entirely nuclear by cellular 
fractionation (90%–98%). In situ hybridization confirmed enrichment of 
PELATON in areas of plaque inflammation, co-localising with macrophages 
around the shoulders and necrotic core of human plaque sections. Consistent 
with its nuclear localization, and despite containing a predicted open reading 
frame, PELATON did not demonstrate any protein-coding potential in vitro. 
Functionally, knockdown of PELATON significantly reduced phagocytosis, 
lipid uptake and reactive oxygen species production in high- content analysis, 
with a significant reduction in phagocytosis independently validated. 
Furthermore, CD36, a key mediator of phagocytic oxLDL (oxidized low-density 
lipoprotein) uptake was significantly reduced with PELATON knockdown.  
Taken together, these data demonstrate that a novel lncRNA (PELATON) is 
important to macrophage function in atherosclerotic plaque. Future work 
should focus on manipulation of PELATON, to reduce plaque instability, and 





It is recently understood that RNA (ribonucleic acid) molecules have more 
significance in human physiology than previously known. Whilst it has long 
been accepted that RNA molecules are nature’s middle man; between cellular 
DNA (deoxyribonucleic acid) and the body’s manufacture of proteins - they 
play many other critical roles in healthy and disease processes, quite aside 
from regular transcription.  
One particular type of RNA called long non-coding RNA is not extensively 
studied, but has already been associated with many disease processes, 
including atherosclerosis. Atherosclerosis or ‘hardening of the arteries’ is the 
disease process in the body that causes ‘plaques’ form in the walls of arteries 
which can suddenly rupture, to cause heart attacks or strokes. The objective 
of this project was to discover previously unknown long non-coding RNAs 
(lncRNAs) which are important in human atherosclerosis, and could be 
manipulated to reduce the risk of vascular diseases and complications.  
Using RNA sequencing; a technique to identify all of the different RNAs within 
a sample, a panel of novel lncRNAs from the arteries of patients who had had 
strokes were identified. Of these, LINC01272, subsequently renamed 
PELATON, was studied further. PELATON (plaque enriched lncRNA in 
atherosclerotic and inflammatory bowel macrophage regulation) was mostly 
present in macrophages, one of the body’s important immune system cell 
types. To further confirm this, sections of diseased arteries taken from patients’ 
arteries were stained, and highlighted PELATON in the most critical regions.  
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Further experiments to investigate PELATON’s function in macrophages then 
demonstrated it actually controls macrophage behaviour in certain aspects. In 
reducing the amount of PELATON in macrophages grown in petri dishes, the 
cells were less good at carrying out their usual functions. This included 
phagocytosis, the process of eating nearby foreign bodies; and lipid uptake, 
which occurs in the walls of diseased arteries contributing to plaque 
progression.   
In summary, PELATON is a newly discovered and characterised species of 
long non-coding RNA. It has been shown to be important in controlling 
macrophage behaviour, which is a critical cell type in the plaques of diseased 
arteries. Future work should be aimed at manipulating levels of PELATON in 
human arteries to reduce the risk of heart attacks and strokes. 
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Atherosclerosis is the principal driver of cardiovascular disease worldwide. 
Atherosclerotic plaques develop over decades in the arterial walls of 
susceptible individuals, in response to numerous well-known risk factors, 
including inflammation and high levels of circulating lipids. The clinical effect 
of atherosclerosis varies widely dependent on site, severity, and co-morbidity, 
and can range from completely asymptomatic to clinically catastrophic in the 
case of myocardial infarction (MI), stroke, and the acutely ischaemic limb. 
These acute events are usually sudden, often unexpected, and result from 
atherosclerotic plaque rupture. In its early stages, atherosclerosis is sub-
clinical with endothelial dysfunction, intimal thickening, and plaque formation 
occurring silently and insidiously, only becoming clinically apparent when the 
plaque becomes large enough to impinge on luminal blood flow or becomes 
unstable and ruptures. In the coronary arteries, luminal stenosis results in 
angina, manifest most commonly as chest pain on exertion, and the equivalent 
in the peripheral vasculature, “intermittent claudication”, can be completely 
disabling to those affected. These chronic diseases, whilst not in themselves 
immediately life- threatening, reduce quality of life and consume large amounts 
of healthcare resources annually. Atherosclerosis in the carotid arteries is 
usually asymptomatic, until plaque rupture results in transient ischaemic attack 
(TIA) or stroke. Other sites of atherosclerosis result in chronic kidney disease 
and hypertension if present in the renal arteries; cognitive impairment in 
cerebrovascular disease in the brain; and abdominal angina in mesenteric 
disease.  
1.2 Pathology of atherosclerosis 
The precise and complete aetiology of atherosclerosis remains undiscovered, 
but there are multiple risk factors well-known to contribute to plaque formation, 
progression and rupture which may be genetic or acquired.  
Risk Factors 
In terms of genetics, the presence of a family history alone increases an 
individual’s chances of atherosclerosis by up to 2.5-fold in some studies, 
particularly when occurring earlier in a parent or sibling’s life (<60 years) (1-3). 
Whilst the genes and loci implicated in this condition are quite clear in specific 
scenarios such as familial hypercholesterolaemia (FH), a more general genetic 
susceptibility has never been identified (4, 5). In the particular case of FH, the 
most common abnormality is in the gene encoding the low-density lipoprotein 
receptor (LDLR) (60-80%), whilst aberrant genes encoding the apolipoprotein 
B (APOB), and proprotein convertase subtilisin/kexin 9 (PCSK9) are now also 
implicated. The syndrome was first characterised in 1939 by Muller, when high 
levels of circulating LDL and clinical evidence of xanthomata were correlated 
with an increased cardiovascular risk (6). It was in fact these early findings 
which, in no small part, contributed to the development of the ‘diet–heart 
disease hypothesis’, which is still commonly held today (7). Current 
recommendations in FH include familial screening and aggressive treatment 
with 3-hydroxy-3 methylglutaryl CoA (HMGCoA) reductase inhibitors (statins) 




Whether it is hence considered genetic or acquired, hypercholesterolaemia 
has long been deemed one of the principal risk factors for cardiovascular 
disease. It would be considered household knowledge that “high-cholesterol” 
leads to atherosclerosis (and by extension cardiovascular disease) (9). Early 
insights from large epidemiological registries such as Framingham 
demonstrated the association in the 1960s, and the World Health Organisation 
still states that one third of ischaemic heart disease is attributable to high 
cholesterol, and it may cause up to 2.6 million deaths globally each year (10, 
11). However, after decades of public health activity in the Western world 
directed at lowering cholesterol levels in the population, it is now clear that the 
involvement of lipids in the pathophysiology of atherosclerosis is more 
complex, and that the differing contributions of the different lipid particles in the 
human body ought to be recognised.   
‘Cholesterol’ itself is the traditional lipid target for reduction in humans, to 
promote a healthy cardiovascular system. This sterol (C27H46O) is one of 
several major lipids, as well as triglycerides, that is actually essential for normal 
physiology in the production of steroid hormones and bile acids, and in the 
maintenance of cell membranes throughout the body. The majority of 
cholesterol (80%) is synthesised in the liver and intestines, with a relatively 
smaller contribution from dietary intake.  
Triglycerides similarly are essential for cell membrane function, and are the 
storage form of fatty acids, an important energy source. Both triglycerides and 
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cholesterol are packaged and transported in lipoproteins, along with fat soluble 
vitamins, for delivery around the body. 
 
 
Figure 1-1: Lipoprotein structure 
Adapted from British Journal of Cardiology lipids and metabolism module (12)  
Lipoproteins have a common structure, comprised of an outer layer of phospholipids and 
embedded apolipoproteins, surrounding the inner cargo of cholesterol esters, triglycerides 
and fat-soluble vitamins. 
Each of the lipoproteins share the same basic structure (Figure 1-1) but vary 
in their size and relative composition. They have been classified into the 
following well-known groups: 
- Chylomicrons 
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- High-density lipoprotein (HDL) 
- Intermediate-density lipoprotein (IDL) 
- Low-density lipoprotein (LDL) 
- Very low-density lipoprotein (VLDL) 
Chylomicrons are the largest form of lipoprotein, formed by the intestine after 
ingestion of lipids from food. These large particles, which are of the lowest 
density of all the lipoproteins, are triglyceride rich and are rapidly digested into 
VLDL. HDL has the highest cholesterol density of the lipoproteins and primarily 
transports lipids to the liver; LDL transports lipids around the body and is the 
lipoprotein most closely associated with atherosclerosis (Figure 1-2). 
 
Figure 1-2: Human circulating lipoproteins 
Chylomicrons are the largest and least dense of the lipoproteins, emanating from the 
intestines. HDL: high-density lipoprotein, LDL: low-density lipoprotein, IDL: intermediate-
density lipoprotein, VLDL: very low-density lipoprotein (adapted from Chiva-Blanch G et al) 
(13)  
Apolipoproteins have recently become recognized as important proteins in 
atherosclerosis and form the central structure of lipoproteins. They increase 
stability, whilst also serving as cell surface receptors and enzymatic activators. 
Lipoproteins that transport lipids to the liver (HDL) contain apolipoprotein-A, 
and those transporting lipids to the extra-hepatic tissues (LDL, VLDL) contain 
apolipoprotein-B. (14) 
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In maintenance of cholesterol homeostasis, the rates of cholesterol synthesis 
by the liver and absorption in the small intestine are principally regulated in a 
feedback mechanism by cellular levels of cholesterol via the HMGCoA 
reductase system. This is an important catalytic enzyme in the production of 
cholesterol, and of course the target of serum cholesterol lowering drugs 
statins.  
 
Early Plaque Formation 
The arterial wall is a trilaminar structure, consisting of tunica adventitia in the 
outermost layer; tunica media; and tunica intima with endothelium on the 
innermost aspect (Figure 1-3).  
The adventitia is a layer comprised of fibroblasts and perivascular nerves 
within connective tissue, also containing the vasa vasorum – an important 
microvascular network, critical for maintenance of the adjacent medial layer 
(15). 
The tunica media is itself composed of transversely laid down contractile 
smooth muscle cells in a well-organised matrix made of collagen, elastin and 
extra-cellular matrix. This smooth muscle structure allows constriction and 
relaxation of the vessel in response to local and neural stimuli. 
The intima consists of an innermost single layer of endothelial cells, supported 
by an underlying network of connective tissue and elastic fibres. 
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Adaptive intimal thickening (AIT) or intimal thickening is defined by Virmani et 
al as the “normal accumulation of smooth muscle cells (SMCs) in the intima in 
the absence of lipid or macrophage foam cells” (16). Such lesions are well 
noted in children, and although not all progress to become atheromas, the 
majority of atheromas are thought to have arisen from areas of intimal 
thickening (17). It may represent a response to variability in shear stress, and 
indeed is commoner in sites of arterial bifurcation, where shear stress is lower, 
and flow is non-laminar (18). Whether AIT it is considered physiologic or 
pathologic remains an area of controversy. Pathologic intimal thickening (PIT) 
is different, currently defined by the absence of endothelium on histology, and 
the presence of thrombus. Of course, this is a histologic classification based 
on post mortem specimens, where a diagnosis of plaque erosion is given. 
Plaque classification is discussed later in this section.   
The early atherosclerotic plaque begins to form when lipid particles are 
deposited in the intima triggering a cascade of events. In normal endothelial 
function, LDL which is the principal carrier of cholesterol passes through the 
arterial sub-intimal space in the delivery of cholesterol back to the liver. 
However, when there is endothelial dysfunction, LDL begins to aggregate (19).  
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Figure 1-3: Normal arterial structure 
Human arteries have a trilaminar structure consisting of adventitia, media and intima from 




When apoB-containing lipoproteins are retained in the sub-endothelial space 
they can be oxidized and in-turn activate endothelial cells to attract and recruit 
immune cells including monocytes, dendritic cells, mast cells, regulatory T 
cells, and T helper 1 (Th-1) cells via increased expression of vascular cell 
adhesion molecules (VCAMs) and selectins.  Monocytes attach to the 
endothelium and begin to roll along it, before adhesion and finally trans-





Figure 1-4: Early atherosclerotic plaque development 
LDL particles invade the sub-endothelial space and monocytes begin to roll along the 
endothelium, before they are recruited into the plaque. Monocytes differentiate into 
macrophages, and macrophages absorb lipid particles to become foam cells. Smooth 
muscle cells migrate into the sub-endothelium and T-cells begin to invade (adapted from 
Libby et al (21)) 
 
Within the now expanding sub-endothelial space or plaque, monocytes then 
differentiate into macrophages, which sequester LDL, VLDL and ApoE 
remnants to become foam cells (22). Phagocytosis is the key mechanism by 
which the macrophages ingest the lipid via receptors including: CD36, CD68, 
SRA (scavenger receptor class A), and LOX-1 (lectin-like oxidized low-density 
lipoprotein receptor-1. LDL particles become oxidised to oxidised LDL 
(oxLDL), in the presence of oxidative stress, resulting in a higher affinity for 
these receptors. Once sequestered inside the macrophage the apoB-
containing lipoproteins are degraded by lysosomes, when free cholesterol is 
transported to endoplasmic reticulum (ER) for esterification by acyl 
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CoA:cholesterol acyltransferase, and the resultant cholesteryl ester is 
packaged into characteristic lipid droplets. Foam cells then continue to activate 
inflammation and contribute to the inflammatory milieu.  
Foam cells are just one subset of cells derived from the monocyte / 
macrophage lineage critical to the development of atherosclerotic plaque. 
Lesional subsets of each cell type are thought to have differing roles within the 
plaque and polarisation is thought to be determined by the particular micro-
environment within it, encompassing a variety of signalling molecules. Whilst 
classical macrophage phenotypes ‘M1’ and ‘M2’ have been previously 
described, this is more a representation of simpler in vitro conditions, than the 
complex atherosclerotic plaque in vivo (23, 24).   
 
The complex plaque 
Plaque progression is a highly variable and complex process. Once lipid has 
started to deposit in the sub-endothelial space, and monocyte-macrophage 
infiltration has begun, the plaque can progress at variable rates into many 
different phenotypes. Further, each lesion can display characteristics of 
multiple different phenotypes at different points in time, due to the dynamic 
nature of their evolution in a patient’s (and a plaque’s) life (Figure 1-5).  
Foam cells go on to further stimulate inflammation, as the plaque continues to 
grow with the retention of more lipid particles, and the invasion of more 
immune cells. Foam cells are not only evolved from the monocyte-macrophage 
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lineage, but also from vascular smooth muscle cells (VSMC) migrating into the 
sub-endothelial space from the media (25). These too can become engorged 
with lipid, and a adopt a foam cell phenotype (26). Much of the matrix 
accumulation of a growing atherosclerotic lesion is owed to an expanding 
mass of migrated VSMCs, which are large and undergo a transition into a more 
synthetic phenotype. Extra-cellular matrix is secreted, comprising collagen, 
elastin, proteoglycans and glycosaminoglycans, and contributes to the 
framework of the growing plaque.  
Whilst lymphocytes and T-cells migrate from the luminal aspect, they can also 
infiltrate from the vasa vasorum, and may also proliferate within the plaque 
(27). They reside within the extracellular matrix, and TH1 cells secrete IFNγ  – 
a pro-inflammatory cytokine, whilst TH2 cells secrete anti-inflammatory 
molecules including transforming growth factor beta (TGF-ß) and IL-10 which 
dampen the atherogenic response.  
As foam cells of either origin begin to undergo programmed cell death, or 
apoptosis, the number and volume of dead cell bodies increases. 
Efferocytosis, or removal of dead cells, is characteristically impaired and this 
cellular debris adds to the necrotic core.  
Calcification inevitably occurs as the plaque progresses. The process within 
the plaque bears many similarities with mineralisation and ossification of 
bones, and results from dysregulation of calcium deposition and impaired 
clearance (28). Spotty calcification develops first, and correlates with plaque 




Figure 1-5: The complex plaque 
A lipid and necrotic core forms in the sub-endothelial space, composed of macrophages, 
lipid particles and dead cells. Macrophages and SMCs undergo apoptosis and contribute to 
the volume of the core. A fibrous cap comprised of extra-cellular matrix forms between the 
core and the endothelium and begins to thin. SMC=smooth muscle cell (adapted from Libby 
et al (21)). 
 
 
To rationalise the considerable variability and complexity observed in plaque 
morphologies, the American Heart Association proposed a classification 
system, published in Circulation in three parts by Stary et al in the mid-1990’s. 
They described phenotypes I-VI, with some specific sub-types in group V and 
VI, to account for the heterogeneity found between lesions. 
Each of the types of lesions they described were characterised as follows: 
Type I (Initial) – Lipid deposits become detectable in the subintimal space. 
These features can be seen as early as infancy, and are not necessarily a 
pathological state  (30). Type II (fatty streak) – Layers of foam cells form and 
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lipid droplets are taken up by intimal VSMCs. T-cells and mast cells invade the 
plaque. Type III (preatheroma) – A further increase in lipid droplets and foam 
cells which form separate pools, but no confluent lipid core has yet formed, 
this is an intermediate stage. Type IV (atheroma) – A lipid core which forms 
from the confluence of multiple smaller pools. This stage represents 
‘advanced’ atheroma, which is potentially symptom producing. Type V – 
(fibroatheroma) – Characterised by thickening of the tissue between the core 
and the endothelium. There is luminal narrowing of the artery, and subtypes 
include Va – lipid core, Vb – calcium, Vc – fibrous. Type VI (complicated) – 
As V, but with surface defects of fissure / haematoma / thrombus.  
 
Whilst this earlier classification provided the framework to build on, updates to 
to it have since been proposed and adopted. Notably, a classification system 
devised by Professor Renu Virmani et al, published in ATVB in May 2000 is 
the most frequently used (16). In this paper, several key problems with the 
original AHA classification were identified, and steps taken to try to address 
them. Modifications were principally in the description of intermediate and 
advanced plaques, which are heterogenous and complex, but also in the 
description of very early lesions initial xanthoma and intimal thickening.  
Virmani et al. recognised that plaque types IV, V and VI do not necessarily 
follow in order, and that thrombosis is observed to occur in circumstances 
other than plaque rupture, namely calcified nodule and plaque erosion (16).  
Whereas the original AHA classification relied on a long list of Roman 
numerals to identify plaque types, the modified classification instead uses 7 
categories of lesion: Initial xanthoma; intimal thickening (both pre-
atheromatous); fibrous cap atheroma; pathologic intimal thickening, calcified 




This classification scheme relies on descriptive morphology rather than 
mechanistic implications, and can more simply be followed when considering 
Figure 1-6: A Comprehensive Morphological Plaque Classification Scheme for 
Atherosclerotic Lesions (Adapted from Virmani et al, ATVB May 2000) 
Boxed terminologies represent the 7 proposed plaque types. Dashed line boxes indicate that  the 
role each of these types play in early plaque formation is controversial, and each may represent 
normal physiology. Lines represent how one process may progress to another, dashed lines 
indicating a lower strength of evidence to support it  
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that classification relies largely on the accumulation of lipid and also the status 
of the fibrous cap.
1.3 The Vulnerable Plaque 
The phenomenon of the vulnerable plaque has been the centre of much 
research endeavour in the last 2 decades. It was originally thought that the 
mechanism of coronary occlusion and resultant myocardial infarction was 
exclusively due to the rupture of unstable or vulnerable plaque, which exposed 
the enclosed thrombogenic material to platelets and clotting factors in the 
blood, precipitating clot formation and vessel occlusion. This is still held in the 
main, but it is an oversimplification, and other mechanisms such as plaque 
erosion and calcific nodule protrusion are now recognised (31-34). Studies at 
post mortem examination have demonstrated that acute thrombosis of the 
coronary artery in cases of sudden coronary death is associated with an 
obvious plaque rupture in 59-75% of patients (16, 35), and denudation of the 
endothelium (or erosion) in 36-44% of cases (16, 31). Calcified nodule causing 
luminal obstruction probably does lead to myocardial infarction, but in a 
minority of only 2-7% of cases (36).  
Stage IV atherosclerotic plaques or atheromas are characterised by the 
presence of a large lipid pool or necrotic core which lies in the centre of the 
plaque, itself shielded from the lumen by a fibrous cap principally composed 
of collagen, secreted by smooth muscle cells. The perceived vulnerability of 
the plaque relates to its propensity to rupture, meaning the chance that the cap 
will be disrupted and either the necrotic core is exposed to the lumen triggering 
thrombosis, or arterial blood enters the plaque (or more likely a combination of 
the above).  
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When a plaque ruptures in a coronary artery causes thrombosis, the cascade 
of events is invariably rapid and devastating. Necrotic cores contain extremely 
thrombogenic material including various cell types, dead cells and oxidised 
lipids, but notably tissue factor (TF) (Figure 1-7). Tissue factor is produced by 
macrophages and smooth muscle cells within the plaque and is highly 
thrombogenic. When TF comes into contact with blood it triggers platelet 
activation and aggregation and the generation of thrombin (37, 38), leading to 
thrombosis and occlusion of the vessel.  
 
 
Figure 1-7: The mechanism of plaque rupture 
MMPs secreted by macrophages degrade the collagenous matrix of the fibrous cap. Smooth 
muscle cells produce less collagen in response to IFNy secreted by T-cells (adapted from 
Libby (32)) 
 33 
The thickness of the fibrous cap in ruptured coronary plaques is observed to 
be just over 100 µm on both post-mortem and OCT studies (31, 39), and is 
recognised as one of the main factors in plaque rupture. The term thin-capped 
fibroatheroma (TCFA) was hence coined by Virmani et al (16). Gradual 
degradation of the collagenous cap structure is likely mediated by 
inflammatory cells macrophages and T-cells.  Production of cytokines such as 
IFNy by T-cells is shown to downregulate production of extracellular matrix by 
VSMCs, even in the presence of TGFβ which are also found to fewer in 
number at sites of plaque rupture (40, 41). Further, macrophages secrete a 
family of enzymes known as matrix metalloproteinases (MMPs). Although 
collagen is generally resistant to the action of most organic proteases, MMP1, 
MMP8 and MMP13 over-production by activated macrophages has been 
demonstrated to cleave collagen, thus weakening and thinning the fibrous cap 
further (42-45). The weakest area of the cap is thought to be the shoulder 
region (46).  
Plaque erosion attracts less attention than plaque rupture as a mechanism for 
coronary thrombosis but is likely causative in approximately one quarter of 
cases. More mature and complex plaques tend to be more proteoglycan rich, 
and fibrous as a result. There may be no lipid core at all, and the cap may not 
be thinned. Gradually there is desquamation of the superficial layer of 
endothelial cells overlying this tough internal plaque structure, which is 
thrombogenic when it comes into contact with the circulation and leads to 
thrombosis. The endothelial cells undergo apoptosis and as they do so 
produce tissue factor, and may sever their own underlying basement 
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membrane (47). This mechanism has now been well seen on both post-
mortem and OCT studies in vivo (48-51).   
However, the mere presence of a vulnerable plaque alone is not sufficient to 
generate thrombosis and myocardial infarction. In fact, most vulnerable 
plaques do not rupture. As complex plaques grow, the artery first undergoes 
‘positive remodelling’ before there is luminal narrowing. Effectively the vessel 
grows outwards, to preserve its internal diameter (52, 53). As a result, only 
around half of culprit lesions actually cause luminal stenosis (54). It is the high-
risk features of large lipid pool, thin-cap, and microcalcification which seem to 
be predictive of events, rather than luminal impingement. 
Furthermore, it should be noted that not all plaque ruptures trigger thrombosis 
and result in fatality. Continual rupture and subsequent healing of plaques is 
part of the natural history of atherosclerosis, with only a minority of plaque 
ruptures resulting in clinical events. Studies of autopsy specimens 
demonstrate that healed plaque ruptures and the increasing number of healed 
plaque ruptures correlates with increasing luminal stenosis (55, 56). This 
mechanism may also explain why increases in luminal stenosis appear to be 
phasic rather than gradual, noted particularly when antecedent angiography 
had shown significantly less luminal narrowing (57).  
The PROSPECT study followed up 697 patients using IVUS for 3 years after 
acute coronary syndrome to understand the natural history of non-culprit 
plaques. Strikingly, of over 3000 non-culprit lesions identified by IVUS at 
baseline, of which 595 were thin-capped fibroatheromas, only 6 were 
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subsequently related to myocardial infarction and death after 3 years. Other 
coronary features postulated to contribute to the perfect storm to precipitate 
coronary thrombosis include low shear stress, coronary vasospasm, 
inflammation, and micro-calcification (58-60). However multiple systemic and 
environmental features such as emotional stress, infections, temperature 
changes and even earthquakes have been associated with increased risk (61). 
Even the time of day is important as more myocardial infarctions are observed 
during the small hours of the morning. The common factor here is likely to be 
sympathetic nervous system activation, which increases blood pressure, heart 
rate and arterial stress. Hypercoagulability and platelet reactivity also seem to 
be higher at this time of day, and whether this is due to circadian rhythm or 
other factors such as cortisol release remains unknown (62, 63).  
The identifiable features of a vulnerable plaque were first described by 
appearance on post-mortem as previously discussed, but subsequently more 
modern imaging techniques have characterised several hallmark 
appearances. Advances in the resolution of cardiac CT now permits detailed 
analysis of not only the vessel lumen to estimate stenosis, but also the 
structure of the arterial wall.  When Motoyama et al followed up 1,059 patients 
who underwent coronary CT, features of either positive remodelling or low-
attenuation plaque (<30 Hounsfield units [HU]) were predictive of acute 
coronary syndrome compared with neither with a hazard ratio of 22.8 (7-75, 
p<0.001) (64). These results were corroborated by similar CT studies, 
characterising the ‘napkin-ring’ sign and demonstrating microcalcification as 
predictive features (65-67). 
1.4 Current therapies for atherosclerotic diseases 
Besides lifestyle interventions, attempts at managing atherosclerosis have to 
date largely focused around the now well-accepted dogma that high levels of 
circulating lipid lead to accumulation of an expanding lipid-rich necrotic core in 
the sub-intimal space of the arterial wall forming predominantly in areas of low 
shear stress and endothelial dysfunction. Consequently, lipid lowering 
strategies have predominated with no less than 7 different available statins, 
other drugs like ezetimibe, fibrates, and most recently the development of 
monoclonal antibodies against the PCSK9 receptor, such as Evolocumab (68) 
and alirocumab (69). However, despite initially impressive results in the statin 
trials, some now doubt their efficacy in primary prevention, and staggering 
levels of LDL reduction as in the FOURIER trial (68) do not seem to translate 
into dramatically improved clinical outcomes. This suggests that lipid lowering 
may not be the only mechanism of action at play. The anti-inflammatory effect 
of statin drugs may be a major factor, and new drugs targeted at reducing 
inflammation such as canakinumab look promising. In the recently published 
CANTOS trial, canakinumab which targets interleukin-1β, reduced the relative 
risk of myocardial infarction in ischaemic heart disease patients by 16%, 
without affecting lipid levels (70).
1.5 The Universal Definition of Myocardial Infarction 
The definition of myocardial infarction has evolved markedly over the last few 
decades. It is a condition which progresses rapidly and severely and can result 
in immediate fatality. When untreated there may be a shortened lifespan and 
for that a reduced quality of life. Critically it is also an eminently treatable 
condition, and modern therapies such as primary PCI (and earlier thrombolysis 
to a lesser degree) can halt it in its course, and potentially prevent all of the 
above adverse consequences. However, like many conditions the diagnosis 
remains a clinical one, and it is the role of the physician to assess the patient’s 
history and examination, along with ECG findings and biomarkers to ascertain 
the likelihood of MI before instituting treatment. A type 1 or a type 2 error on 
the part of the physician would often be extremely costly. A false positive 
diagnosis would subject the patient to potent blood thinning drugs and quite 
likely an unnecessary invasive procedure carrying significant risks; whereas a 
false negative could be potentially worse, allowing the sequelae of an acute 
coronary syndrome to play out.  
Furthermore, a diagnosis of myocardial infarction has significant psychological 
and legal implications for the individuals, groups and society. It is one of the 
leading health problems in the world, and an outcome measure in myriad 
clinical trials and studies.  
The first Universal Definition of Myocardial Infarction (UDMI) was published in 
2007 to unify the diagnosis of this important condition (Figure 1-8). The 
document published in Circulation described key diagnostic criteria to make a 
 38 
diagnosis of myocardial infarction, and is now in its fourth iteration. The original 
criteria are detailed below: 
 
Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at 
least one value above the 99th percentile of the upper reference limit (URL) 
together with evidence of myocardial ischaemia with at least one of the 
following: 
- Symptoms of ischaemia 
- ECG changes of new ischaemia  
- Development of pathological Q waves on ECG 
- Imaging evidence of new loss of viable myocardium, or new regional 
wall motion abnormality 
The guidelines also described the criteria for post-mortem diagnosis, as well 
as peri-procedural diagnosis in and around PCI and surgical coronary artery 




Figure 1-8: Diagnostic criteria for myocardial infarction as per First Universal 
Definition of Myocardial Infarction. 
Adapted from Thygesen et al (71) (CABG=coronary artery bypass graft; 
ECG=electrocardiogram; LBBB=left bundle branch block; PCI=percutaneous coronary 
intervention; URL=upper reference limit) 
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Thus far the term ‘myocardial infarction’ has been used almost exclusively to 
refer to what is known as a “type 1 myocardial infarction”. That is, infarction 
and myocardial necrosis resulting from a coronary plaque rupture or erosion 
event.  
However, its worthy of note at this stage that nomenclature around myocardial 
infarction is variable, complex and to many quite confusing. At the time of 
writing there are several ways of semantically describing essentially the same 
thing, and how it is written or spoken about can depend highly on local culture, 
as well as knowledge of contemporaneous trends. This current section will go 
on to describe the UDMI types 1-5, with particular attention to types 1 and 2. 
However, myocardial infarction is still sometimes classified with respect to 
ECG changes: ST-elevation myocardial infarction (STEMI); non ST-elevation 
myocardial infarction (NSTEMI); or unstable angina, and might also generally 
be referred to in the context of ‘acute coronary syndrome’. The presence of 
myocardial injury (which implies no acute ischaemic event) can cloud matters 
even further.  
Although the standard definitions will be adopted here and referred to 
throughout, its acknowledged that the most commonly used syntax in a clinical 
setting is that related to ECG change, and this is appropriate. The vast majority 
of chest pain presentations and suspected myocardial infarctions are owing to 
type 1 myocardial infarction, and the immediate management thereof is 
dependent on the severity of the ischaemia (indicated by ST change), rather 
than the underlying pathophysiological mechanism. STEMI is treated with 
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primary percutaneous coronary intervention, whereas NSTEMI is managed 
medically in the first instance, with a downstream invasive approach.  
The different types of myocardial infarction as per the UDMI is summarised in 
Figure 1-9.  
 
Figure 1-9: Types of myocardial infarction as per the Universal Definition of Myocardial 
Infarction 
Adapted from Stary et al (71) 
Type 2 Myocardial Infarction 
Type 2 myocardial infarction is now increasingly recognised and may even be 
as common as type 1 MI (72). In this condition, myocardial ischaemia is not 
caused by the classical plaque rupture phenomenon, but rather an imbalance 
between myocardial oxygen supply and myocardial oxygen demand. Common 
mechanisms reducing supply include hypoxia, anaemia, and some (possibly 
misplaced) coronary mechanisms including coronary spasm and embolism. 
Causes of an increase in demand include tachyarrhythmia, ventricular 
hypertrophy and hypertension (73) (Figure 1-10).  
 
Figure 1-10: Supply demand mismatch in type 2 myocardial infarction 
Type 2 myocardial is suspected when there are clinical features of cardiac ischaemia in the 
context of another illness or process (adapted from Stary et al (74)) 
Patients with type 2 myocardial infarction are older, more often have 
comorbidities and are at higher risk of adverse outcomes with as few as 30% 
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of patients alive at 5 years (75).  Despite a significant increase in risk of non- 
cardiovascular death, patients with type 2 myocardial infarction appear to have 
a similar risk of future cardiovascular events as those with type 1 myocardial 
infarction (76).  
Despite the severe consequences of type 2 MI, well-evidenced investigation, 
management and risk stratification pathways are still lacking. Presenting 
features differ from type 1 MI usually in that patients are less likely to have 
chest pain, have less impressive ECG changes, and generally lower 
magnitude biomarker increases (77). Coronary disease is less frequent than 
in type 1 MI (which is universal), but remains common, and when present 
portends a higher risk of future events (75). Distinguishing between type 1 and 
type 2 MI remains difficult, and novel diagnostic approaches are needed (78). 
It may be that treatment with the usual regimen of anti-platelets, statins, beta-
blockers and ACE-inhibitors are beneficial, as is well-established in type 1 MI, 
but whilst diagnosis and discrimination of the condition remains problematic, 
studies to identify the most appropriate management are not possible, and 
progress has been slow.  
The Fourth Universal Definition of Myocardial Infarction is the most recent 
iteration, and has brought some changes with respect to type 2 myocardial 
infarction (74). The guideline characterises the aetiology of type 2 MI with 
respect to the coronary arteries and recommends consideration of the 
presence or absence of coronary artery disease when implementing 
treatments. Furthermore, high sensitivity troponin I and troponin T assays are 
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now recommended in diagnosis, and the guideline distinguishes between 
myocardial infarction, and acute or chronic myocardial injury. If there is 
absence of ischaemia in the way of symptoms, ECG changes, or regional wall 
motion abnormality, then a diagnosis of myocardial injury is more appropriate, 
If there is a rise or fall in troponin then it would be considered ‘acute myocardial 
injury’, and if it is static then ‘chronic myocardial injury’. 
With the advent of highly sensitive troponin assays and their incorporation into 
the UDMI, much research is needed to define optimal diagnostic, investigative 
and treatment strategies for these groups of patients.  
 
1.6 Non-coding RNA 
The non-coding genome represents an exciting, yet complex layer in human 
physiology and pathology. Initially some function had been ascribed to 
ncRNAs as early as the 1950s as transfer RNA and ribosomal RNA. However,  
its only in the last few decades upon the discovery that approximately 98% of 
the human genome is non protein-coding (79) (Figure 1-11), that the potential 
biological significance of ncRNA has been even partly appreciated (80). 
MicroRNA (miRNA) is the best studied family of ncRNA, known to regulate 
thousands of protein-coding genes through messenger RNA (mRNA) 
degradation (81). MiRNAs are 20–25 nucleotides in length and form a 
characteristic “hairpin” structure. They are inherent in multiple pathologies, and 
due to their stability in plasma, miRNAs have also been proposed as 
biomarkers of atherosclerosis (82), MI (83), cancers (84), rheumatological, and 
other diseases. In terms of therapies, clinical trials are currently ongoing to 
determine the efficacy and safety of “antimiRs” in diseases such as cancer, 




Figure 1-11: Contribution of coding vs noncoding RNAs in the human genome 
The vast majority of the human genome is non-coding (adapted from Uchida et al(79)) 
 
 
1.6.1 Micro RNA 
Since their discovery in 1993 in C.elegans nematode (86), miRNAs have now 
taken up an important niche in genomics with almost 2000 known sequences 
in the human genome. Usually, transcription of intronic miRNA is regulated by 
the same promoter as the host gene. Some miRNAs however, are shown to 
have multiple transcription start sites (87) and may be transcribed by a 
promoter distant from the gene they occupy (88). MiRNA transcription is 
controlled by RNA polymerase II and RNA Pol II-related transcription factors 
(89). The first product in the process is a primary miRNA (pri-miRNA) 
molecule, with a characteristic stem-loop structure, and lengths reaching up to 
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1 kilobase (kb). The next product in the sequence is a smaller precursor 
miRNA (pre-miRNA) molecule, which is generated by RNase III enzyme 
Drosha that cleaves the stem-loop of pri-miRNA (90). The small, hairpin-
shaped pre-miRNA is then transported into the cytoplasm by exportin 5, where 
the Dicer enzyme further processes it to generate a double-stranded molecule, 
ready for assembly with the Argonaute (Ago) protein (91, 92). The final product 
in the miRNA biogenesis pathway is formation of the RNA-induced silencing 
complex (RISC), consisting of a mature, single-stranded miRNA molecule and 
Ago protein, which induces post-transcriptional gene silencing (93). 
Importantly, human miRNA lacks Ago specificity and can bind to all Ago 
variants (93). Recent evidence demonstrates that the Ago-unbound miRNA 
strand isn’t always cleaved, and both the 5p and 3p strands are found in 
different sorts of tissues (94). The mature miRNA then facilitates gene 
silencing, whereby mRNA degradation occurs in 66-90% of cases (81) and 
mechanistically depends on mRNA deadenylation, decapping and cleavage 
by XRN1 nuclease (95). On the contrary, miRNA-induced repression of 
translation targets only 6-26% of genes (96) using primarily RNA helicases 
eIF4A and DDX6, which repress cap-dependent translation (81). 
1.6.2 Long non-coding RNA 
Long non-coding RNAs (lncRNAs) are much less well characterised to date, 
but their importance in gene expression is increasingly being recognised. In 
contrast to miRNAs, lncRNAs are much longer at >200 nucleotides, with more 
complex secondary structures. They may act both to activate and to repress 
genes, exerting their effects by a variety of mechanisms at both transcriptional 
and translational levels (97, 98).  
Remarkably, lncRNAs outnumber not only miRNAs, but also protein-coding 
genes. In fact, the number of lncRNAs annotated continues to rise, due to 
recent advances and new strategies in RNA sequencing and bioinformatic 
techniques, and hence a much greater depth of sequencing (99). Despite this, 
there is still no strict classification method, and the most accurate definition of 
lncRNA at present is “long RNA transcripts that do not encode proteins” (100). 
It is generally accepted that lncRNAs are longer than 200 nucleotides, 
separating them from other shorter ncRNA molecules such as miRNAs, 
snoRNAs, an piRNAs amongst others, but confusingly, some lncRNAs do 
actually contain cryptic open reading frames (ORFs) (101), and short open 
reading frames (sORFs) encoding micropeptides.  These micropeptides can 
act independently from large proteins, regulating essential biological 
processes (102). For example, a skeletal muscle-specific RNA, annotated as 
lncRNA LINC00948, encodes a cryptic micropeptide ‘myoregulin’ (MLN). MLN 
interacts with sarcoplasmic reticulum Ca2+-ATPase (SERCA), preventing 
Ca2+ uptake into the sarcoplasmic reticulum in skeletal muscle, while MLN 
silencing improves Ca2+ handling (103). Similarly, it was reported that lncRNA 
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LINC00961 also encodes a polypeptide termed ‘small regulatory polypeptide 
of amino acid response’ (SPAR). Mechanistically, SPAR prevents mTORC1 
activation via interaction with  lysosomal v-ATPase while SPAR deletion 
induces mTORC1 leading to  muscle regeneration (104). Sanders et al found 
that although SPAAR (AKA SPAR in previous reference) is transcribed from 
within the LINC00961 locus, the micropeptide and the lncRNA actually have 
opposing roles in endothelial cell biology (105).  
Given these clear mechanistic roles for encoded micropeptides, one might 
consider then that the parent lncRNA transcripts are in fact ‘misannotated’. 
How can a transcript that is experimentally proven to contain genetic code for 
a protein be referred to as ‘non-coding’? Nomenclature naturally evolves with 
new knowledge over time, and perhaps this will change. Clearly though there 
are differences between a simple mRNA which has one function only, to 
produce a peptide, and the complex lncRNA molecule, with its myriad of 
interactions and functions, which remain largely undiscovered.  
Within the class of lncRNA, there are different sub-classes of lncRNAs which 
include long intervening/intergenic ncRNAs (lincRNAs), promoter upstream 
transcripts (PROMPTs), enhancer RNAs (eRNAs) and natural antisense 
transcripts (NATs). These are transcribed from intergenic and promoter 
upstream regions, enhancers and reverse strand of protein-coding genes, 
respectively (106). Interestingly, lncRNAs do not require polyadenylation to be 
functional and upon transcription a significant proportion of lncRNA remains 
non-polyadenylated. In fact, many lncRNA are bi-morphic and can exist in both 
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polyadenylated and non-polyadenylated states (107). Furthermore, lncRNAs 
can exist in different forms and structures: some lncRNAs are capped by 
snoRNAs at 5’ (108) or both ends (109); others can occur in a circular form as 
circular intronic RNAs (ciRNAs) and circular RNA from back-splicing of exons 
(circRNAs) (110-112). ANRIL (discussed in more detail later) is the most well-
known ncRNA that can take a circular form. Currently considered to be a form 
of ncRNA, these transcripts exist in loops with a bond between the 3’ and 5’ 
ends. Much like other lncRNA, they are thought to regulate gene transcription 
and expression, acting as sponges for miRNA, and are extremely abundant in 
the circulation.  
It is now accepted that lncRNAs can modulate gene expression on 
transcriptional, post-transcriptional and translational levels. The function of a 
specific lncRNA depends much on its cellular localization and context of the 
cell (i.e. basal/stressed). In particular, nuclear lncRNAs mainly act on 
transcription, while cytoplasmic lncRNAs modulate expression of gene post-
transcriptionally. In the nucleus, lncRNAs regulate the epigenome, facilitate 
transcriptional control and participate in alternative splicing (113). A good 
example of lncRNA-mediated epigenetic control is  ANRIL, which facilitates 
the recruitment of the chromatin-modifying complex PRC2 and promotes 
silencing of p15INK4B tumour suppressor gene (114). Interestingly, after the 
discovery of enhancer RNAs (eRNA) (115), it has been further suggested that 
eRNAs are able to modulate chromatin and facilitate its assembly (116) and 
interact directly with DNA structure to guide the enhancer to its promoter (117). 
A similar type of lncRNA, termed activating ncRNAs (ncRNA-as), can also 
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regulate transcription and are expressed from independent genes (118). 
Further, lncRNAs modulate different aspects of transcriptional control ranging 
from modulating the expression of transcription factors, such as ncRNA-a7 
(118) and OCT4 pseudogene 5 (119), to acting as co-activators and 
repressors independently, such as Alu RNA inhibiting RNA polymerase Pol II 
directly (120). MALAT1 is an example of lncRNA modulation of alternative 
splicing. Specifically, MALAT1 is enriched in nuclear speckles and upon 
interaction with sarcoplasmic reticulum (SR) splicing factors promotes 
alternative splicing (121). Within the cytoplasm, lncRNAs can stabilise or lead 
to mRNA decay and promote/inhibit translation. Cytoplasmic lncRNAs can also 
act as miRNA precursors or sponges, mimicking mRNA for miRNA binding 
(113). Mainly, lncRNA-induced mRNA degradation occurs via Staufen1 
(STAU1)-mediated mRNA decay (SMD), where STAU1 binds to the pairing of 
mRNA 3'-UTR sequences with lncRNA due to complementary Alu elements 
(122). On the other hand, a natural antisense lncRNA BACE1-AS forms a bond 
with mRNA of BACE1 and protects it from miR-485-5p-induced degradation 
by masking the miRNA binding site (123). LncRNA such as Uchl1-AS can 
recruit ribosomes to Uchl1 mRNA and thus facilitate protein translation (124). 
Conversely, a subset of lncRNAs termed translational regulatory lncRNA 
(treRNA) can repress translation. TreRNA facilitates the assembly of a new 
ribonucleoprotein (RNP) complex, which interacts with translation initiation 
factor eIF4G1 resulting in translational repression of E-cadherin (125). Finally, 
a well-studied lncRNA in cancers, H19, has been recently demonstrated to be 
a precursor for miR-675, which targets a tumour suppressor RB (126). H19 is 
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considered to be an effectual molecule itself, rather than just the primary 
transcript giving rise to miR-675. In the setting of keratinocyte differentiation 
H19 acts as a sponge to miR-130b-3p, its target (127). Further to that, it has 
been reported that circRNA CDR1-as contains 63 binding sites for miR-7 and 
can act a “sponge” or decoy for miR-7, thus reactivating the expression of its 
target genes in neuronal tissues (110, 128).
1.6.3 Long non-coding RNA in atherosclerosis 
Discovery of novel non-coding RNAs in disease-specific context continues to 
increase, largely due to the widespread application of high-throughput gene 
expression arrays and development of next generation RNA sequencing. By 
far the most studied field in this area is cancer, but already a significant number 
of miRNAs are implicated in vascular disease and biology, and although much 
less studied, several long non-coding RNAs have been discovered and are 
currently being investigated (See Table 1-1 for a list of important non-coding 
RNAs in atherosclerosis). Development, cellular differentiation and 
commitment is a logical starting point to identify novel RNA candidates, and 
evidence of endothelial cell growth and phenotype regulation in a long non-
coding transcript such as in the case of MALAT1 would suggest a strong 
likelihood of an important function in pathology for this. Below are described 
some of the most important long non-coding RNAs findings to date.. 
 
Increasingly, long non-coding RNAs emanating from multiple sources are 
shown to be implicated in cardiovascular disease. The long non-coding RNA 
anti-sense noncoding RNA in the INK4 locus (ANRIL) is transcribed from the 
now well-known 9p21 locus, which has been strongly implicated in vascular 
disease (129-131) and ANRIL itself has been associated with pathogenic 
changes in atheroslerotic plaques (130).  
It was initially discovered through genome-wide association studies detecting 
several polymorphisms, which were predictive of myocardial infarction (132, 
133). Notably, important tumour suppressor genes CDKN2A and CDKN2B are 
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also found near this region, but are not found to be dysregulated in 
atherosclerosis models and patients, unlike ANRIL (134). ANRIL was one of 
the first lncRNAs described in atherosclerosis, and multiple interactions have 
now been demonstrated, although the full extent of its regulation in vascular 
disease remains unclear. As is the case with most long non-coding RNAs, 
ANRIL is alternatively spliced, and expressed as multiple ‘isoforms’. Ensembl 
currently reports 21 splice variants, each of which may interact differently to 
the others. Further adding to its complexity, ANRIL is found in multiple cell 
types including VSMCs, ECs, and inflammatory cells. Initially ANRIL appeared 
to be grossly associated with pathogenic changes; reduced cell viability and 
proliferation in VSMCs (131), upregulation of inflammation and apoptosis in 
endothelial cells (135),  and  a consistent correlation with atherosclerotic 
burden in human PBMCs and plaque samples (130). More recently though a 
circular variant has been characterised, circANRIL, which seems to be 
atheroprotective in its behaviour; by controlling ribosomal RNA biogenesis and 
modulating some atherogenic processes in VSMCs and macrophages (136). 
Unless otherwise stated, ANRIL would hence usually refer to the linear 
transcript (linANRIL). This alternatively structured RNA from the same locus 
exemplifies the added layers of complexity in lncRNA biology compared with 
















Biological context Reference 
miRNA miR-21 Biomarker of coronary artery 
disease, upregulated in vein 
grafts 
(137-139) 
miR-126 Promotes endothelial cell 
proliferation, atheroprotective 
(140, 141) 
miR-92a Endothelial inflammation, 
atherogenic 
(142) 





Complex interaction in 
atherosclerosis and pulmonary 
hypertension: upregulated in 
human unstable carotid plaque, 
knockout blocks pulmonary 




Dysregulated in acute plaque (145, 147) 











lncRNA ANRIL Transcribed from 9p21 locus, 
associated with pathogenic 
changes in atherosclerotic 
plaques 
(130) 






SENCR Downregulated in human critical 
limb ischemia and in premature 
coronary artery disease 
(154) 
SMILR Induces smooth muscle cell 
proliferation, upregulated in 
human carotid plaques 
(155) 
meXis Improves cholesterol efflux, 
atheroprotective 
(156) 
MALAT1 Downregulated in plaque, 
endothelial phenotypic switch 
(157) 
LIPCAR Predictive of heart failure post 
myocardial infarction 
(158) 
Until now, in vitro work has led to limited characterisation of some other 
vascular lncRNAs in relevant cell types, but translation into definite therapeutic 
targets in humans requires complex mechanistic unravelling, which in most 
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cases is in the early stages. Long non-coding RNAs identified in circulatory 
samples from atherosclerosis patients, or from GWAS may provide a starting 
point for vascular targets, but confounding processes such as myocardial 
injury and repair, or the general upregulation of inflammation are equally likely 
to account for these correlative findings. Notable examples include myocardial 
infarction associated transcript (MIAT) (151), another transcript discovered by 
large case-control genome association study in patients with MI, and 
myocardial infarction related transcript 1 and 2 (MIRT1, MIRT2) in a murine MI 
model (152). Whilst dysregulation in myocardial infarction has been 
demonstrated has been demonstrated, mechanistic work to understand if 
these transcripts are important in atherosclerosis or a different pathway is 
needed.  
As with miRNAs, a certain insight has been achieved from in vitro cellular 
models. Although cultured cell lines representing one cell type are not truly 
analogous to the multicellular in vivo environment, it is possible to investigate 
candidate novel transcripts, and to identify at least if these are important in 
cellular function in the first instance. In coronary artery smooth muscle cells, 
the smooth muscle and endothelial cell–enriched migration / differentiation-
associated long non-coding RNA (SENCR) is an example of a transcript 
discovered by RNA sequencing, and functionally characterised in relevant cell 
types. SENCR was shown to be anti-migratory in VSMCs, and subsequent 
RNA-Seq after SENCR knockdown then demonstrated a reduced expression 
of myocardin and numerous contractile genes, consistent with the observed 
phenotype (159). Subsequently, lower levels of SENCR in human critical limb 
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ischemia and in the endothelial cells of patients with premature coronary artery 
disease were observed (154), again supporting that hypothesis that SENCR is 
downregulated in pathology. As SENCR appears to be a regulator of VSMC 
behaviour, it could be hypothresised that targeted delivery of SENCR in areas 
of deficiency might then ameliorate maladaptive smooth muscle cell 
behaviours in atherosclerosis. Another vascular lncRNA, smooth-muscle 
induced long non-coding RNA (SMILR), was investigated in a similar manner, 
but in this case upregulation of SMILR was associated with vascular smooth 
muscle cell proliferation, and in human atherosclerotic plaque SMILR is 
enriched. Mechanistic investigation showed that SMILR may exert its effects 
by interaction with cis protein HAS2, which codes for hyaluronic acid. HAS2 
was also reduced on SMILR knockdown, and the VSMC phenotype was of 
reduced proliferation (155). Therapeutic targeting of SMILR with in vivo locked 
nucleic acids (LNAs) might prove useful in preventing neointima formation in 
clinical settings.  
Aside from the cells which are inherent to the vascular wall, immune cells 
monocytes and macrophages, are known to be key regulators of lipid handling 
within the plaque, and recently it was shown that the lncRNA meXis is an 
amplifier of the ABCA1 gene, via the sterol activated liver X receptors (LXRs). 
LXRs are sterol-activated nuclear transcription factors, and may be important 
in the pathology of atherosclerosis, as key regulators of genes involved in 
cholesterol transport. MeXis interacts with and guides promoter binding of the 
transcriptional coactivator DDX17, so loss of the gene resulted in impaired 
cholesterol efflux, and accelerated atherosclerosis in murine models. As 
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discussed, any novel target for improving cholesterol efflux (which is beneficial 
in plaque disease) certainly warrants further investigation (156). 
Utilising human samples excised at coronary endarterectomy a recent study 
compared lncRNA expression from diseased left anterior descending (LAD) 
artery plaque with inferior mammary artery control tissue. This is a rarely 
performed procedure, and coronary artery samples from live patients are not 
usually readily available. The inferior mammary artery used as a control here 
is preferentially used for LAD coronary artery bypass and tends to be quite 
resistant to atherosclerosis with low failure rates (160). Differential lncRNA 
expression was observed in 3 of the 5 plaques chosen for analysis, with 
upregulation of ANRIL and MIAT whilst metastasis-associated lung 
adenocarcinoma transcript 1 (MALAT1) was downregulated (157). This 
reinforces the initial premise that these lncRNAs which had been previously 
proposed as atherosclerosis related lncRNAs, and had been found in the 
circulation of patients with acute myocardial infarction (153), are in fact 
reproducibly found in human atherosclerotic tissue.  
MALAT1 briefly described above is frequently cited in vascular disease and 
widely in multiple pathologies (primarily cancer) is a very well-conserved and 
highly expressed long non-coding RNA (161). Having initially been 
demonstrated as a prognostic marker in non-small cell lung cancer (162), 
MALAT1 may also be relevant in vascular disease, and was shown to control 
phenotypic switch in endothelial cells, as well as impair vessel recovery in a 
hind-limb ischaemia model when knocked down using in vivo GapmeRs (163, 
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164). In atherosclerosis, MALAT1 has been shown to be downregulated in 
atherosclerotic plaque (157). The use of in vivo GapmeRs to knock down 
chosen ncRNAs will be discussed later. 
1.6.4 Non-coding RNA therapies 
 
Figure 1-12: Proposed delivery methods of non-coding RNA-based therapeutics in 
vascular disease.  
RNA therapeutics can be delivered to the vascular system using vehicles such as viral 
vectors, nanoparticles and pluronic gel; intravascular devices such as drug eluting stents; or 
by direct injection. 
 
MiRNA as therapeutic agents 
In the large class of non-coding RNAs, miRNAs currently possess the 
strongest therapeutic potential due to our greater knowledge of them, clearer 
mode of action and ability to regulate multiple genes in multiple molecular 
pathways. Moreover, due to their pleiotropic mechanism of action, a 
manipulation of a single miRNA could potentially induce a therapeutic effect 
within several cells and tissues. With re-emerging interest in RNAi therapeutics 
(165), it is possible that miRNA-based therapies will progress further in the 
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coming years. Figure 1-12 summarises current and proposed approaches to 
non-coding RNA therapy and delivery. 
Ultimately, efficacy depends on both modification of the RNA molecule, and its 
vehicle for delivery. The two principal strategies for miRNA therapeutics 
include overexpression of miRNA by synthetic oligoribonucleotide (ORN) 
delivery or targeted miRNA inhibition using single-stranded antisense 
oligonucleotides (anti-miRs). In order to obtain better delivery efficiency, the 
ORNs can be subjected to chemical modifications, such as  2′-O-methoxyethyl  
(2′-MOE) substitutions and LNA bases, which stabilise the oligoribonucleotides 
(166-168). In particular, the 2′-MOE modification is generally used to prevent 
degradation of ORN as well as to mask it from the immune response, whereas 
LNA enhances the affinity of miRNA and stabilises the ORN further (169, 170). 
The use of such modifications to improve expression modulation of certain 
miRNA has been validated numerously in the vascular disease setting, 
including examples such as delivery of 2′OMe-miR-21 to rat carotid artery 
(171), systemic downregulation of miR-92a with LNA-anti-miR to induce re-
endothelialisation (172) as well as intravenous delivery of LNA-anti-miR-15b 
to reduce cardiac remodeling in mice post-MI (173). 
In addition to ORN modifications, efficient RNA delivery vehicles are required 
to facilitate their uptake. There are several studied thus far, as discussed 
below. The most common delivery method to date is the use of lipid-based 
nanocarriers, which package the RNA, allowing it to cross the cellular 
membrane (174, 175). Notably, in a study carried out by Weber‘s group it was 
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shown that miR-126-5p mimics  packaged in this way were effectively and 
efficiently transfected in vivo. The cargo was delivered intravenously to high 
cholesterol diet mice, resulting in a marginal decrease in atherosclerotic lesion 
formation, and an increase in luminal EC proliferation. They reported in the 
same study that using pluronic gel-based delivery was also effective, in this 
case for local delivery of anti-miRs injected around the mouse carotid artery 
(141). Pluronic gel can be used internally or topically and was also used 
effectively in a recent study by Miscianinov et al., where miR-148b mimics 
were topically administered to efficiently enhance angiogenesis and wound 
healing in vivo. It was noted in this case however that the delivery of anti-miR-
148b within the pluronic gel had impaired wound closure and induced EndMT 
in the wound vasculature, possibly a result of the target manipulation more-so 
than the mode of delivery (176). Alternative methods to package and deliver 
RNA based therapies involve polymer- and peptide-based systems, such as 
polylactic-co-glycolic acid (PLGA) and Polyamine-co-ester terpolymer (PACE) 
nanoparticles. The latter are able to release the oligoribonucleotides steadily 
over time (177, 178). PLGA was used in the vascular setting when an anti-miR 
to miR-92a encapsulated by PLGA microspheres was delivered directly to pig 
coronary arteries. MiR-92a expression was downregulated locally, preventing 
left ventricular remodeling in a model of reperfused MI (179).  
Of course, viral vectors such as adenovirus (AV) and adeno-associated virus 
(AAV) are amongst the best-known vehicles for gene therapies due to their 
natural ability to infect and transfer genetic information. Viruses have been 
used to efficiently deliver many different cargoes in vivo previously like the 
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tissue inhibitor of metalloproteinase-3 (TIMP3) in vein graft failure, which 
reduced neointimal formation consistently (180). The commonly used vector 
AAV has been equally well-studied, and delivery of hsa-miR-590 and hsa-miR-
199a pre-miRs to the neonatal rat heart was shown to significantly reduce 
infarct size and improve cardiac function post-MI (181). Despite concerted 
efforts to optimise this process however, viral delivery can be hampered by 
several drawbacks, namely the triggering of immune response (especially in 
the case of AV), off target effects, and the sometimes undesirable long-term 
incorporation of the virus’s genes into those of the host.  
Specificity of site action hence represents one of the major barriers to 
developing successful miRNA therapies, as in both of the above classes of 
examples. Some success has been seen with attempts to deliver miRNA 
therapies locally. In the vasculature in particular, drug-eluting stents (DES) 
were already widely used in percutaenous coronary intervention, releasing 
anti-proliferative and immunosuppressive drugs to prevent re-stenosis. In a 
similar approach, it was shown that delivery of LNA anti-miR-21 by DES 
significantly attenuated in-stent restenosis in the humanised rat myointimal 
hyperplasia model (182). Photoactivatable antimiRs, which have photolabile 
cages attached to the oligonucleotide structure are only activated by light, 
therefore generating an inducible model (183, 184). This ensures that the miR 
treatment is only efficiently released at the intended site. Clearly this is useful 
in skin, but perhaps less so internally. Efficacy of a miR-92a light-inducible 
compound was demonstrated in superficial mice wounds and was able to 
enhance proliferation and angiogenesis (185). Finally, incorporation of miRNA 
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therapy with a thioaptamer, specifically interacting with a chosen ligand, E-
selectin in this example, may be useful to ensure specificity.  The aptamer 
binds to the chosen molecule and guides the miR therapy, miR-146a and miR-
181b to inflamed endothelium, reducing atherosclerosis in mice (186).  
 
Non-nascular ncRNA therapeutics 
As there are currently no clinical trials focused on ncRNAs in vascular disease, 
we will describe studies in liver and heart and translational relevance for 
vascular disease. The most successful example of miRNA-based therapeutics 
to date is anti-miR-122 compound for hepatitis C. It has been demonstrated in 
Jopling et al. study that miR-122 is highly and specifically expressed in human 
liver. Moreover, it has been shown that inhibition of miR-122 was able to 
strongly decrease viral RNA of hepatitis C, introducing the novel idea for a 
potential miR-122-modulating therapy (187). Since then a lot of work has been 
done to achieve an efficient miR-122 inhibition method in vivo, primarily using 
2′-MOE-modified anti-miR (188, 189). Furthermore, anti-miR-122 LNA 
modification approach was efficient in downregulating miR-122 expression in 
mice, which was delivered intravenously (190). Notably, the preclinical trials 
on chimpanzees have confirmed that LNA-anti-miR-122, now known as 
SPC3649 or Miravirsen, leads to significant reduction in hepatitis C viral load 
with no side-effects (191). Currently, Miravirsen is being developed by Santaris 
Pharma and is since 2017 in Phase II clinical trials (192). 
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In other translational studies, direct intra-cardiac injection of miR-21, miR-1 
and miR-24 reduced infarct size in mice, with LAD ligation, at 24 hours (193). 
The mice underwent ischaemic preconditioning, forcing an altered miRNA 
expression profile, with the hypothesis that these miRNAs would be protective 
in the case of infarct. The miRNAs were then extracted and injected into the 
infarct model, resulting in an increase of eNOS, HSF-1, and HSP70. Direct 
injection of miRNA seems to be effective therefore in altering tissue expression 
of important mRNAs and proteins. In a mesenchymal stem cell vector, miR-1 
was overexpressed and injected into infarcted myocardium again in a mouse 
model of infarct, resulting in enhanced cell survival and improved cardiac 
function (194). In a similar way but with a different mode of delivery, polyketal 
(PK3) nanoparticles (a solid polymer) were used to deliver miRNA mimics miR-
106b, miR-148b and miR-204 to macrophages in mice hearts, all targeting 
Nox2 expression. Infarct size was significantly reduced, and function improved 
(195). The alternative approach of miRNA inhibition has also been shown to 
be effective in the cardiovascular setting, and in some cases may be 
technically easier to achieve. Anti-miRs can be quickly designed and 
developed, and in vivo delivery of the anti-miR-143 is protective in the 
development of pulmonary arterial hypertension in mice (196). MiR-143-3p is 
selectively upregulated in cell migration, and its modulation significantly 
reduces cell migration and apoptosis.  
Coronary artery bypass vein graft failure has been a longstanding problem, 
and the setting for some significant advances in ncRNA therapy. The 
underlying pathologies are of neointima formation and superimposed 
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atherosclerosis. MiR-21 expression is elevated in mice, porcine and human ex 
vivo models of vein graft failure and localises to the smooth muscle cell layers 
of the forming neointima in the failing grafts. Delivery of anti-miR-21 to inhibit 
miR-21 was effective to reduce expression and attenuate the pathological 
neointima formation in a model of vein graft failure (139), and now further 
clinical investigation is needed before this can be applied in patients. In a 
completely different disease system its also been reported that inhibition of 
miR-21 using anti-miR can prevent Alport syndrome in mice. This disease 
which is characterised by glomerulonephritis and progressive renal failure also 
results in sensorineural deafness in the human form (197). As a result of these 
findings, Regulus Therapeutics is now carrying out a Phase II clinical study 
(NCT02855268) of the safety and efficacy of RG-012 drug (anti-miR-21) 
administered to patients with Alport syndrome.  
In another important study, from the Dimmeler group, they demonstrated that 
downregulation of miR-92a expression using 2′O-methyl anti-miR 
oligoribonucleotides enhanced in vivo angiogenesis, neovascularisation as 
well as enhanced post-MI recovery in mice (198). The pro-angiogenic and 
cardioprotective effect of anti-miR-92a therapy was further confirmed in a 
further study from the same group. Specifically, it has been demonstrated that 
the catheter-based delivery of anti-miR-92a with LNA modification (LNA-92a) 
led to the decrease in the infarct size in pig hearts and improved cardiac 
function (199). A recent publication by the same group demonstrated that 
delivering a LNA-based antisense oligonucleotide that targets miR-92a-3p did 
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in fact reduce circulating levels of the same. This is one step closer to a human 
in vivo study, to quantify the effects of this transcript knockdown  (200). 
With the advances of CRISPR/Cas9 technology and the ability to modify the 
genome at the base pair level, this method has become a very attractive and 
promising approach to generate both gain- and loss-of-function miRNA 
phenotypes. Interestingly, an in vitro transfection of CRISPR/Cas9 vectors, 
which contain sgRNAs, targeting the biogenesis processing sites of miR-17, 
miR-200c, and miR-141, decrease the expression of these miRNAs up to 96% 
(201), an impressive knockdown. Moreover, subcutaneous injection of HT-29 
cells with CRISPR/Cas9-mediated miR-17 knockdown into nude mice resulted 
in almost complete knockout of miR-17 expression in the in vivo environment 
after 28 days (201). Despite the clear benefits of the CRISPR/Cas9 approach 
in modulating miRNAs in vivo, the usual obstacles, such as off-target effects 
and lack of delivery vehicles with tissue specificity are yet to be overcome. 
 
LncRNA based intervention strategies 
Given the fact that lncRNAs guide gene expression from start of transcription 
to protein translation, this class of molecules possess a promising therapeutic 
potential. The first study involving modulation of lncRNA expression for 
therapeutic purposes described the oncogenic lncRNA H19. In particular, it 
has been reported that H19 is specifically expressed in over 30 tumors. Based 
on those findings, a plasmid expressing diphtheria toxin under control of the 
H19 promoter (BC-819) has been intra-tumorally injected into bladder tumour 
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leading to a significant reduction in size in mice (202). This led to initiation of 
phase I and II human clinical trials, in which a H19 promoter-based plasmid is 
used to treat patients with different malignancies such as bladder, pancreatic 
and ovarian cancers (202). Recently reported results seem promising, 
including in the treatment of early stage bladder cancer, BioCanCell report that 
BC-819 treatment resulted in 54% of patients recurrence-free at 24 months 
(203). 
Currently, there are two main approaches to silence lncRNA expression, which 
are employed in pre-clinical models: the use of RNAi-based methods, such as 
siRNA, and LNA-GapmeR antisense oligonucleotides (ASOs), which induce 
RNase cleavage. Generally, the RNAi approach, including siRNA and short 
hairpin RNA (shRNA), which can be delivered via viral vectors, is used 
predominantly for lncRNA that are localised in the cytoplasm. In particular, it 
has been demonstrated that siRNA targeting cytoplasmic lncRNA SMILR can 
reduce SMILR expression and attenuate pathological human saphenous vein 
smooth muscle cell proliferation (155). On the other hand, GapmeRs can be 
used for nuclear-localised lncRNA due to the fact that it induces degradation 
by RNase-H and is RISC-independent (204). Furthermore, GapmeRs can be 
used to modulate lncRNA expression in vivo. In particular, intraperitoneal 
injection of GapmeRs in mice model of hindlimb ischemia was able to 
significantly reduce MALAT1 expression in the muscle tissue leading to poor 
blood flow recovery and diminished capillary density (205). In another study 
GapmeRs were used to inhibit the lncRNA Chast, which is upregulated in 
hypertrophic heart tissue from aortic stenosis patients. Notably, the in vivo 
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delivery of GapmeR targeting Chast resulted in a decrease in pathological 
cardiac remodelling with no significant side effects (206). Finally, the 
CRISPR/Cas9 genome editing method is an attractive emerging tool for 
modulation of gene expression including manipulation of lncRNAs. To date, 
the CRISPR-inhibition (CRISPRi) approach has been shown to knockdown the 
expression of six lncRNAs including GAS5, H19, MALAT1, NEAT1, TERC and 
XIST (207). The CRISPR/Cas9 method is in its nascent stages but coupled 
with viral-based delivery systems, it holds much potential in terms of non-
coding RNA-based therapeutics.  
 
1.7 Hypothesis 
This thesis will incorporate clinical and pre-clinical studies, to combine the 
strengths of large clinical data and fundamental laboratory research. It is my 
overall hypothesis that: 
‘Long non-coding RNAs play important roles in the pathology of 
atherosclerosis’ 
The results chapters detailed below aim to address this hypothesis step-by-
step, to identify areas of need in the management of myocardial infarction, and 
understand how lncRNAs could be used investigatively and or therapeutically 
to improve the care of patients with atherosclerosis.  
 
Aims 
• In Chapter 3, the risk stratification of patients with type 2 myocardial 
infarction using the GRACE 2.0 score will be analysed. The aim of this 
chapter is to explore how patients with different clinical syndromes within 
myocardial infarction are risk stratified, to gain insight into the gaps that 
exist in scientific knowledge, and what potential there is for development of 
new strategies to improve their care. The existing GRACE 2.0 score is well-
validated in patients with type 1 myocardial infarction, but its performance 
in patients with type 2 myocardial infarction is unknown. The objective of 
this analysis is to assess the utility of GRACE 2.0 score in a large 
population of patients with type 1 and type 2 myocardial infarction to 
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investigate if patients with type 2 myocardial infarction can be risk stratified 
using the GRACE 2.0 score. 
 
• In chapter 4, a large RNA-sequencing dataset from human carotid stable 
and unstable atherosclerotic plaque will be validated and analysed to 
derive a shortlist of dysregulated long non-coding RNAs. Candidates will 
be selected for further investigation in the following chapter. 
 
• In chapter 5, a candidate lncRNA will be manipulated in vivo by modulation 
of expression (knockdown), to investigate its role in atherosclerosis. The 
objective of this series of experiments is to understand if knockdown of the 
candidate lncRNA changes the phenotype of its host cells, to demonstrate 
that long non-coding RNAs are important in the biology of unstable 
plaques. 
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Carotid plaques were harvested in accordance with Bioresource local ethical 
approval (15/ES/0094, 15/HV/013). All studies were approved by East and 
West Scotland Research Ethics Committees, and all experiments were 
conducted according to the principles expressed in the Declaration of Helsinki. 
Blood harvested by venepuncture was taken in accordance with local Blood 
Bank conditions, under ethical approval via the Centre for Inflammation 
Research, University of Edinburgh (AMREC Reference number 15-HV-013). 
The High-STEACS trial was approved by the Scotland A Research Ethics 
Committee, the Public Benefit and Privacy Panel for Health and Social Care, 
and by each National Health Service (NHS) Health Board. All data were 
collected prospectively from the electronic patient record, deidentified and 
linked within secure NHS Safe Havens. In the Karolinska University Hospital 
cohort, the study protocol was approved by the Regional Ethical Review Board 
in Stockholm. Both studies were conducted in accordance with the Declaration 
of Helsinki. 
 
2.2 GRACE 2.0 Score in Type 2 Myocardial Infarction Study 
2.2.1 Study populations 
We assessed the performance of the GRACE 2.0 score in two cohorts of 
consecutive patients presenting to the Emergency Department with sus- 
pected acute coronary syndrome in Scotland and in Sweden. 
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High-Sensitivity Troponin in the Evaluation of patients with suspected Acute 
Coronary Syndrome (High-STEACS) is a stepped-wedge cluster randomized 
controlled trial to evaluate implementation of a hs-cTnI assay in consecutive 
patients with suspected acute coronary syndrome across 10 hospitals in 
Scotland (76). Troponin was measured using the Abbott ARCHITECT STAT 
high-sensitive troponin I assay (Abbott Diagnostics, Chicago, IL, USA). This 
assay has an inter-assay coefficient of variation of <10% at 4.7 ng/L and a 99th 
centile of 16 ng/L in women and 34 ng/L in men (208). All patients attending 
the Emergency Department between June 2013 and March 2016 were 
identified as having suspected acute coronary syndrome by the attending 
clinician at the time troponin was requested. using an electronic form 
integrated into the clinical care pathway. Patients were excluded if they had 
been admitted previously during the trial period or were not resident in 
Scotland. We used regional and national registries to ensure complete follow-
up.  
The study population from the Karolinska University Hospital in Stockholm was 
derived from an observational cohort study of all patients >25 years old with a 
visit to the Emergency Department with chest pain and at least one hs-cTn 
measurement from January 2011 to October 2014 (209, 210). Troponin was 
measured using the Roche Elecsys hs-cTnT assay (Roche Diagnostics, 
Mannheim, Germany). This assay has a limit of detection of 5 ng/L, and a limit 
of blank of 3 ng/L. The 99th percentile cut-off point is 14 ng/L, and the 
coefficient of variation is <10% at 13 ng/L. The hospital’s local administrative 
database was used to identify eligible patients. Patients were excluded if they 
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had an estimated glomerular filtration rate of <15 mL/min/1.73 m2. The 
obtained data, together with laboratory data, were sent to the Swedish National 
Board of Health and Welfare who linked information on comorbidities and 
outcomes, use of medication, and dates and causes of death from the National 
Patient Register, the Prescribed Drug Register, and the Cause-of-Death 
register, respectively. The Patient Register has nationwide coverage on 
diagnoses at discharge and surgical procedures coded according to the 
International Classification of Disease.  
 
2.2.2 Adjudication of myocardial infarction and outcomes 
All diagnoses were adjudicated in accordance with the Fourth Universal 
Definition of Myocardial Infarction (74). In both cohorts two physicians 
independently reviewed all clinical information with discordant diagnoses 
resolved by a third reviewer (Scotland) or by consensus discussion (Sweden). 
Type 1 myocardial infarction was defined in those with suspected acute 
coronary syndrome with symptoms or signs of myocardial ischaemia on the 
electrocardiogram and evidence of myocardial necrosis: hs-cTnI concentration 
above the sex-specific 99th centile with a rise and/ or fall in concentration 
where serial testing was performed (Scotland); hs-cTnT concentration above 
the uniform 99th centile with a delta of 3 ng/L (Sweden). Patients with 
myocardial necrosis, symptoms or signs of myocardial ischaemia, and 
evidence of increased myocardial oxygen demand or decreased supply 
secondary to an alternative condition without evidence of acute 
atherothrombosis were defined as type 2 myocardial infarction. Patients with 
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hs-cTn concentrations above the 99th centile without symptoms or signs of 
myocardial ischaemia were classified as having myocardial injury. All non-
ischaemic myocardial injury was classified as acute, unless a change of < 20% 
was observed on serial testing (74), or the final adjudicated diagnosis was 
chronic heart failure or chronic renal failure, where the classification was 
chronic myocardial injury. 
The primary outcome was all-cause death at 1 year, and the secondary 
outcome was all-cause death or type 1 myocardial infarction at 1 year. All in-
hospital and community deaths are recorded on the National General Register 
of Scotland, and the Swedish Patient Register. Subsequent myocardial 
infarction events were identified through the electronic patient record in 
Scotland with adjudication as for the index diagnosis, and using ICD-10 coding 
(I21 and I22) from the Swedish Patient Register in the Swedish cohort.  
 
2.2.3 Statistical Analysis 
Baseline characteristics were summarized for each cohort and in groups 
according to adjudicated diagnosis. Group-wise comparisons were performed 
using x2, Kruskal–Wallis, or one-way analysis of variance tests as appropriate. 
We determined the GRACE 2.0 score for all-cause death, and for all-cause 
death or type 1 myocardial infarction at 1 year. This score includes age, heart 
rate, systolic blood pressure, creatinine as continuous variables, with 
categorical variables for Killip class, cardiac arrest at admission, ST-segment 
deviation, and elevated cardiac biomarkers (defined here as any hs-cTn 
concentration above the 99th centile). Where data were missing within the 
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Scottish cohort, this was assumed to be at random, and we applied multiple 
imputation using chained equations with five imputations of the dataset. For 
imputation, we applied Bayesian linear regression models for continuous data 
(creatinine, heart rate, and systolic blood pressure), multinomial logistic 
regression for ordinal data (Killip class) and logistic regression for binary data 
(e.g. cardiac arrest status). We assessed overall GRACE 2.0 model 
discrimination by determining the area under the receiver operating curve 
(AUC) and compared performance in patients with type 1 and type 2 
myocardial infarction using the DeLong method. We assessed model 
calibration both graphically, and by using the Hosmer–Lemeshow goodness 
of fit test. In addition, we assessed GRACE performance by evaluating 
previously defined categories of mortality risk (<3% low, >_3 and <_8% 
intermediate and >8% high risk) using the Kaplan–Meier method. We explored 
the impact of multiple imputation by performing a sensitivity analysis in which 
we evaluated the complete dataset only. These results were similar to the 
primary analysis and are presented in Table 7-1. In post hoc analyses, we also 
determined performance of the GRACE 2.0 score for in-hospital death and of 
hs-cTn alone to predict all-cause death at 1 year. All analyses were performed 
in R (Version 3.5.1), with thanks to Dr Andrew Chapman for statistical support. 
 
2.3 Carotid Artery Plaque Samples for RNA 
Excised carotid plaque tissue was harvested from patients undergoing carotid 
endarterectomy following acute neurovascular event. Local ethical approval 
was obtained via the NHS Lothian BioResource Tissue Governance 
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committee (15/ES/0094). Plaques were assessed macroscopically for 
dissection into stable and unstable sections. Areas of plaque rupture with 
associated intraplaque haemorrhage were considered ‘unstable’, and 
relatively healthy adjacent sections taken to be ‘stable’. Samples were stored 
in RNA later (Sigma-Aldrich) for 30-60 minutes, before snap freezing and 
storage at -80°C, until use for downstream validation of RNA sequencing 
candidates. Patient characteristics are described below (Table 2-1).
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Table 2-1: Carotid endarterectomy patient characteristics 
Carotid endarterectomy patient demographics, clinical presentation, past medical 
history and serum parameters. Data presented as mean and either standard 
deviation (SD) or percentage (%) in brackets, as stated. TIA= transient ischemic 
attack, ACEi/ARB= angiotensin-converting enzyme inhibitor/angiotensin receptor 
blocker.   
 
Carotid Endarterectomy Patients (n=5) 
Age in years, mean (SD) 74 (7.1) 
Men, n (%) 5 (100) 
Systolic BP (mmHg), mean (SD) 144 (15.2) 
Diastolic BP (mmHg), mean (SD) 86 (15.4) 
Presenting syndrome, n (%)  
    Stroke 2 (40) 
    TIA / amaurosis fugax 4 (80) 
Cardiovascular history, n (%)  
    Ischaemic heart disease 3 (60) 
    Myocardial infarction 0 (0) 
Risk factors  
    Hypertension 3 (60) 
    Diabetes 0 (0) 
    Hypercholesterolaemia 1 (20) 
    Smoker 0 (0) 
Medication  
    Aspirin 2 (40) 
    Clopidogrel 2 (40) 
    Anticoagulant 1 (20) 
    Statin 3 (60) 
    ACEi/ARB 1 (20) 
    B-blocker 3 (60) 
Haematology, mean (SD)  
    Hb 146 (15.2) 
    WBC 7.2 (0.9) 
    PLT 236 (32) 
Biochemistry, mean (SD)  
    Creatinine (mmol/L) 85.6 (22.3) 
    Total cholesterol (mmol/L) 4.4 (1.1) 
    HDL 1.2 (0.45) 
    LDL 2.3 (0.88) 





2.4 Normal aortic samples for RNA analysis 
Aortic tissue was harvested from patients undergoing coronary bypass 
grafting, with no known aortic disease. Local ethical approval was 
obtained via the NHS Lothian BioResource Tissue Governance 
committee (15/ES/0094). Punch biopsy samples taken from grafting 
sites were stored in RNA later (Sigma-Aldrich), for 30-60 minutes, 
before being snap frozen and stored at -80°C, until use.  
 
Table 2-2: Normal aorta patient characteristics  
Patient demographics, clinical presentation, past medical history and serum 
parameters. Data presented as mean and either standard deviation (SD) or 
percentage (%) in brackets, as stated. TIA= transient ischemic attack, ACEi/ARB= 
angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. 
Normal Aorta Patients (n=3) 
Age in years, mean (SD) 65 (7.2) 
Men, n (%) 3 (100) 
Cardiovascular history, n (%)  
    Ischaemic heart disease 3 (100) 
    Myocardial infarction 3 (100) 
Risk factors  
    Hypertension 2 (67) 
    Diabetes 2 (67) 
    Hypercholesterolaemia 2 (67) 
    Smoker 0 (0) 
Medication  
    Aspirin 0 (0) 
    Clopidogrel 0 (0) 
    Anticoagulant 0 (0) 
    Statin 1 (34) 
    ACEi/ARB 1 (34) 
    B-blocker 1 (34) 
Haematology, mean (SD)  
    Hb 122 (17.0) 
    WBC 8.7 (5.4) 
    PLT 254 (45) 
Biochemistry, mean (SD)  
    Creatinine (mmol/L) 79 (6.9) 
    Total cholesterol (mmol/L) 4.0 (1.1) 
    HDL 1.1 (0.1) 
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    LDL 2.1 (0.8) 
    Trig 1.7 (0.9) 
 
 
2.5 Human carotid plaque sections for ISH/IHC 
Human atherosclerotic plaque samples were obtained from patients 
undergoing carotid endarterectomy. The tissue was part of the 
‘Maastricht Pathology Tissue Collection’, and collection, storage, and 
use of tissue and patient data were performed in agreement with the 
Dutch Code for Proper Secondary Use of Human Tissue, the 
Declaration of Helsinki, and was approved by the local Medical Ethical 
Committee (protocol number 16-4-181). Immediately after resection, 
each atheroma was divided into parallel segments of 5mm. Formalin-
fixed segments were stained with haematoxylin-eosin and according to 
Virmani et al (16), fibrous cap atheroma with or without intraplaque 
hemorrhage, termed stable or unstable respectively, used for ISH/IHC.  
 
2.6 Human Tissue Panel 
A commercially available human tissue panel, Human MTC™ Panel I (Takara 
Clontech), was used to characterise expression of LINC01272 across different 




Healthy volunteers were selected based on their availability from the University 
blood donor bank, Centre for Inflammation Research, University of Edinburgh 
(AMREC Reference number 15-HV-013). Blood was collected from healthy 
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volunteers using standard venepuncture equipment including 50ml syringe 
and 16g needle, into 50ml Falcon tubes, and anticoagulated with sodium 
citrate 3.8%.  
 
 
2.7 Cell Culture 
Cell culture was undertaken in standard biological safety class II vertical 
laminar flow cabinets under sterile conditions. Cabinets were sterilised before 
and after use with 70% ethanol. 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood 
of anonymised healthy control subjects, for use in fractionation RNA-FISH, 
phagocytosis and efferocytosis assays, with local ethical approval 
(15/HV/013). All studies were approved by East and West Scotland Research 
Ethics Committees, and all experiments were conducted according to the 
principles expressed in the Declaration of Helsinki. In Edinburgh, porous 
membrane separation tubes (Greiner Bio-One GmbH, Germany) were used to 
isolate human PBMCs, and monocytes were isolated by positive selection 
performed with lyophilised CD14 microbeads (Miltenyi Biotech, Gladbach, 
Germany). The protocol in Maastricht differed slightly, with PBMCs isolated by 
Ficoll-Paque gradient, using buffy coat samples from Uniklinik RWTH Aachen, 
Germany, rather than the porous membrane tubes. Purification with CD14 
microbeads and subsequent steps were the same.  
For differentiation to macrophages, monocytes were cultured for 1 week at 
37°C, 5% CO2, and stimulated with 10ng/ml M-CSF (Immunotools, Friesoythe, 
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Germany) in RPMI 1640 Glutamax (Life Technologies, Netherlands, Europe) 
supplemented with 10% FBS (Gibco / Thermo Fisher, UK) and 1% Pen/Strep 
(Gibco), with one medium change after 4 days of culture. Coronary artery, 
pulmonary artery and saphenous vein smooth muscle cells and endothelial 
cells included in cell expression panel were cultured using supplemented 
Smooth Muscle Cell Growth Medium 2 (PromoCell, Heidelberg, Germany) and 
endothelial cell growth medium (EGM-2 BulletKit™) (Lonza, Basel, 
Switzerland)  respectively, at 37°C, 5% CO2.  
 
 
2.8 GapmeR knockdown 
For selective knockdown of LINC01272 (PELATON), GapmeRs were 
designed using a sequence common to all isoforms (Table 2-3) (Exiqon, 
Denmark). GapmeRs were resuspended with RNase free water to a stock 
concentration of 10μM, and frozen at -20°C until use. Macrophages were 
transfected with Lipofectamine RNAiMax (ThermoFisher Scientific) with 
GapmeR concentration of 20nM for 6 hours, followed by quiescence for 18 
hours.  
Table 2-3: GapmeR sequences 
Gapmer ID Sequence 
GapmeR control AACACGTCTATACGC 
GapmeR 1 GAAGGGCTTGGGTCG 




2.9 Macrophage polarisation 
Macrophages were polarised into 4 different subtypes, M1, M2a, M2b and 
MoxLDL (foam cells), achieved by incubation for 24 hours at 37°C with the 
relevant stimuli for each; IFNγ 20ng/ml and LPS 10ng/ml for M1; IL-4 for M2a 
at 50ng/ml; IL- 10 at 10ng/ml for M2c and human oxLDL at 50µg/ml for 
MoxLDL (Table 2-4). Polarisation was confirmed by qRT-PCR for subtype 
specific markers (M1, CD86; M2a, CD200R; M2b, CD163; MoxLDL, iNOS) 
(Chapter 5.3.3). 
 
Table 2-4: Polarisation stimuli 
ID Supplier Cat no 
LPS Thermo, UK 00-4976-93 
IFNγ Immunotools 11343534 
IL-4 Immunotools 11340042 
IL-10 Immunotools 11340102 
 
2.10 RNA isolation 
Total RNA was isolated from human tissue and cultured cells using the 
miRNEasy kit (Qiagen, Hilden, Germany).  
For tissues, disruption was performed in 700µL of Qiazol for each sample 
using TissueLyser II (Qiagen) for normal aortic samples, and pestle and mortar 
in liquid nitrogen for carotid plaque samples.  
For cultured macrophages, the yield is notoriously low when cells are 
differentiated and harvested from plates with small wells. To optimise the 
number of cells needed to obtain adequate quantities of RNA, wells were 
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pooled at the Qiazol stage, and various numbers of wells compared for yield 
and quality of RNA (Table 2-5).  
Table 2-5:Optimising RNA extraction from macrophages in 96 well plates 
 
DNase treatment was also carried out during the extraction with a 
complimentary RNase- free DNase Kit (Qiagen). As per standard protocol, 
140µL chloroform was added for separation of RNA fraction over 3 minutes. 
Samples were then centrifuged at 12,000 x g 4°C for 15 min, allowing 
separation into 3 phases: upper aqueous phase containing total RNA; middle 
interphase containing DNA; lower organic phase, containing protein. The 
upper aqueous phase was carefully transferred without disturbing the 
interphase and transferred to a new tube for precipitation with 550µL of 
absolute alcohol. Samples were passed through columns, when RNA should 
bind to the column, and a DNase treatment was performed. DNase solution 
 86 
was prepared with 10μL of enzyme and 70μL of buffer per sample. 80 μL of 
the mix was then added directly to each column and incubated for 15 minutes 
at room temperature. RWT and RPE washes were then added to each column, 
and briefly centrifuged, to wash away contaminating phenol. The flow through 
was discarded following each wash. Finally, RNase free water was added to 
each column, quantity dependent on the expected yield of RNA. RNA 
concentration was estimated using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific, Paisley, UK) and samples stored at -80°C until use.  
 
2.11 cDNA Preparation 
For quantitative gene expression analysis, cDNA was prepared from total RNA 
using the Multiscribe Reverse Transcriptase kit (Life Technologies, Paisley, 
UK).   
Each reaction contained 200-400ng of total RNA. Constituents of the 
Multiscribe mix were added as follows: 1x reverse transcription buffer, 5.5 mM 
MgCl2, 0.5 mM of each dNTP, 2.5 μM random hexamers, 0.4 U/μL RNase 
inhibitor enzyme, 1.25 U/μL Multiscribe Reverse Transcriptase. A final total 
volume of 20μL was achieved with addition of nuclease-free water.  
Samples were then placed on a thermal cycler (Thermo) adhering to the 
following protocol:  
- 10 min at 25°C to allow for annealing of random primers 
- 30 min at 48°C for reverse transcription 
- 5 min at 95°C to inactivate the reverse transcriptase 
Samples were then stored at -20°C until required. 
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Quantitative real time polymerase chain reaction (qRT PCR) was performed 
using SYBR green (Life Technologies) and custom PCR primers (Eurofins 
MWG, Ebersberg, Germany) or Taqman Master Mix™ (Applied Biosystems) 
with Taqman probes (primer and probe sequences. Ubiquitin C (UBC) was 
used as housekeeping gene for normalisation. Relative quantifications were 
calculated by using the 2-ΔΔCT method (211). When ‘undetermined’, a cycle 
threshold of 40 was used arbitrarily.   
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2.12 Real-time Quantitative PCR 
For novel lncRNAs quantitative real time polymerase chain reaction (qRT 
PCR) was performed using SYBR green (Life Technologies) and custom PCR 
primers (Eurofins MWG, Ebersberg, Germany) or Taqman Master Mix™ 
(Applied Biosystems) with Taqman probes for known protein targets (primer 
and probe sequences Table 2-6 + Table 2-7). Ubiquitin C (UBC) was used as 
housekeeping gene for normalisation. Relative quantifications were calculated 
by using the 2-ΔΔCT method (211). When ‘undetermined’, a cycle threshold 
of 40 was used arbitrarily.   
 
2.12.1 SYBR 
Primers were designed to span intron-exon boundaries when possible, and 
were reconstituted and used at [100μM], stored at -20ºC. SYBR green dye in 
the PCR mixture fluoresces when it binds to double stranded DNA, which is 
formed by annealing of the primer to any available transcript in the mixture. 
The level of fluorescence detected is therefore proportional to the quantity of 
the target.  
cDNA 2.5μl was added to a standard PCR mastermix as follows: 
- Power SYBR Green master mix - 5 μL 
- Nuclease-free H2O - 4.9 μL 
- Forward (fw) and reverse (rv) SYBR green primers - 0.05 μL each (at [100 
μM])  
All reactions incorporated housekeeping control genes, to compare relative 
expression between samples. A non-template control with no cDNA was also 
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tested, when there should be no fluorescence. All samples were performed in 
triplicate, or duplicate when sample quantities were less plentiful. Once 
pipetted, qPCR plates were centrifuged briefly to ensure all mixture was sent 
to the bottom of the well. Samples were analysed on the Quantstudio 7 or 
Quantstudio 12 real time PCR system with the following protocol: 
- 10 min at 95°C before undergoing  
- 40 cycles of denaturing at 95°C for 15 s 
- 60 s at 60°C for primer annealing and primer extension 
 
Primer sequences are listed below (Table 2-6). 
 
Table 2-6: SYBR Primer sequences 


























Standard curves with serial dilutions were performed to assess the optimum 
concentration of cDNA per reaction, at a given concentration of primer (10μM). 
Amplification of samples at 20ng/uL and 4ng/uL would be adequate, yielding 
CT values within the desired range (20-30). My usual input of 400 ng of total 
RNA into a final reaction of volume 40 µL means 10 ng/ µL, would yield a CT 





Figure 2-1: Standard curves for SYBR primers: RNA input 
Amplification of samples at 20ng/uL and 4ng/uL would be adequate, yielding CT values 
within the desired range (20-30) 
 
To determine the optimum concentration of primer, standard curves 
were produced, indicating that the standard concentration of 10uM 
would allow detection of the target in the desirable range, without 






Figure 2-2: Standard curves for SYBR primers: Primer concentration 




TaqMan® qRT-PCR was performed using TaqMan® Gene Expression assays 
and TaqMan® Universal Master Mix II (both Thermo Fisher). TaqMan® qRT-
PCR assays are labelled with a 5’ fluorescent reporter dye (FAM) and 
quencher molecule at the 3’ end. When the TaqMan® probe is intact, 
fluorescence released from the 5’ dye is transferred to the 3’ quencher 
molecule 88 by a phenomenon known as fluorescence resonance energy 
transfer (FRET). During the amplification process, if the target sequence is 
present in the sample, the probe anneals and the quencher is cleaved via the 
action of Taq DNA polymerase – present in the reaction mixture. The Taq 
polymerase enzyme contains a 5’ nuclease domain, which allows degradation 
of DNA bound to the target, downstream of DNA synthesis. This results in the 
degradation of the TaqMan® probe, and cleavage of the 3’ quencher molecule, 
therefore preventing FRET and allowing for the detection of the reporter 
fluorophores. The strength of the fluorescence is increased with each 
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amplification cycle and is relative to the amount of a specific mRNA within a 
sample.  
Reactions were performed in 384-well plates using the following mixture: 
- 1 x Taqman® assay (5 μL) 
- 1 x TaqMan® master mix (0.5 μL)  
- 1.5 μL cDNA 
- 3 μL nuclease free H2O – total reaction volume of 10 μL.  
As per SYBR qPCR, samples were pipetted in triplicate where possible, and 
reactions performed using the the Quantstudio 7 or Quantstudio 12 real time 
PCR system with the following protocol: 
- 10 min at 95°C  
- 40 cycles at 95°C for 15 seconds 
- 60 seconds at 60°C 
 
Table 2-7: Taqman probes 








2.13 Cellular Fractionation for LINC01272 Localisation 
Fractionation of monocytes and macrophages was carried out using the 
Ambion PARIS kit (Thermo Fisher, UK), as per the manufacturer’s guidelines. 
Cells were initially treated with cell fractionation buffer, resulting in a nuclear 
and cytoplasmic fraction. Nuclear material was further subjected to cell 
disruption buffer, and then both fractions processed for RNA isolation using a 
column purification method.  
 
2.14 Cloning and in vitro translation 
Open reading frame sequences from PELATON and LINC00948 were 
incorporated into pcDNA 3.1 (+) vectors (Geneart, Thermo Fisher), with Kozak 
sequence upstream, and haemagglutinin (HA) tag downstream, and flanking 
restriction enzyme sites (Supplementary Material – Table 3). Translation 
potential was assessed using the PURExpress In Vitro Protein Synthesis Kit 
(New England Biolabs, Massachusetts, US). 
Table 2-8: Open reading frame sequences. 
Both genes were flanked with restriction enzyme digestion sites, Kozak sequence, appended 
with HA tag, and inserted into pcDNA 3.1 (+) vectors. 















2.15 Western Blot 
Protein lysates were prepared in Novex™ Tricine sodium dodecylsulfate 
(SDS) sample buffer, (Thermo Fisher Scientific, Massachusetts, USA) and 
Dithiothreitol (DTT), incubated at 85°C, centrifuged briefly, and loaded onto a 
Novex™ 10-20% Tris-Glycine Mini Gel, alongside a the Spectra™ low range 
multicolour protein ladder (1.7 – 40 kDa range). Electrophoresis was 
performed at 120V, 300A, for 1 hour, in Novex™ Tris-Glycine SDS Running 
Buffer. Membrane transfer was carried out in a Mini Blot transfer module at 
20V, 300A for 1 hour in Novex™ Tris-Glycine Transfer Buffer. Membranes 
were incubated overnight at 4°C with anti HA-tag (Abcam, ab9110, 1/1000). 
After washing, membranes were incubated with the appropriate Licor IRDye® 
680 secondary antibody (1:10,000) at room temperature for 1 hour. Following 
additional washing, protein levels were visualised via Licor.  
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2.16 High content analysis 
For all screening high content assays primary human monocytes were seeded 
at a density of 75-100,000 cells per well in Corning Falcon 96-Well Imaging 
Microplates (Fisher Scientific), from 3 biological donors. In the initial high 
content analysis, 7-day differentiation into macrophages was performed and 
cells were then transfected with LNA GapmeR targeting LINC01272, as 
described above. Functional assays were then carried out and are described 
below. In each case Hoechst nuclear staining was used to identify nuclei, and 
images were acquired using BD Pathway 855 High Content Bioimager (BD 
Biosciences, California, USA). Nine images were taken of each individual well. 
Using Attovision software, stitched images were corrected for background 
variations and Attovision cell segmentation (Polygon based on Hoechst signal) 
was carried out using appropriate threshold, watershed and object size in- and 
exclusion criteria. Data was further analysed using DIVA software (BD 
Biosciences) to enable quantification of output parameters. 
 
Apoptosis of macrophages was first assessed at 24 hours post-transfection 
(baseline) and after a further 24 hours treatment with 300nM staurosporine 
(Sigma, Dorset, UK) for chemical induction of apoptosis. Apoptosis was 
detected by binding of Annexin-V-OG (locally prepared, courtesy of C. 
Reutelingsperger, MUMC) at 2.5ng/ml, incubated for 15 minutes at 37°C in 
binding buffer. Images were acquired and apoptotic cells expressed as a 
proportion of total cells.  
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Phagocytosis was assessed by incubation with pHrodo™ Red Zymosan 
Bioparticles™ (Life Technologies) at 5μL in 150μL per well for 1 hour. Cells 
shown to have positive uptake of the particles were considered positive, and 
expressed as a percentage of total cells in each well. For validation 
experiments the same protocol was used, but images acquired with the 
Operetta High-Content Imaging System (Perkin-Elmer, Ohio, USA) and image 
analysis was performed using Columbus (Perkin-Elmer, Ohio, USA) software. 
Image analysis produced an image that pseudo labelled cells positive (green) 
and negative (red) for bead uptake to allow for clear visual representation. 
 
Lipid uptake was assessed by incubation with a mixture of 0.8μg oxidised 
LDL (derived locally) and 0.2μg Topfluor (Avanti Polar Lipids, Alabama, US) 
for 3 hours. Cells with uptake of Topfluor and oxLDL were expressed as a 
percentage of total cells in each well.  
 
Mitochondrial stress was induced using 1.2µM staurosporin for 2 hours. 
Mitotracker mitochondrial stain (Thermo Fisher, UK) was then added at 
250nM, and cells incubated for 30 minutes. Reduced mitochondrial membrane 
potentials result in less uptake of Mitotracker and so a lower signal intensity. 
Relative average intensity was compared between wells.  
 
Reactive Oxygen Species (ROS) production was stimulated using 10µM 
menadion (Sigma, Dorset, UK) for 30 min, and ROS were detected with 20µM 
DCFDA (Invitrogen, California, USA). ROS positive cells were expressed as a 
percentage of total cells per well. 
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2.17 Operetta High Content Analysis 
Primary human monocytes were seeded at a density of 75-100,000 cells per 
well in Corning Falcon 96-Well Imaging Microplates (Fisher Scientific), N=3 
biological replicates, 4-5 wells per condition, 9 images per well acquired.  
Columbus software was used to analyse the fluorescence based assays, in a 
similar manner to previous. Populations of cells were identified by nuclear 
Hoechst stain, and subsequently the cytoplasm was identified surrounding 
each nucleus by autofluorescence. ‘Spots’ or areas of TRITC intensity 
identified in each cell were identified, and intensity <100 excluded. The number 
of spot positive cells were then calculated. 
 
2.18 Efferocytosis Assay 
Monocytes were differentiated to macrophages and transfected with LNA 
GapmeR as described previously. Jurkat T cells (JC) (ATCC), were induced 
to undergo apoptosis by incubation with 20nM Staurosporine for 1.5hrs at 
37°C, then labelled with Calcein (ThermoFisher). The macrophages were 
incubated with the JC for 1 hour with and washed thoroughly. Macrophages 
were then detached on ice with 0.05% EDTA in phosphate buffered saline, and 
run on an Attune NxT Flow Cytometer to quantify the percentage of cells which 
have taken up the Calcein labelled JC (FITC+ cells) with analysis performed 





2.19 In-situ Hybridisation + Immunohistochemistry 
For in-situ hybridisation (ISH), formalin-fixed, paraffin embedded tissue 
sections were firstly deparaffinised and rehydrated by washing in Xylene for 5 
min, followed by sequential washes in 100%, 96% and 70% ethanol 
respectively, for 5 min each, then washed in water, followed by PBS for 5 min. 
The miRNA buffer set (Qiagen, 339450) was then used, providing proteinase 
K for tissue digestion (incubated 1:1000 at 37°C for 4 min) and hybridisation 
buffer which was used to dilute the ISH probes (Supplementary Material – 
Table 5) to 25nM. The ISH probes were incubated on the sections overnight 
at 55°C, sealed using coverslips and rubber glue to prevent drying out.  The 
sections were washed with 5X saline-sodium citrate buffer (SSC) at 55°C and 
room temperature to increase hybridisation specificity. Subsequently, the 
sections were washed with PBS, and incubated for 1hr with Digoxigenin wash 
and block buffer set (Roche, 11585762001), which was subsequently used to 
dilute anti-Digoxigenin-AP (Roche, 11093274910) at 1:500 and left for 1hr at 
room temperature. After washing with TBS-T, NBT/BCIP AP tablets 
(Roche, 11697471001) were used for detection to visualise probe in the 
presence of levamisole to reduce background staining (Vector laboratories, 
Peterborough, UK). Detection occurred at approximately 3 hours. For 
immunohistochemistry co-staining, slides were incubated in 0.3% hydrogen 
peroxide for 15 minutes, washed with TBS-T 0.1% BSA, before incubation in 
5% goat serum for 1 hour. Antibodies were then added (Supplementary 
Material – Table 6) for 30 minutes, before washes with TBS, and incubation 
with anti-mouse-HRP Brightvision (Immunologic, Netherlands) for 30 minutes. 
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After TBS washes, Polydetector HRP green kit (Bio SB, California, USA), 1 
drop in 2ml was added to tissues and allowed to develop for 3 minutes. After 
rinsing with water, tissues were counterstained with nuclear fast red (Sigma 
Aldrich), before further washing. Rehydration was done with sequential 
washes of 70%, 96% and 100% ethanol respectively, followed by xylene and 
mounting with Pertex. 
 
Table 2-9: In-situ hybridisation probes 
Probe ID Sequence 
Scramble control GTGTAACACGTCTATACGCCCA 
PELATON TTATTCTCCAAGCAACAGAGAT 
 
Table 2-10: Immunohistochemistry probes 
Antibody Supplier Concentration Dilution 
CD68 Dako 185mg/L 1:500 
SMA Dako 71mg/L 1:8000 
IgG Invitrogen 3000mg/L 1:4000 
2.20 RNA-Fluorescent In-Situ Hybridisation (RNA-FISH) 
Custom RNA-FISH probe sets were generated to the full sequence of 
PELATON (Thermo Fisher Scientific). Monocytes were differentiated to 
macrophages as previously described, grown on 16-mm coverslips for one 
week, before being washed in PBS and fixed in 4% paraformaldehyde. RNA-
FISH was performed according to manufacturer’s instructions (ViewRNA™ 
cell FISH, ThermoFisher Scientific). Briefly, the coverslips were permeabilised 
using detergent QS and digested in protease solution at 1:4000, then 
incubated with a probe sets at 1:100 (PELATON, SNORD3 (small nucleolar 
RNA, C/D box 3A) and UBC). The coverslips were then subsequently 
incubated with pre amplifier, and amplifier, before finally being incubated with 
the label probe, which provides the fluorescent signal. Coverslips were then 
mounted onto glass slides using Prolong Gold Antifade Mounting Medium with 
DAPI (Vector Laboratories).  
 
2.21 Microscopy 
An Axioscan slidescanner (ZEISS) was used to image both in situ and 
immunofluorescence, using Zen software (ZEISS). All settings for the 
Axioscan and software were optimised and then maintained for each set of 
experiments, so that sections can be compared accurately. RNA-FISH was 
imaged using the Andor Revolution XDi spinning disk confocal microscope. 
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2.22 Pseudo Fluorescent Image Analysis  
Bright field images for PELATON (Purple in-situ staining) and CD68/aSMA 
(green immunohistochemistry staining) in human plaque were converted into 
pseudo fluorescent images using Image J Software. Images were opened in 
Image J, and the colour deconvolution tool used, selecting regions of interest 
for each stain (Purple in situ staining, green immunohistochemistry staining, 
and pink nuclear red counterstain), generating RGB values for each colour, 
and splitting the images into these components. The RGB values generated 
for each colour were kept consistent for further analysis across all samples. 
Once the images were split into the 3 colours, the nuclear stain was 
discounted, so that the in-situ and immunohistochemistry staining could be 
seen clearly. These were then inverted, and given pseudo colours of red and 
green respectively, and the resulting images merged to create a dual 
fluorescent image.  
 
 
2.23 Statistical analysis 
Statistical analyses in chapters 4 and 5 were performed according to figure 
legends using Graphpad Prism version 8.0. Data are expressed as mean ± 
standard deviation. Normality of data was assessed using the Shapiro-Wilks 
test. Statistical difference between 2 groups was assessed using 2-tailed 
unpaired or paired t-test for parametric data and Mann-Whitney or Wilcoxon 
matched pairs signed rank tests for non-paired and paired non-parametric data 
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respectively. One-way ANOVA ± multiple comparisons was used for ≥ 3 
groups. Post-hoc testing with Dunnett’s test has been performed as 
appropriate. Statistical significance is indicated when p value of less than 0.05 
(p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=****).  
 
2.24 RNA Sequencing Analysis 
For sample and library preparation see GEO database: GSE120521. Data was 
analysed using RSEM and DESeq2 packages to derive FPKM, fold change, 
and p-values, with thanks to Dr Julie Rodor (senior scientist) for bioinformatic 
support in conducting this analysis, and production of some figures. Filtering 
was performed using Microsoft Excel for Mac, version 16.  
 
 
 Results – Performance of the GRACE 
2.0 score in patients with type 1 and 
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3.1 Introduction  
Coronary heart disease is responsible for around 2 million deaths across 
Europe every year (212). To improve prognostication and promote consistency 
in the investigation and management of patients with acute coronary 
syndrome, the Global Registry of Acute Coronary Events (GRACE) score was 
developed (213-216). The score applies clinical variables, the 
electrocardiogram, and cardiac biomarkers to estimate risk of future all-cause 
mortality and myocardial infarction. The use of the GRACE 2.0 score in 
patients with non-ST-segment elevation acute coronary syndrome has a class 
Ia recommendation for guiding prognosis and IIa recommendation for guiding 
management across all international guidelines (217-219).  
Since the introduction of the GRACE score, there have been significant 
changes in the way we diagnose myocardial infarction, driven by major 
improvements in the sensitivity of cardiac troponin. The Fourth Universal 
Definition of Myocardial Infarction recommends the use of high-sensitivity 
cardiac troponin (hs-cTn) assays and a sex- specific 99th centile diagnostic 
threshold for myocardial injury and infarction (74). These assays have the 
ability to quantify myocardial injury at a threshold 10-fold lower than was in use 
at the time of the original GRACE study. This increase in diagnostic sensitivity 
has led to an understanding that myocardial infarction can occur in a number 
of different clinical settings (73, 220, 221).  
The Fourth Universal Definition recognises that myocardial infarction may 
occur due to atheromatous plaque rupture and thrombosis (type 1 myocardial 
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infarction), or secondary to an imbalance in myocardial oxygen supply or 
demand without coronary atherothrombosis (type 2 myocardial infarction) (74). 
Patients with type 2 myocardial infarction are older, more often have 
comorbidities and are at higher risk of adverse outcomes with as few as 30% 
of patients alive at 5 years (75). Despite a significant increase in the risk of 
non- cardiovascular death, patients with type 2 myocardial infarction appear to 
have a similar risk of future cardiovascular events as those with type 1 
myocardial infarction (222). To date, there are no validated prognostic tools to 
estimate all-cause mortality or future cardiovascular events in this population. 
Our aim was to evaluate the performance of the GRACE 2.0 score for the 
prediction of all-cause death in patients with type 1 and type 2 myocardial 
infarction.  
 
3.2 Methods  
We assessed the performance of the GRACE 2.0 score in two cohorts of 
consecutive patients presenting to the Emergency Department with suspected 
acute coronary syndrome in Scotland and in Sweden (see full description in 
Chapter 2.2.1). In brief, the Scottish cohort was derived from the High-
STEACS study, which included patients with suspected ACS from 10 hospitals 
across Scotland between June 2013 and March 2016.  The Swedish cohort 
comprised patients presenting to Karolinska University Hospital, Stockholm 
with chest pain and at least one hs-cTn measurement from January 2011 to 
October 2014 (209, 210).  
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All diagnoses were adjudicated in accordance with the Fourth Universal 
Definition of Myocardial Infarction (74), (see Chapter 2.2.2 for full details). In 
both cohorts two physicians independently reviewed all clinical information 
with discordant diagnoses resolved by a third reviewer (Scotland) or by 
consensus discussion (Sweden).  
The primary outcome was all-cause death at 1 year, and the secondary 
outcome was all-cause death or type 1 myocardial infarction at 1 year. All in-
hospital and community deaths are recorded on the National General Register 
of Scotland, and the Swedish Patient Register. Subsequent myocardial 
infarction events were identified through the electronic patient record in 
Scotland with adjudication as for the index diagnosis and using ICD-10 coding 
(I21 and I22) from the Swedish Patient Register in the Swedish cohort.  
We determined the GRACE 2.0 score for all-cause death, and for all-cause 
death or type 1 myocardial infarction at 1 year. We assessed overall GRACE 
2.0 model discrimination by determining the area under the receiver operating 
curve (AUC) and compared performance in patients with type 1 and type 2 
myocardial infarction using the DeLong method. We assessed model 
calibration both graphically, and by using the Hosmer–Lemeshow goodness 
of fit test. In addition, we assessed GRACE performance by evaluating 
previously defined categories of mortality risk (<3% low, >_3 and <_8% 
intermediate and >8% high risk) using the Kaplan–Meier method (see Chapter 






The Scottish cohort consisted of 48 282 consecutive patients (61 ± 17 years, 
47% women) with suspected acute coronary syndrome of whom 10 360 (21%) 
had hs-cTnI concentrations above the 99th centile. It was possible to 
adjudicate the diagnosis in 88% (9115/10 360) of patients. The final diagnosis 
was type 1 myocardial infarction in 55% (4981/9115), type 2 myocardial 
infarction in 12% (1121/ 9115), and acute or chronic myocardial injury in 18% 
(1676/9115) and 14% (1287/9115), respectively. The remainder of patients 
had type 4a (9/9115) or 4b (41/9115) myocardial infarction. 
The Swedish cohort consisted of 22 589 consecutive patients with suspected 
acute coronary syndrome of whom 3853 (17%) patients had hs-cTnT 
concentrations above the 99th centile. The final diagnosis was type 1 
myocardial infarction in 28% (1080/3853) of patients, and type 2 myocardial 
infarction in 6% (247/3853), with acute or chronic myocardial injury in 30% 




Compared to patients with a diagnosis of type 1 myocardial infarction, those 
with type 2 myocardial infarction were older (74 ± 14 vs.68 ± 14 years), more 
likely to be women (55% vs. 40%), and more likely to have a history of 
cardiovascular disease. Similar differences were apparent in both cohorts 
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(Table 3-1). Patients with type 2 myocardial infarction were less likely to be 
offered coronary angiography, revascularization or secondary prevention than 
those with type 1 myocardial infarction (Table 3-2). There were differences in 
the covariates which influence the GRACE 2.0 score between groups, with 
higher heart rates (101 vs. 77 b.p.m.), lower systolic blood pressures (130 vs. 
141 mmHg) and a higher proportion of patients with increased Killip class 
observed in those with type 2 myocardial infarction (Table 3-3).  
 
Table 3-1: Characteristics of the Scottish and Swedish cohorts of patients diagnosed with type 1 and type 2 myocardial infarction 
 Scottish cohort  Swedish cohort 
 All patients Type 1 myocardial infarction 
Type 2 myocardial 
infarction  
All patients Type 1 myocardial 
infarction 
Type 2 myocardial 
infarction 
No. of participants 48,282 4,981 1,121 22,589 1,080 247 
Age (years), mean (SD) 61 (17) 68 (14) 74 (14) 56 (17) 69 (13) 72 (13) 
Men, n (%) 25,720 (53) 2,995 (60) 501 (45) 11,817 (52) 743 (69) 122 (49) 
Past medical history       
  Myocardial infarction, n (%) 4,214 (9) 667 (13) 163 (15) 1,885 (8) 184 (17) 47 (19) 
  Ischemic heart disease, n (%) 11,912 (25) 1,519 (30)a 454 (40) 2,570 (11)b - - 
  Cerebrovascular disease, n (%) 2,949 (6) 368 (7) 135 (12) 940 (4) 66 (6) 20 (8) 
  Diabetes mellitus, n (%) 3,518 (7) 802 (16) 147 (13) 2,191 (10) 204 (19) 54 (22) 
  Heart failure hospitalisation, n (%) 4,322 (9) 792 (16) 292 (26) 1,244 (6) 86 (8) 40 (16) 
Previous revascularisation       
  Previous PCI or CABG, n (%) 4,464 (9) 592 (12) 129 (12) 1,979 (9) 210 (19) 53 (22) 
Medications at presentation       
  Aspirin, n (%) 13,163 (27) 1,694 (34) 471 (42) 4,258 (19) 414 (38) 101 (41) 
  Statin, n (%) 19,366 (40) 2,377 (48) 632 (56) 4,265 (19) 362 (34) 86 (35) 
  ACE inhibitor or ARB, n (%) 15,618 (32) 1,995 (40) 514 (46) 5,547 (25) 456 (42) 130 (53) 
  Beta-blocker, n (%) 13,173 (27) 1,598 (32) 489 (44) 5,508 (24) 441 (41) 140 (57) 
  Oral anti-coagulant, n (%) 3,253 (7) 292 (6) 170 (15) - - - 
Electrocardiogramc       
  Myocardial ischemia - 1,872 (38) 383 (34) - 281 (26) 67 (27) 
Physiological parametersd       
  Heart rate, beats per minute - 79 (20) 105 (35) - 76 (17) 94 (31) 
  Systolic blood pressure, mmHg - 142 (28) 132 (30) - 153 (28) 142 (34) 
Hematology and clinical chemistry       





  eGFR, ml/min 54 (13) 51 (14) 46 (15) 88 (23) 74 (23) 66 (25) 
  Peak hs-cTnI, ng/L 4 [2, 16] 855 [104, 6775] 125 [48, 604] - - - 
  Peak hs-cTnT, ng/L - - - - 182 [49, 616] 77 [32, 173] 
 
eGFR calculated according to the MDRD equation (mL/min). 
aDefined as prior angina, myocardial infarction, or revascularization. 
bDefined as prior myocardial infarction or revascularization. 
c,dElectrocardiogram findings and physiological parameters provided for patients with myocardial infarction only. 
 
 
Table 3-2: Rates of angiography, revascularisation and prescription for medical therapy on discharge in the Scottish and Swedish cohorts 
 Scottish cohort Swedish cohort 
 
Type 1 myocardial 
infarction 
(n=4,981) 
Type 2 myocardial 
infarction 
(n=1,121) 
Type 1 myocardial 
infarction 
(n=1,064) 




Angiography† 3,083 (62) 123 (11) - - 
PCI or CABG† 2,217 (45) 24 (2) 543 (51) 7 (3) 
Aspirin 3,934 (79) 588 (52) 918 (86) 101 (44) 
P2Y12 inhibitor 3,544 (71) 319 (28) 871 (82) 26 (11) 
ACE or ARB 3,572 (72) 618 (55) 725 (68) 118 (52) 
Beta-blocker 3,476 (70) 708 (63) 169 (74) 946 (89) 
Statin therapy 4,141 (83) 700 (62) 883 (83) 92 (40) 
     
Information from the Swedish cohort available in 99% (1064/1080) with type 1 and 92% (228/247) with type 2 myocardial infarction. 
Values are number (%). † Angiography and revascularisation within 30 days of presentation. 




Table 3-3: Components of the GRACE 2.0 risk score in patients with type 1 and type 2 
myocardial infarction 
 Type 1 myocardial infarction Type 2 myocardial infarction 
 Scottish 
cohort  
Swedish cohort  Scottish cohort Swedish 
cohort 
Age 68 (14) 69 (13) 74 (14) 72 (13) 
Heart rate (bpm) 77 [65-92] 73 [64-84] 101 [81-125] 89 [72-109] 
Systolic blood pressure 
(mmHg) 
141 [123-160] 152 [135-170] 130 [111-150] 140 [120-160] 
Creatinine 0.93 [0.80-
1.19] 
0.93 [0.79-1.13] 1.05 [0.82-1.39] 0.98 [0.78-
1.27] 
Killip class (%) 


















Cardiac arrest (%) 278 (5.6) 8 (0.1) 30 (2.7) 1 (0.4) 
Troponin >99th centile at 
presentation (%) 
4,092 (82.2) 929 (86.0) 881 (78.6) 199 (80.6) 
ECG ischaemia (%) 1,627 (32.7) 281 (26.0) 311 (27.7) 67 (27.1) 
STEMI (%) 915 (18.4) 0 (0) 5 (0.5) 0 (0) 
GRACE 2.0 risk of death 
at 1 year, % 
4.9% 
[2.3 - 11.7%] 
3.8% 
[1.9 - 8.2%] 
11.2% 
[5.4 - 22.1%] 
7.7% 
[3.5 - 19.9%] 
GRACE 2.0 risk of death 
or MI at 1 year, % 
9.4% 
[5.6 - 18.2%] 
7.7% 
[4.9 - 14.0%] 
17.8% 
[10.2 - 29%] 
13.3% 
[7.4 - 25.9%] 
 
Values are Mean (SD) or Median [IQR].
GRACE risk score and prediction of death at 1 year 
We obtained follow-up in 100% of participants for primary and secondary 
outcomes at 1 year. In patients with type 1 myocardial infarction, 15% 
(720/4981) and 10% (112/1080) died from any cause at 1 year in the Scottish 
and Swedish cohorts, respectively. The GRACE 2.0 score was higher in those 
with type 2 compared to type 1 myocardial infarction across both cohorts 
(Table 3-3) and had good discriminative ability with an AUC of 0.83 [95% 
confidence interval (CI) 0.82–0.85] and 0.85 (95% CI 0.81–0.89), respectively 
(Figure 3-1). 
In patients with type 2 myocardial infarction 23% (258/1121) and 23% (57/247) 
died from any cause at 1 year in the Scottish and Swedish cohorts 
respectively. The GRACE 2.0 score had moderate discriminative ability, with 
an AUC of 0.73 (95% CI 0.70–0.77) and 0.73 (95% CI 0.66–0.81), respectively, 
and performed less well than in patients with type 1 myocardial infarction 
(DeLong test p<0.001 and p<0.008 vs type 1 myocardial infarction in Scottish 
and Swedish cohorts respectively (Figure 3-1) .  
Similar performance was observed in men and women with type 1 and type 2 
myocardial infarction in both cohorts (Appendix, Table 7-3). Calibration plots 
and the Hosmer–Lemeshow test indicated the GRACE 2.0 score 
underestimated future all-cause death across all deciles of risk in both type 1 
and type 2 myocardial infarction (Figure 3-2, Appendix Table 7-2). 
 
Figure 3-1: Receiver-operator-curve for GRACE 2.0 score.  







Figure 3-2: Calibration plot.  
Observed versus predicted all-cause mortality in type 1 and type 2 myocardial infarction according to the GRACE 2.0 score in the Scottish cohort
GRACE risk categories 
In the Scottish cohort, we evaluated conventional GRACE categories of low, 
intermediate, and high predicted risk of mortality. Observed event rates were 
higher in patients with type 2 myocardial infarction who had a low or 
intermediate predicted risk of death (Figure 3-3). Baseline demographic 
information was similar across all categories of risk irrespective of the 
diagnosis of type 1 and type 2 myocardial infarction (Appendix Table 7-4). In 
patients with type 2 myocardial infarction in the Scottish cohort at low risk of 
death, there were fewer new prescriptions for aspirin (25% vs. 67%), statin 
(11% vs. 56%), angiotensin-converting enzyme inhibitor or angiotensin II 
receptor blocker (15% vs. 49%) compared to those with type 1 myocardial 
infarction. Similar patterns were observed in patients at intermediate or high 
risk of death. 
GRACE score and prediction of death or myocardial infarction 
In patients with type 1 myocardial infarction, a total of 22% (1075/4981) and 
16% (173/1080) of patients died or had a myocardial infarction at 1 year in the 
Scottish and Swedish cohorts, respectively. The AUC for the GRACE 2.0 
model incorporating death or future myocardial infarction was 0.76 (95% CI 
0.74–0.77) and 0.81 (95% CI . 0.77–0.85), respectively. 
In patients with type 2 myocardial infarction, there were 27% (297/1121) and 
26% (63/247) deaths or myocardial infarctions at 1 year. Here, the GRACE 2.0 





0.80), respectively (P = 0.007 and P = 0.042 vs. type 1 myocardial infarction). 
Calibration plots showed the GRACE 2.0 model underestimated future risk in 
type 1 and type 2 myocardial infarction in both cohorts. (Appendix Figure 7-1). 
 
Post hoc analysis 
In a post hoc analysis, the GRACE 2.0 score had better discrimination for in-
hospital death in patients with type 1 compared to type 2 myocardial infarction, 
where performance was moderate (Appendix Table 7-5). When applied as a 
continuous variable, both hs-cTnI and hs-cTnT were moderate predictors of 
all-cause death at 1 year (Appendix, Table 7-6) 
 
3.4 Discussion 
We evaluated the performance of the GRACE 2.0 score for the prediction of 
all-cause death, and all-cause death or myocardial infarction in consecutive 
patients with type 1 and type 2 myocardial infarction from two independent 
cohorts across two countries. We observe that the GRACE 2.0 score provides 
good discrimination for all-cause death in patients with type 1 myocardial 
infarction diagnosed using hs-cTn assays and for both cardiac troponin I and 
T. Consistent with the original validation study (215), discrimination for all-
cause death was better than for death or myocardial infarction. In patients with 
type 2 myocardial infarction, the GRACE 2.0 score provided moderate 
discrimination in the prediction of all-cause death and performed less well in 





score performed better in patients with type 1 myocardial infarction, there may 
be opportunities to develop a bespoke model for risk prediction in patients with 
type 2 myocardial infarction. 
The GRACE 2.0 score was derived prior to the publication of the first Universal 
Definition of Myocardial Infarction (71), which introduced a classification based 
on the underlying mechanism. Whilst type 1 myocardial infarction is caused 
exclusively by atherosclerotic plaque rupture and thrombotic coronary artery 
occlusion, type 2 myocardial infarction is a heterogeneous condition, occurring 
due to an imbalance in myocardial oxygen supply or an unmet need in 
myocardial oxygen demand in the context of another acute illness. A type 2 
myocardial infarction may occur due to coronary pathology such as 
vasospasm, spontaneous dissection or coronary embolism, or with bystander 
stable coronary artery disease or normal coronary arteries in the context of 
tachyarrhythmia, severe hypoxia or hypotension. Whilst we have a strong 
evidence base for treatments which reduce all-cause mortality and future 
cardiovascular events in patients with type 1 myocardial infarction, at present, 
we have no guidelines to support investigation or management of patients with 
type 2 myocardial infarction, and in these patients clinical outcomes are worse, 
with as few as 30% of patients alive at 5 years(223-228). 
We recently demonstrated future cardiovascular risk was increased in all 
patients with myocardial injury and infarction, irrespective of diagnostic 
classification, despite a vast excess in non-cardiovascular death in patients 





were at almost four-fold increased risk of cardiovascular events relative to 
those without myocardial injury. This risk appears to be highest in those with a 
history of prior coronary artery disease, suggesting underlying coronary 
atheroma may at least in part be driving future cardiovascular risk (229, 230). 
In order to identify patients with type 2 myocardial infarction who may benefit 
from further investigation and treatment, accurate risk stratification is required. 
In this analysis, we demonstrate the GRACE 2.0 score performed well in the 
prediction of all-cause mortality and future cardiovascular events in patients 
with type 1 myocardial infarction, but discrimination was lower in those with 
type 2 myocardial infarction. At the time the GRACE score was derived, the 
diagnosis of myocardial infarction was based on contemporary cardiac 
biomarkers with a diagnostic threshold at least 10-fold higher than advocated 
in current guidelines (74). The subsequent increase in sensitivity of cardiac 
troponin led to a reduction in the diagnostic threshold, and an increase in the 
recognition of myocardial injury and infarction in other conditions (222). A 
number of studies indicate a phenotypic distinction between patients with type 
1 and type 2 myocardial infarction(222-229, 231) Those with type 2 myocardial 
infarction are older, more often female, with lower haemoglobin and 
impairment in renal function. The GRACE 2.0 score was not derived in these 
patients, and although we found its performance to be acceptable with an AUC 
of 0.72 for all-cause death, it is perhaps not surprising it performed less well 





Some attempts have been made to derive risk stratification tools in patients 
with type 2 myocardial infarction. The TARRACO risk score was derived in 611 
patients with type 2 myocardial infarction and myocardial injury (230). This 
score applies troponin concentrations from a contemporary sensitive assay 
and the covariates age, hypertension, dyspnoea, anaemia, and the absence 
of chest pain and had moderate discrimination for future major adverse 
cardiovascular events (AUC 0.74, 95% CI 0.70–0.79). However, in a recent 
direct comparison of the GRACE, TIMI, and TARRACO scores in 359 patients 
with type 2 myocardial infarction from a single tertiary cardiac centre, only the 
GRACE score was predictive of all-cause mortality at 90days (AUC 0.70, 95% 
CI 0.63–0.77), performing better than the bespoke TARRACO score (AUC 
0.52, 95% CI 0.46–0.58) (230, 231). 
Analysis of the calibration of the GRACE 2.0 model in type 1 and type 2 
myocardial infarction identified underestimation of risk across all outcomes. 
This likely reflects differences between the population of consented patients 
recruited into the GRACE registry, and the consecutive patient cohort 
evaluated here. There are a number of potentially important comorbidities not 
included in the GRACE 2.0 score which are common in clinical practice and 
could influence survival, particularly in those with type 2 myocardial infarction. 
These include atrial fibrillation, chronic obstructive pulmonary disease, heart 
failure, malignancy, dementia, and frailty. Furthermore, as suggested in a post-
hoc analysis, incorporating troponin concentration as a continuous variable 





concentration, comorbidities or additional covariates, such as haemoglobin 
concentration, could improve model performance requires exploration. 
Given that implementation of hs-cTn assays has been shown to increase 
recognition and the prevalence of type 2 myocardial infarction, there is an 
urgent and unmet need to improve risk prediction in these patients. Until 
bespoke risk prediction tools are available for patients with type 2 myocardial 
infarction, the GRACE 2.0 score allows identification of patients at increased 
risk of death, both in-hospital and at 1 year. This may be helpful to guide 
clinicians when reviewing patients with type 2 myocardial infarction and 
deciding who may benefit from more intensive monitoring or further 
investigation for underlying coronary disease. We observed lower prescription 
rates for secondary prevention therapy in patients with type 2 myocardial 
infarction. This was most evident in those classified by GRACE as low- or 
intermediate risk, where rates of prescriptions for new anti-platelet or statin 
therapies in type 2 myocardial infarction were half those of type 1 myocardial 
infarction, and outcomes were worse. In those classified as high risk, 
prescription rates and outcomes between patients with type 1 and type 2 
myocardial infarction were similar. Whether secondary prevention therapy in 
patients with type 2 myocardial infarction will improve clinical outcomes 
requires evaluation in prospective trials (222). 
We acknowledge some limitations. Firstly, whilst the GRACE 2.0 score was 
derived and validated across 14 countries, we only evaluate performance in 





different healthcare systems using different high-sensitivity troponin assays 
and found consistent results. The consistency in results was evident despite 
differences in the original study design and in the selection of patients between 
the two healthcare sites. Second, whilst we adjudicated all diagnoses 
according to the latest Fourth Universal Definition of Myocardial Infarction 
using all available clinical information, we acknowledge that diagnostic 
misclassification is possible. In the Scottish cohort, where there was 
consensus amongst the adjudication panel that there was insufficient clinical 
information to make a definitive diagnosis because of missing admission or 
discharge letters, we did not attempt to adjudicate the diagnosis. Third, where 
information on covariates required for calculating the GRACE score was 
missing this was determined to be at random, and to minimize bias we applied 
multiple imputation. As data were missing in patients with type 1 and type 2 
myocardial infarction in equal proportion, and we observed consistent 
performance in a sensitivity analysis restricted to the dataset where complete 
case data were available, we do not think this impacted on the results 
observed. Fourth, we acknowledge that our analysis of in-hospital events was 
post hoc and is limited by a small number of events. Finally, we acknowledge 
that the rates of coronary angiography were lower here than in other registries 
or clinical trials of selected patient populations (232, 233). We enrolled all 
consecutive patients in both cohorts, where older patients with comorbidities 
managed out with the coronary care unit were included rather than excluded. 
This improves the generalisability of our findings, and whilst angiography is not 





contributed to diagnostic misclassification and influenced performance of the 
GRACE 2.0 score. 
The GRACE 2.0 score provided good discrimination for all-cause death at 1 
year in patients with type 1 myocardial infarction, and moderate discrimination 
for those with type 2 myocardial infarction. Until specific risk prediction tools 
are derived and validated, clinicians should consider applying the GRACE 2.0 




Future work to derive a bespoke risk stratification score for type 2 myocardial 
infarction may allow more accurate risk prediction, and allow clinicians to treat 
patients accordingly. At present, those in low and intermediate risk groups 
according to GRACE have worse outcomes in type 2 MI than type 1, and there 
is a marked discrepancy in the medications prescribed. Further work must 
define new parameters to better predict outcome in type 2 MI, and novel or 
adapted risk scores may incorporate known parameters such as troponin or 
frailty. Both are already known and utilised as predictors of outcome and could 
improve the predictive strength of risk-stratification scores. 
Pathways for diagnosis of type 2 MI are in their naissance, and the Fourth 
Universal Definition of Myocardial Infarction now incorporates an element of 
subjectivity when determining if there has been a supply / demand imbalance. 
Troponin and other indices of myocardial damage are not specific to ‘type’ of 
MI, whereas a biomarker that is specific to plaque rupture would enable 
discrimination from other types, and allow clinicians to employ the most 
appropriate treatment strategies. 
Treatment of type 2 myocardial infarction remains highly variable and remains 
an area where further evidence is required to determine the most appropriate 
invasive and pharmacological strategies. In many cases of type 2 MI, the most 
important intervention is to treat the underlying cause, such as in cases of 
anaemia or sepsis for example. However, the high rates of coronary artery 





quiesce and improve the coronary vasculature may yield improved outcomes. 
Further study is needed to define the profile of type 2 myocardial infarction 
patients, particularly with respect to coronary artery disease and the potential 
benefit of treatment with aspirin, statins, beta blockers and ace inhibitors. 
Further study should help to guide clinicians as to which patients should 
undergo and invasive strategy, and which would be better managed 
conservatively.  
 Results – RNA-sequencing validation 







RNA sequencing is a well-established transcriptome profiling approach which 
has been used to great effect to study the transcriptome of eukaryotic and 
prokaryotic organisms. Using high-throughput ‘next-generation sequencing’ 
(NGS) technology provides accurate, quantitative data, describing the relative 
abundance of each transcript and its isoforms in a given sample (234, 235). 
The increased depth and resolution this platform provides allows not only more 
accurate quantification than the previous ‘Sanger’ or micro-array hybridisation 
based technologies, but also allows discovery of novel transcripts, alternatively 
spliced genes, and detection of allele specific expression (236). 
Total RNA is isolated from each sample, converted into cDNA, then used to 
prepare a RNA sequencing library which involves selection of the RNA 
population of interest. Ribosomal and other small RNAs can account for more 
than 95% of the total RNA sample, hence it is important to either positively or 
negatively select out these transcripts to ensure adequate read-depth of the 
remainder of the sample, if that is where the interest lies. Polyadenylation 
selection is useful for study of mRNA, but perhaps less useful for non-coding 
RNAs when only around 16% may be polyadenylated. In this case, ribosomal 







4.1.1 RNA-sequencing of carotid artery plaque 
The starting point for novel long non-coding RNA discovery was to utilise the 
output of a previously conducted RNA-sequencing experiment from our 
laboratory in human carotid atherosclerotic plaque. Plaque samples were 
obtained from patients undergoing clinically indicated carotid endarterectomy 
for stroke or transient ischaemic attack (TIA), and dissected into ‘stable’ and 
‘unstable’ regions for comparison of RNA transcriptome by RNA-sequencing 
(238). Each patient had undergone 18F-NaF and 18F-FDG positron emission 
tomography combined with computed tomography scans to demonstrate 
plaque instability before surgery and had signs and symptoms consistent with 
a cerebrovascular event, most likely resulting from ischaemia caused by 
embolisation of plaque material to a cerebral artery. Each of the 4 patients’ 
plaques was macroscopically divided into ‘stable’ and ‘unstable’ sections, 
giving 2 groups of 4 matched samples. Patient 1 having donated a stable and 
unstable section, patient 2 the same etc (Figure 4-1). High-depth Illumina RNA 






Figure 4-1: RNA sequencing design 
Patients with stroke / TIA who had positive 18F-NaF CT/PET and underwent carotid 
endarterectomy. Plaques were dissected into stable and unstable sections, resulting in 4 
paired samples  
4.2 Aims 
 
• RNA sequencing validation 
• Analyse RNA sequencing data to shortlist interesting lncRNAs 






4.3.1 18FNaF Micro PET/CT 
Ruptured plaques typically demonstrate disruption of the fibrous cap and 
haemorrhage into the lipid core on a macroscopic level (239), features which 
had enabled dissection of the plaques into what were defined as ‘stable’ and 
‘unstable’ regions.  
To further validate this approach, fresh endarterectomy specimens were 
harvested and dissected in the same manner as before (Figure 4-2) and 
subjected to 18FNaF Micro PET/CT imaging (Figure 4-3). 
 
 





Atherosclerotic plaque specimens harvested at carotid endarterectomy were dissected into 
‘stable’ and ‘unstable’ regions. ‘Unstable’ regions are characterised by disruption of the 
fibrous cap, and intraplaque haemorrhage. The surrounded relatively healthy areas were 
considered ‘stable’. 
 
Unstable plaques are easily identified by the constellation of luminal 
encroachment of the plaque with evidence of fibrous cap disruption and red 
discolouration resulting from intraplaque haemorrhage. Although adjacent 
areas cannot be described as truly “healthy”, in relative terms these areas are 
best described as ‘stable’ plaque. 
Imaging with PET/CT and the tracer 18F-NaF has been shown to identify and 
localise high risk and ruptured plaques in patients with carotid and coronary 
atherosclerosis (240-242). When used in ex vivo specimens on a microscopic 
level, it can also accurately detect areas of active calcification (243).  
Images of plaques excised as described above demonstrate that 18F-NaF 
uptake it observed at sites of active calcification, in what would be determined 
as the unstable regions. There was no tracer uptake observed in ‘stable’ 
regions.  
This additional ex vivo validation step confirms that the macroscopic method 
used previously to generate phenotypically distinct groups of samples is likely 










(A) Positive 18F NaF CT/PET scan in patient with stroke, white arrow: high fluoride uptake in right common carotid artery. Plaque tissue excised 
during carotid endarterectomy (B) divided macroscopically into unstable and stable regions. Ex-vivo micro CT/PET demonstrates calcification in 








Figure 4-3: Micro CT/PET of human atherosclerotic plaque. 
 
4.3.2 Bioinformatic validation 
Before in-depth analysis of the RNA-sequencing data is undertaken it is 
possible to demonstrate similarities and differences in the clustering of genes 
from each patient sample using principle component analysis.  
Visualisation of data generated from RNA-sequencing is complex, because 
typically multiple levels of data are yielded from multiple patient samples, 
resulting in multi-dimensional results. In this case, there are 4 patients in each 
group, and each patient sample will result in quantification of thousands of 
RNA species. Broadly speaking, each sample should contain approximately 
the same number of different RNAs, but it is expected that each RNA will be 
represented in a different quantity for each sample. The precise differential 
levels of each of these species between the 2 phenotypic groups is ultimately 
what the experiment is designed to prove.  
Principal component analysis is a mathematical algorithm that reduces the 
dimensionality of the data, whilst retaining the majority of the variation within 
the dataset. This simplification is achieved by identifying a few key ‘directions’ 
within which, most of the variation of the data is contained. In-so-doing, each 
sample can be represented by relatively few numbers (rather than thousands), 
to demonstrate gross similarities between datasets from each sample (244). 
Each of these ‘principal components’ can be used to plot samples against each 
other. The output then demonstrates how each of the samples compare 








Stable plaque samples (red) and unstable plaque samples (blue) cluster together, indicating 
similarity in gene expression profiles within the groups, and differences in the principal 
components between the 2 groups of samples. Thanks to Dr Julie Rodor, senior scientist for 
contribution of this Figure. 
A stable and unstable sample from each plaque was analysed resulting in 4 
matched pairs.  The principal component analysis demonstrates clustering of 
the stable samples (red) and the unstable samples (blue). This indicates 
mathematically that the principal components (variables where most deviation 
between samples exists) identified for these samples as a whole, vary most 
between the group of stable vs unstable samples.  This result gives confidence 
that the method of dissection had at least yielded consistent results across 
plaque specimens. 





4.3.2.1 RNA sequencing analysis and filtering 
The carotid plaque RNA-seq identified a total of 58,037 genes, according the 
GRCh37 annotation of the human genome. A filtering process was then 
undertaken to first start to characterise the RNA population in the sample in 
broad terms, and second to narrow down a candidate list of long non-coding 
RNAs suitable for further study (Figure 4-5). 
The first cut-off applied was mean FPKM > 1, resulting in 18,101 remaining 
transcripts. ‘Fragments per kilobase million’ is a normalised quantification of 
gene expression commonly used in RNA-seq data which is taken to 
approximate to ‘copy number per cell’. Transcripts with a lower mean FPKM 
would be too low in quantity to allow their study, and less likely to be 
biologically important. 
Of these 18,101 transcripts which were deemed to be present in sufficient 
quantity, only those that were differentially expressed between the stable and 
unstable groups were carried forwards, resulting in 1,822 transcripts. 
Differential expression between the conditions is a key discriminator, as this 
indicates some role for the transcript, whether active or passive, in the 
pathology (or whatever phenotypic differences exist between the groups). A 
lenient log2 fold change of ≤1 or ≥1 (p<0.01) was applied to capture transcripts 
which were downregulated and upregulated respectively. For the purpose of 
this project it should be taken that the ‘stable’ condition is considered to be the 
baseline (control) and that ‘unstable’ is the disease condition. Hence if a 
transcript is deemed to be ‘upregulated’, it is expressed more highly in the 





Of the well expressed and differentially regulated genes, 1,655 (90.8%) were 
protein coding; 135 (7.4%) long non-coding; 30 (1.6%) pseudogenes; 2 
(0.001%) small RNA.  
A final filter was then applied to the long non-coding category, mean FPKM > 5, to eke out the most highly expressed 
transcripts amongst them. The principle again being that greater expression is likely to correlate with functionality. This 
resulted in 47 candidate lncRNAs. 
 
Figure 4-5: RNA seq filtering strategy.  
The complete set of genes mapped to the genome were filtered by mean FPKM and differential expression to identify well-expressed / differentially 
expressed transcripts. They were then classified by type into protein coding genes, long non-coding RNA, pseudogenes, small RNA. Highly 
expressed lncRNA mean FPKM > 5 were then shortlisted for further study.  
4.3.3 Protein coding gene analysis 
The protein-coding gene component of the well- and differentially regulated 
transcripts identified is in the majority, at 90.8%. For further validation of the 
dataset, a panel of the most dysregulated protein-coding genes was analysed 
for Gene Ontology (Go) term enrichment. The top 200 terms for upregulated 
coding genes corresponded largely with immune system processes and 
inflammation (Figure 4-6), whilst downregulated genes were involved mainly 





Figure 4-6: GoTerm analysis, up-regulated protein-coding genes. 
Processes involved in immune response and inflammation are associated with 








Figure 4-7: GoTerm analysis, down-regulated protein-coding genes. 
Processes involved in muscle structure and function are associated with down-regulated 
genes  
 
In a more selective approach, a panel of important protein-coding genes 
associated with key pathophysiological processes in plaque instability, which 




Figure 4-8: Protein coding gene expression in RNA-sequencing. 
Protein coding genes associated with plaque rupture, calcification, lipid handling and 
inflammation are dysregulated. (n=4 paired samples, paired t-test for parametric data for 
statistical significance, mean (+SD), p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=****) 
 
 
Matrix metalloproteinases (MMP1, MMP7, MMP9) and cathepsin (CTSB) 
which are genes associated with degradation of the fibrous cap were up- 
regulated in unstable plaque (42, 43, 245, 246).  
Proteins associated with the process of active plaque calcification (IBSP, 
SPP1) were upregulated in unstable plaque. Osteoglycan, which has been 
shown to be upregulated in patients with atherosclerosis, was decreased.  
There was a significant increase in the expression of lipid transport proteins 
(CD36 and MARCO) and also in pro-inflammatory molecules (CCL19, CCL21). 
PCSK6 has been strongly implicated in the degradation of the fibrous cap in 
symptomatic carotid plaques and was also upregulated (247).
4.3.4 Candidate lncRNAs 
The shortlist of 47 lncRNAs with expression levels of mean FPKM > 5 as 
demonstrated in the heatmap in Figure 4-9 comprised 8 upregulated and 39 
downregulated lncRNAs. This indicates that the majority of ‘well-expressed’ 
lncRNAs are well-expressed in the stable condition, but then less so in the 
unstable condition.  
 
Figure 4-9: Heatmap showing differentially expressed transcripts across 4 paired 
patient samples.  
Red through to blue colour indicates high to low expression level. Each column represents 
one sample, and each row indicates a transcript. Top 8 rows demonstrate mostly higher 
expression of genes in unstable samples compared with stable. Thanks to Dr Julie Rodor, 





To further narrow down the selection of candidate lncRNAs, the top 5 up- and 




Table 4-1: Top 5 upregulated candidate lncRNAs 
 
# Gene ID Gene symbol Log2FC p-value 
1 ENSG00000280096.1 RP11-294N21.2 + 2.47 5.86 x10-4 
2 ENSG00000224397 LINC01272 + 2.23 2.36 x10-8 
3 ENSG00000279117.1 CTD-2562J17.6 + 1.72 3.8x10-13 
4 ENSG00000251442.5 LINC01094 + 1.49 3.17x10-11 
5 ENSG00000226674.8 TEX41 + 1.26 6.44x10-8 
 
 
Table 4-2: Top 5 downregulated candidate lncRNAs 
 
# Gene ID Gene symbol Log2FC p-value 
1 ENSG00000233098.8 LINC00982 - 2.65 1.85x10-12 
2 ENSG00000275830.1 RP11-403A3.3 - 2.53 6.26x10-8 
3 ENSG00000253105.5 KB-1448A5.1 - 2.21 6.88x10-8 
4 ENSG00000226833.5 AC097724.3 - 2.13 3.76x10-6 
5 ENSG00000233098.8 CCDC144NL-AS1 - 2.09 1.55x10-11 
 
From this starting point with a shortlist of candidate lncRNAs, the decision on 





A significant fold change in either direction is suggestive of an important role 
in pathophysiology. However, an increase in concentration in the diseased 
pathology does represent a more attractive prospect for study. 
The top upregulated lncRNA RP11-294N21.2 had a log2FC of +2.47 and 
mean FPKM 65.5 in unstable plaque. However, on close inspection of the raw 
read mapping profile for each sample, read coverage extends outside the 
annotation and thus likely corresponds to background signal emanating from 
the nearby intron of MAPRE2 a protein coding gene (Figure 4-10).  
On this basis the result was considered a false positive and RP11-294N21.2 
excluded from further study. 
 
Figure 4-10: RP11-294N21.2 read coverage from RNA sequencing. 
Mapped reads for RP11-294N21.2 are randomly distributed, not consistent with an exonic 
structure and likely emanate from the nearby protein coding gene MAPRE2, and therefore 


































The second most upregulated lncRNA, LINC01272, was then analysed in the 
same way. 
 
Figure 4-11: LINC01272 read coverage from RNA sequencing. 
Stable vs unstable read coverage for each patient, with annotated exonic structure 
underneath (GRCh 38), scale to right. Thanks to Dr Julie Rodor, senior scientist for 
contribution to this figure. 
 
The read profile of LINC01272 is consistent with the up-regulation in unstable 
plaque and shows the expression of a 4 exon-transcript, corresponding to the 
longest annotated isoform (203, ENST0000425497.5) (Figure 4-11). Each 
isoform shares a common region at the start of the final exon, which was 
































One other previously annotated lncRNA ‘LINC01094’ was also upregulated in 
unstable plaque, log2FC 1.49 (p =3.17x10-11) and detected in good quantity 
(mean FPKM 21.8) in unstable samples.  
 
4.3.5 lncRNA validation in plaque qPCR 
From the RNA sequencing dataset, LINC01272 expression was 4.6-fold higher 




Figure 4-12:  LINC01272 expression in RNA sequencing dataset (as FPKM).  
Stable versus unstable plaque, p-value of 2.36x10-8 obtained using DESeq2 based on the 
raw read count. (Coloured dots represent each biological replicate, mean (+SD), p<0.05=*, 









This differential expression was further confirmed in a qRT-PCR validation set 
of 5 independently collected carotid plaque samples (Figure 4-13). Each paired 
sample demonstrated higher LINC01272 levels in the unstable condition, 
compared with stable.  
 
  
Figure 4-13: LINC01272 expression in fresh carotid plaque samples 
Relative quantification of LINC01272 expression determined by qRT-PCR in additional 
samples of stable and unstable plaque (N=5) obtained by qRT-PCR (p=0.02, t-test, paired, 
two-tailed), mean (+SD), p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=****). 
 
Similarly, LINC01094 was uniformly upregulated in the unstable condition, 




Figure 4-14:  LINC01094 expression in fresh carotid plaque samples 
Relative quantification of LINC01094 expression determined by qRT-PCR in additional 
samples of stable and unstable plaque (N=5) obtained by qRT-PCR (p=0.02, t-test, paired, 
two-tailed, mean (+SD), p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=****)
Novel lncRNAs in unstable plaque: LINC01272 and LINC01094 
Both candidate lncRNAs were considered ‘novel’, having been annotated but not interrogated in any detail as to their 
character, role in physiology, disease, or mechanism previously. To begin to predict if a role in atherosclerosis is likely, their 
loci were then studied closely. Long non-coding RNA regulation of genes in cis is well understood to be a common mechanism 
by which they can exert effects on physiologic or disease processes. ‘Cis’ is a terminology used to describe genes whose 
activity is based at, and is dependent on the loci from which they are transcribed (248). If protein coding genes that were 
already known to be important in atherosclerosis were nearby and showing signs of interaction, this would raise suspicion of 





LINC01272 has 5 isoforms and is situated on Chromosome 20 (50,267,483-50,279,795). The locus it occupies is busy, with 
several interesting nearby genes (Figure 4-15):
 
Figure 4-15: Locus of LINC01272 
LINC01272 is transcribed in a ‘sense’ direction, from a locus with several interesting nearby genes. The RNA-seq fold change of nearby genes is 
denoted underneath. Only BCAS4 is significantly dysregulated in the RNA-seq.  
 
- CEBPB situated 73kb upstream from LINC01272 has a role in macrophage 
inflammation by regulation of M2 activation, likely interacting with Arg1 and 
Il10 promoters (249-251). There was a slight but significant trend to 
upregulation in unstable plaque in the RNA-seq, log2FC 0.57 (p=0.03).  
- PTPN situated 226kb downstream is theorised to have a role in 
atherosclerosis as a major regulator of insulin resistance, and has been 
shown to reverse atherosclerosis in mice when inhibited (252, 253). In the 
RNA-seq it was not significantly dysregulated, log2FC 0.15 (p=0.6). 
- BCAS4 is the only gene within a 1Mb span of LINC01272 that was 
significantly dysregulated in the RNA-seq, log2FC -1.0 (p=1.1x10-5).  It is a 
gene previously characterised in the pathology of breast cancer (254). ] 
 
Due to their potential for interaction with LINC01272 these genes were later 
assessed for dysregulation in macrophages when LINC01272 was knocked 
down by GapmeR. None exhibited a significant change in expression. 
 
Figure 4-16: Locus of LINC01094 
LINC01094 is transcribed in a ‘sense’ direction, from a locus with several interesting nearby 
genes. Both ANXA3 and BMP2K were significantly upregulated in the RNA-seq. 
 
LINC01094 has 6 isoforms and is situated on Chromosome 4 (78,645,903-
78,682,699) (Figure 4-16). Nearby genes are described below. 
- BMP2K situated 94kb immediately downstream was upregulated, log2FC 
1.0 (p=2x10-6). Bone morphogenic proteins (BMPs) are growth factors that 
belong to the TGF superfamily. Thought to have a regulatory role in 
osteoblast differentiation.  
 
 
LINC01272 was henceforth chosen for deeper investigation, based on its 
relatively higher expression, differential regulation and interesting locus. 
4.3.6 Atherosclerotic cell type expression 
Both the magnitude of expression, and specificity to particular cell types within 
the atherosclerotic plaque are critical features in ascribing the likelihood of 
importance to the novel lncRNAs. 
A panel of relevant cell types including immune cells, smooth muscle cells and 
endothelial cells of multiple origins demonstrated that LINC01272 expression 
is very high in monocytes and macrophages, but barely expressed by other 
common vascular cell types (Figure 4-17). 
 
 
Figure 4-17: LINC01272 expression across different cell types 
LINC 01272 is highly expressed on monocytes and macrophages, but not other 
atherosclerotic cell types. Raw CT values of 21 in monocytes and 20 in macrophages 
indicate a relative abundance of transcript within the sample (n=3 for each cell type, ANOVA 
with multiple comparisons, mean (+SD), p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=****). 







endothelial cells, PAEC=pulmonary artery endothelial cells, HSVEC=human saphenous vein 
endothelial cells, CASMC=coronary artery smooth muscle cells, CASMC chol=coronary 
artery smooth muscle cells + oxLDL, PASMC=pulmonary artery smooth muscle cells, 
Ao=aortic 
 
Human tissue expression  
 
 
Figure 4-18: Expression of LINC01272 in human tissues 
Highest expression of LINC01272 in panel of healthy human tissue was seen in adipose, 
liver and spleen (n=1 sample with 3 technical replicates for each, mean (+SD), p<0.05=*, 
p<0.01=**, p<0.001=***, p<0.0001=****) 
 
To corroborate the finding that LINC01272 expression is specific to the 
circulating monocyte and monocyte derived macrophage lineage, a panel of 
healthy human tissue RNA was examined for relative expression by PCR.  
LINC01272 expression was highest in spleen, adipose tissue and liver (Figure 
2F), all macrophage-rich tissues, consistent with the cell panel findings 





Figure 4-19: LINC01272 expression is higher in unstable plaque compared with normal 
aortic samples 
Normal samples obtained from punch biopsy samples in otherwise normal aortic tissue, in 
patients undergoing coronary artery bypass grafting.  
(N=3 biological replicates per group, p=0.05 by Mann Whitney test for non-parametric data, 




Normal aortic tissue, without overt atherosclerosis or high-grade arterial 
inflammation, had significantly reduced LINC01272 expression when 
compared to unstable plaque. This again is consistent with most LINC01272 
emanating from monocytes and macrophages, as normal aortic tissue should 
not contain significant numbers of these inflammatory cells.  
4.4 Discussion 
Using data from an existing RNA-seq experiment, it was possible to identify 
several novel, long non-coding RNAs upregulated in unstable atherosclerotic 
plaque. Several additional validation techniques then added to confidence that 
the experimental design and interpretation of the results of the RNA-seq were 
valid, and that the candidate lncRNAs ‘LINC01272’ and ‘LINC01094’ were 
suitable for more detailed and extensive investigation. 
The paired-sample design of the RNA sequencing experiment was important 
in ensuring the discovery of differentially expressed lncRNAs in plaque. Using 
paired stable and unstable samples from the same patient overcomes the 
inherent variability in gene expression between human subjects, which may 
otherwise mask significant fold changes. This is particularly important in lowly 
expressed transcripts such as lncRNAs, when absolute copy numbers per cell 
may be lower than protein coding genes (255). Further, a high read-depth 
enabled accurate alignment of reads to the most recent human genome 
annotation (GRCh37 at time of study). Notably, lncRNAs represent a relatively 
small proportion of all of the differentially expressed genes (7.4%), and protein 
coding genes predominate (90.8%), as would be expected in these 
atherogenic, pro-inflammatory conditions.  
Exploratory experiments that are designed in an unbiased manner such as the 
RNA-sequencing experiment in question inherently have an unknown and 
uncertain outcome. The fundamental intention of the experiment is to discover 





unexpected and have no precedent to compare with. Naturally this approach 
carries risk. Scientifically speaking, there is no control measure that can be 
employed to ensure that the results are true beyond any doubt. There is no 
gold standard that can be prospectively deployed to compare with. Hence, it 
might not be possible in the first instance to know conclusively that the “novel 
findings” of such an experiment are a true representation of the actual 
biological situation, or merely a quirk of experimental design, or an anomaly or 
outlier because of an unknown variable or experimental factor not accounted 
for. It has to be thus, otherwise discovery could never occur.  
In the current example, the information already known includes some species 
of long non-coding RNA which have already been annotated by others. There 
are limited data on these lncRNA indicating their abundance and function in 
certain atherosclerotic environments. However, as this field is in its infancy, 
there should still be a healthy amount of scientific apprehension applied to 
much of this knowledge, and the contribution from the given experiment may 
be as, or more valid.  
To mitigate the risk of over- or under-interpretation of this exploratory RNA-
sequencing experiment a number of additional validation measures were 
performed to confirm that the experimental design at least ensured that the 
input had been appropriate, and that the output, whatever it showed could be 







Gene Ontology analysis of the most dysregulated protein coding genes 
provides further validation of the RNA-sequencing output, demonstrating an 
increase in terms related to inflammatory and immune processes in the 
unstable tissue, whilst muscle cell processes were down (Figure 3-6 and 3-7). 
Though these groupings are typically broad, a reduction in the smooth muscle 
fibrous cap is characteristic in plaque instability, as is enhanced infiltration by 
inflammatory cells (239, 256).  
Following the logical short-listing process by filters of expression levels and 
dysregulation (Figure 4-5) the decision on which lncRNAs to pursue with an 
in-depth investigative strategy is critical, as it is an expensive, time-consuming 
and risky exercise. Although the RNA-seq demonstrates species that are 
differentially regulated between the two experimental conditions, the 
relationship at this stage represents merely an association. In fact, their up- or 
down-regulation could well reflect a distant and unrelated process; or that they 
are only passengers rather than drivers in a large and complicated milieu of 
undiscovered interactions. Further to this, even if a biologically important novel 
species is taken forwards, it may prove too difficult to validate experimentally 
or just open up a new direction which is outside of the usual expertise of the 
investigating scientist. 
LINC01272 and LINC01094 were therefore chosen based on both the hard 
evidence of their existence and expression in unstable atherosclerotic plaque 
and on presumed biological significance. Specifically, their relatively high 





genes at their loci; and preliminary minor prior knowledge from the literature 
demonstrating their previous identification, and a suggestion of biological 
importance in relevant diseases. Whilst neither of the 2 candidate lncRNAs 
had previously been characterised in any detail, both had been identified in 
RNA profiling experiments. Although the objective of the present study was to 
identify ‘novel’ RNA species, the presence of some prior acknowledgement of 
the transcripts’ existence can be taken as minor experimental proof of their 
veracity, over and above a false positive result from the RNA-seq.  
LINC01272 had in fact been known by several identities. In a study of gastric 
cancer and tumour tissue it was found to be up-regulated compared to healthy 
controls and had been termed “GCRL1” (although initially named RP11-
290F20.3). In vitro experiments had subsequently shown it was capable of 
acting as a sponge, post-transcriptionally sequestering miR-885-3p, which 
affected cellular proliferation (257). A different study by Wang et al. aimed at 
identifying biomarkers of inflammatory bowel disease (IBD) had also 
earmarked LINC01272 and several other lncRNAs as potential candidates. 
They too had demonstrated up-regulation of LINC01272 and KIF9-AS1 in 
plasma and tissue of patients in the disease condition compared with healthy 
controls (258). No further characterization was undertaken. To be clear at this 
point, such experiments confirm only an association, without any suggestion 
of biological mechanism or any substantive evidence of a cause and effect 
relationship at all. However, whilst acknowledging the possibility of chance, the 
involvement of LINC01272 in atherosclerosis, another disease process 





Comparatively high expression of LINC01272 was found in monocytes and 
macrophages compared to other cell types (Figure 4-17). This panel includes 
a range of smooth muscle and endothelial cells, but is limited in that other 
immune cells such as T-cells, B-cells and other dendritic cells, or fibroblasts 
are not represented. It is possible that LINC01272 is also well expressed in 
these other species of immune cells, and this would warrant further 
investigation. Cycle threshold values were quite high in all of the endothelial 
and smooth muscle cell types tested however, which is consistent, and does 
not rule out expression of the transcript in these cells, but suggests it would be 
very lowly expressed, if at all. It should also be noted that these cells in vitro 
are not subject to the regulation and ‘cross-talk’ that they would be in vivo, 
which would also be likely to affect their expression levels. 
However, enrichment in monocytes and macrophages is in keeping with 
previous data, which has shown upregulation in inflammatory bowel disease 
tissue (258), and also with the higher expression levels seen in human tissues 
with high levels of immune cells within (Figure 4-18). The human spleen which 
demonstrates highest expression is a reservoir for immune cells, with the 
purpose of filtering blood for ageing red blood cells, pathogens, and regulating 
the immune response. Large populations of macrophages reside in the red 
pulp of the spleen, whereas white pulp is generally restricted to T-cells, B-cells 
and dendritic cells (259). The liver is known for a large population of resident 
macrophages (Kupffer Cells), comprising around 80-90% of the body’s fixed 
macrophages (260); and adipose tissue hosts large fractions of macrophages 





Cell type specificity is a characteristic of lncRNA which may be advantageous 
in their use as biomarkers and in therapeutics (98). Off-target effects of 
therapies can then be prevented or limited, and changes in expression may be 
more attributable to the cell type or tissue in question. With the above evidence 
of LINC01272 enrichment in monocyte and macrophages, this cell line was 
then selected for the cell model to conduct further experiments in. It cannot be 
confirmed by these data that these are the only cells LINC01272 is well-
expressed in, as other immune cells lines have not been investigated, 
however, it is a commonly used cell line, with established protocols, known to 
be critically important in atherosclerosis. 
Limitations 
Although the RNA-sequencing experiment design is now shown to have been 
appropriate, a limitation of this approach was in defining what is ‘stable’ and 
what is ‘unstable’. Due to the macroscopic method of carotid plaque dissection 
by eye, it was critical to retrospectively analyse both the validity of the 
technique used for input, and the quality of the data output from the RNA-seq.  
The micro-CT/PET scans provide reassurance that fresh carotid plaques 
which were harvested and dissected in the same manner did exhibit the 
expected distribution of 18F-NaF uptake in ‘unstable’, and much less so in the 
‘stable’ sections (Figure 4-3). As the radiolabelled sodium fluoride is absorbed 
by actively calcifying cells, it is possible to identify these areas of active micro-
calcification, which are the hallmark of a developing plaque (241). Additionally, 





evident plaque rupture, which had led to symptoms of stroke or TIA. Hence, 
this tissue can be considered ‘unstable’ by definition, having been identified as 
such after the defining event had occurred. The surrounding tissue, which 
demonstrated less or no active micro-calcification on micro CT/PET and had 
been visually ‘normal’ to inspection at the time of dissection was considered 
‘stable’. These areas were not haemorrhagic macroscopically, were less 
thickened, and represent the border regions of the plaque. In the absence of 
micro-calcification and intra-plaque haemorrhage, these sections were 
considered ‘stable’, although because histological confirmation was not 
available, it is not possible to know the stage of plaque development beyond 
“normal” tissue. 
In the context of a comparative experiment, it was necessary to divide the 
plaques into these two phenotypically distinct groups based on the subjective 
criteria described. Whilst there are multiple other ways of defining what 
constitutes unstable atherosclerosis, including histological assessment ex vivo 
which would be the gold standard method, it is essential that during whatever 
process used that the RNA in the plaque was not degraded. Once excised 
from the artery, RNA within plaque degrades rapidly, particularly long non-
coding RNAs which are less stable. Whilst measures can be taken to preserve 
the RNA as much as possible, such as rapid freezing with liquid nitrogen and 
temporary storage in RNA Later® solution, some degradation is accepted. It 
wouldn’t be technically feasible therefore to histologically examine specimens 





It was henceforth reassuring to bioinformatically demonstrate that the ‘stable’ 
and ‘unstable’ groups were broadly dissimilar from each other, and 
transcriptionally similar between samples within group, using principle 
component analysis (Figure 4-4). On deeper assessment of genes within the 
groups it became apparent that protein coding genes were regulated 
appropriately to the condition and in-line with sodium fluoride imaging, with 
inflammatory and calcification genes upregulated in ‘unstable’, and smooth 
muscle genes upregulated in ‘stable’ plaque.  
With these limitations considered, there are then several other reasons that 
LINC01272 could be upregulated in unstable plaque RNA. The proposition in 
the first place is that monocytes and macrophages within the unstable plaque 
express the transcript more highly than their counterparts in stable plaque, due 
to an as-yet undiscovered reason related to their role in plaque instability. This 
is plausible, and seems likely based on pre-existing literature, but two 
alternative hypotheses must be borne in mind. One is related simply to raw 
cell numbers in the stable and unstable plaques. Due to experimental design, 
it was not possible to control the proportion of cells making up each sample, 
and it is conceivable that there are more monocytes and macrophages in the 
unstable compared with stable. If so, this could result in more LINC01272 in 
the unstable sample, merely because of more cells, rather than an increase in 
expression per cell. If this were true it wouldn’t necessarily rule out an 
important role for LINC01272, and could still reflect the fact that more 






The other potential reason is also related to proportions of cells within samples, 
and relates to the phenotype of the “stable” plaque. Due to the rapid and crude 
dissection method employed, tissue was not phenotyped by histology before 
dissection, and therefore not definitely characterised as atherosclerotic 
plaque, beyond intimal thickening or even normal vascular tissue, beyond 
reproach.  This could result in a comparison more akin to “normal tissue” vs 
unstable plaque, which would predictably yield more immune cells in the 
unstable sample, and again result in more LINC01272 due to higher cell 
nunbers, rather than higher expression by each cell.  
With these factors considered, a potentially important role for LINC01272 
within the atherosclerotic plaque remained probable, and investigations were 
taken to the next logical stage, as detailed in the next chapter.  
 
Conclusion 
In conclusion, the data mined from a well-conducted RNA-sequencing 
experiment using unstable human atherosclerotic plaque samples revealed 
several interesting, novel long non-coding RNA candidates. Validation of 
expression in fresh carotid plaque samples confirmed the bioinformatic results, 
and the small amount of existing literature supported some likelihood of an 
important biological role in disease. Finally, LINC01272 is highly enriched in 
monocyte and macrophages, and this cell line was selected for use in further 
experimental approaches. 
 Results – LINC01272 characterisation 
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Long non-coding RNAs are diverse in their distribution, function and 
mechanism, and their discovery has become commonplace since major recent 
advances in, and adoption of high-throughput sequencing technologies. 
However, whilst many scientific papers report the relative abundance of these 
transcripts in various pathological conditions, relatively fewer go on to describe 
their precise role in pathology, and even less their molecular mechanism.  
Elucidating the function and mechanism of a novel lncRNA is a challenging 
prospect. This is because lncRNAs are known to exist in most or all human 
cell types and can exert their effects at any number of stages in a disease 
process. Given that it is impossible to study all pathophysiological processes 
in all cells and systems, its vital therefore to look for and identify any cues in 
preliminary data that hint at specificity to a particular system, cell type, or 
process. Knowledge of these factors can narrow down the scope of the 
experimental approach, and a relevant disease model can be selected as a 
basis for study.  
To deduce a functional role, the commonest experimental approach is by 
either knock-down or overexpression. A well conducted knock-down 
experiment ensures that the only independent variable is the quantity of the 
target, and hence any functional change can be attributed to it. This is 
commonly achieved in non-coding RNA using silencing RNAs (siRNAs) and 
more recently oligonucleotides known as LNA GapmeRs (204, 262). These 





or without transfection reagents and can achieve high levels of lncRNA 
depletion within minutes to hours. Unfortunately, human organisms are 
inherently complicated, highly variable in phenotype, and ethically complex to 
experiment on, so this type of approach is reserved for in vitro experiments 
only in the earlier stages. 
Although both LINC01272 and LINC01094 both emerged as potential 
candidate lncRNAs, this chapter will focus principally on LINC01272 which was 
later renamed PELATON. Preliminary data set out in the previous chapter, had 
already defined LINC01272 as a transcript upregulated in the unstable plaque, 
and also highly enriched in monocytes and macrophages (Figure 4-17). Such 
enrichment in this cell lineage is an important feature which enabled the focus 
of study to be narrowed down to the well-studied processes that monocytes 
and macrophages are known to affect in the unstable plaque.  
Before progressing then to more complex knock-down experiments, some 
further characterisation of LINC01272 would be necessary. An understanding 
of expression patterns within the plaque and within the cell itself would give 
valuable insight to further concentrate down on function and mechanism, as 
well as inform the most appropriate experimental conditions.  
 
5.2 Aims 
• Characterise LINC01272’s expression pattern in the cell, and in unstable 
atherosclerotic plaque 
• Discover what function LINC01272 performs in human macrophages 
• Investigate potential mechanistic pathways underpinning its function 
• Explore the non-coding nature of the transcript 
5.3 Results 
 
5.3.1 Intracellular localisation  
Several lncRNAs have now been described on a mechanistic level, and they 
have been demonstrated to act in all compartments of the eukaryotic cell. 
Transcripts which are principally expressed in the nucleus may function as 
post-transcriptional regulators of gene expression (263), whereas cytoplasmic 
lncRNAs may have roles in modulating mRNA stability, regulating mRNA 
translation, serving as competing endogenous RNAs, functioning as 
precursors of miRNAs, and mediating protein modifications (264). 
To determine the intracellular expression pattern of LINC01272 in monocytes 




Human monocytes and monocyte-derived macrophages were extracted and 
cultured in vitro. Cellular fractionation in both monocytes and monocyte-
derived macrophages revealed that LINC01272 was localised predominantly 
within the nucleus of the cell (91 and 98% respectively).  
NEAT1 is a well-described lncRNA known to only exist in the nucleus of the 







Intracellular Expression of LINC 01272 and NEAT1 In Monocytes 
 
Figure 5-1: Intracellular localisation of LINC01272 in monocytes 
Fractionation by PARIS kit and RTqPCR demonstrates intra cellular localisation of 
LINC01272 is 91% nuclear in monocytes, NEAT1 is a completely nuclear lncRNA (n=3 












Figure 5-2: Intracellular localisation of LINC01272 in macrophages 
Fractionation by PARIS kit and RTqPCR demonstrates intra cellular localisation of 
LINC01272 is 98% nuclear in macrophages, NEAT1 is a completely nuclear lncRNA (n=3 
technical replicates, mean (+SD)).
RNA Fluorescent In Situ Hybridisation 
Following on from the fractionation findings, RNA fluorescent in situ hybridisation (RNA-FISH) was undertaken in monocyte 
derived macrophages. LINC01272 was targeted alongside the cytoplasmic and nuclear protein UBC, and the nuclear target 
SNORD3. Whilst UBC is seen on both cytoplasm and nucleus, SNORD3 is entirely nuclear, as is LINC01272. 
 
Figure 5-3: RNA-FISH for LINC01272 in monocyte derived macrophages 
RNA-FISH in human monocyte derived macrophages of PELATON. Cytoplasmic/nuclear (UBC) and nuclear (SNORD3) markers used as controls. 






5.3.2 Intra-plaque localisation - In situ hybridisation 
Having confirmed the nuclear location of LINC01272, in situ hybridisation was 
performed to localise its expression in vivo, within human atherosclerotic 
plaque. In situ hybridisation allows detection of target mRNAs by hybridisation 
with an anti-sense RNA probe, labelled with a reporter dye.  
Unstable atherosclerotic plaque excised at carotid endarterectomy from 3 
patients was stained. In all specimens LINC01272 co-localised with CD68, 
mainly around the plaque shoulder regions, and also running alongside the 
necrotic core (Figure 5-4 B,E,H,K). In the smooth muscle regions there was 
very strong αSMA staining, and little to no LINC01272 (Figure 5-4 C,F,I,L). A 
non-specific hybridisation probe (scramble) sequence, and 
immunohistochemistry IgG control probe confirmed absence of non-specific 
staining (Figure 5-4 A,D,G,J) 
To increase the intensity of the visually represented results, pseudo 
fluorescent images were produced in Image J from the in situ hybridisation 
originals. These images allow for better visualisation of co-staining (Figure 5-
4 D-F, J-L)  
These data therefore provide in vivo confirmation that LINC01272 expression 
is predominantly in macrophages in unstable atherosclerotic plaque, and 







Figure 5-4: In situ hybridisation and immunohistochemistry in human carotid 
atherosclerotic plaque with pseudo fluorescent images.  
PELATON expression (purple A-C, G-I, Red D-F, J-L) is enriched alongside the necrotic 
core and plaque shoulders. PELATON co-localised with CD68 (green) (B, E, H, K), but not 
with 𝛼𝛼SMA (green) (C, F, I, J). Pseudo fluorescent images (D-F, J-L) were produced with 
Image J, to allow for clearer visualization of PELATON and CD68/aSMA staining and co-
localisation. n=3 biological replicates Scale bars represent 50µm in large plaque images (A-
F) and 5µm in magnified images (G-L).
5.3.3 Macrophage phenotype expression  
Macrophages perform a number of important roles in the atherosclerotic 
plaque (267, 268). Once circulating monocytes invade the subintimal space 
and differentiate into macrophages they begin to accumulate modified lipids 
and further modify accumulating lipid particles and secrete chemo-attractants. 
As foam cells they have a limited ability to migrate, and secrete pro-
inflammatory cytokines producing reactive oxygen species. Apoptosis then 
occurs and dead cells release their lipid rich debris into the expanding necrotic 
core. 
Plaque macrophages have previously been sub-categorised into classically 
activated M1 macrophages, and alternatively activated M2 macrophages 
(269). M1 macrophages are thought to be pro-inflammatory and contribute to 
plaque progression (270, 271), and can secrete cytokines including IL-1, IL-
23, TNF-α, and nitric oxide (272, 273).  
M2 macrophages have the opposite, protective effect, and are thought to be 
anti-inflammatory (274-277). M2 polarised cells inhibit pro-inflammatory 
chemokines by inhibiting STAT1 and the p65 subunit of NFκB (278).  
More recently, this binary classification has been considered somewhat of an 
oversimplification, as macrophages in the plaque are more likely to exist 
somewhere on a spectrum, exhibiting varying degrees of transcriptional 





As a preliminary experiment to achieve some understanding of the potential 
role of LINC01272, human monocyte-derived macrophages were 
differentiated into classical phenotypes (M1, M2a, M2c and MoxLDL). 
Sufficient polarisation was confirmed by modulation of appropriate markers in 
the expected direction for M1 and M2a macrophages, but changes in 
expression were not statistically significant in M2c and MoxLDL macrophages 
(Figure 5-4). 
 
Figure 5-4: Markers of macrophage polarisation.  
The expression of macrophage subtype specific markers was quantified by qRT-PCR on 





phenotypes, M0 (control) macrophages were stimulated with IFNγ +LPS, IL-4, IL-10 and 
oxLDL, respectively (N=3 biological replicates, t-test for statistical significance, bars 
represent mean (+SD), p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=**** 
 
LINC01272 expression was unaltered across most subtypes but was 
significantly reduced in M1 stimulated macrophages (Figure 5-5).  
 
Figure 5-5: LINC01272 expression in classical macrophage phenotypes 
Expression of LINC01272 was reduced in M1 macrophages compared to controls, and 
alternatively stimulated phenotypes. (N=3 biological replicates, t-test for statistical 
significance, bars represent mean (+SD), p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=****) 
 
Across this panel of classically and alternatively stimulated macrophages the 






5.3.4 Long non-coding RNA confirmation 
Ensembl.org is routinely used as the reference genome browser, to support 
research in genomics. It displays the current reference library for all known 
transcripts mapped to the human genome (and others), and archives historical 
versions. To the surprise of the investigators, Ensembl.org changed the 
annotation for LINC01272, designating it as a protein coding gene ‘small-
membrane integral protein 25’ (SMIM25), towards the end of the project. A 
literature search did not yield any publications demonstrating the transcript as 
protein coding or otherwise, and the name was likely the result of in silico 
prediction.  
Several protein coding prediction tools exist, and all that were explored 
predicted no protein coding potential (Table 5-1).  
Table 5-1: Tools to predict likelihood of protein coding potential 
Prediction Score  Result Interpretation 
Phylo CSF -2.17 Non-coding 
CPC2 0.14 Non-coding 
CPAT coding probability 18.2% Non-coding 
PRIDE reprocessing 0 Non-coding 
Bazzini small ORFs 0 Non-coding 
To confirm experimentally if LINC01272 had any protein coding potential, the putative open reading frame (ORF) 
NP_001265584, as predicted by Refseq was inserted into a pcDNA 3.1(+) vector with a haemagglutinin (HA) tag and cloned 
for in vitro translation assay (Figure 5-6).  
 
Figure 5-6: In vitro translation of LINC01272 
LINC01272 predicted ORF (blue) appended with an HA tag (yellow) was inserted into pcDNA 3.1(+) plasmid for in vitro translation assay. 
LINC00948 was used as a +ve control, known to encode the micropeptide MLN. ORF=open reading frame, MLN= myoregulin, HA= haemagglutinin,  
 
Sequencing of the resultant plasmid confirmed the intended base pair sequence was present, along with the transcription 
start site and standard Kozak sequence upstream. The plasmid was then inserted into a proprietary in vitro translation kit, 
with all the cellular components necessary for translation contained. Successful transcription of messenger RNA (mRNA) was 





tag boundary), but the LINC01272 transcript was not translated to a peptide, confirmed by western blotting. A positive control, 






Figure 5-7: Confirmation of lncRNA-HA mRNA transcription from plasmids 
(A) RT qPCR with custom primers spanning ORF/HA boundary (left) and (B) gel 
electrophoresis (right) confirm presence of mRNA and the PCR product, respectively 













Figure 5-8: Western blot showing protein coding potential of MLN and LINC01272 from 
in vitro translation 
In vitro translation product of MLN-HA sequence demonstrates a protein around 5kDa, 
LINC01272 ORF-HA lane is blank indicating absence of protein. 
 
 





5.3.5 GapmeR Knockdown of LINC01272 
Monocyte-derived macrophages treated with LNA GapmeRs targeting 
LINC01272 were tested for knockdown efficiency. RT-qPCR demonstrated a 
good, consistent level of knockdown with 2 GapmeR sequences which were 
selected for further experiments. To ensure that any generic effects of 
treatment with LNA GapmeR oligonucleotides were accounted for, a GapmeR 
control sequence was used as the standard comparator for all knockdown 




Figure 5-9: Efficacy of knockdown for high content analysis experiments 
GapmeRs 1 and 2 achieve a 62% and 53% LINC01272 knockdown, respectively  
(N=3 biological replicates, t-test for statistical significance, bars represent mean (+SD) 
p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=****)
5.3.6 Nearby Gene Expression in Knockdown 
As several lncRNAs are known to act on nearby genes at the same locus (in 
cis), neighbouring genes on chromosome 20 were further analysed for 
regulation when LINC01272 levels were reduced by GapmeR knockdown 
(Figure 5-10) (279). The protein coding gene CEBPB, occupying a locus 74 kb 
upstream from PELATON, is implicated in the human immune response, and 
in macrophage function, and was therefore a potential candidate for 
LINC01272 regulation (280). However, none of the genes in a 1 megabase 
span around LINC01272 were observed to be dysregulated in monocyte-





Figure 5-10: Nearby gene expression in LINC01272 knockdown 
None of the genes within 1 megabase of the LINC01272 locus were significantly reduced by LINC01272 knockdown with x2 GapmeRs, bars 
represent mean (+SD), N=3 biological replicates, t-test for statistical significance, p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=****)
LINC01272 
5.3.7 Phenotype discovery 
High content analysis 
High content analysis is a method in scientific research now commonly 
employed to identify how candidate RNAs (or other targets such as proteins) 
affect the function of a cell or tissue. They may also be known as a 
phenotypical screen, or high content screening (281). The variables can be the 
targets or the phenotypes (in this case 1 target and multiple phenotypes), and 
the common method across various platforms is the use of automated 
microscopy, usually with fluorescence. Automated image analysis is then 
undertaken and yields high statistical validity due to large numbers of 
replicates, and deep image interrogation (282, 283). 
Human monocyte-derived macrophages lend well to the high content platform, 
as they can be cultured in vitro in standard optical 96-well plates, and have 
RNA manipulating treatments performed (such as GapmeR knockdown) in the 
well, before the phenotypic assay is applied. 
Using the 2 GapmeR sequences described above, a high content analysis 
experiment to determine any phenotypic effects of LINC01272 knockdown was 
undertaken (Figure 5-11). Assays modelling atherosclerosis-related 
pathophysiology were performed, using well-established locally optimised 








Figure 5-11: Schematic of high content analysis workflow:  
Human-derived peripheral blood mononuclear cells (hdPBMCs) were differentiated to 
macrophages with MCSF. After 7 days of incubation GapmeR knockdown was performed 
and followed by phenotype specific assays. 
 
As described in Chapter 2.15, a standard approach to each assay was 
undertaken. Monocytes from 3 biological donors were seeded in 96 well optical 
plates and cultured to macrophages over 7 days using human cytokine MCSF, 
at a density of 75,000-100,000 cells per well. Transfection was performed with 
GapmeRs for 24 hours, before phenotypic assays were performed in parallel 
(Figure 5-8). Each well was imaged independently with 9 separate segments, 
GapmeR control wells were compared with GapmeRs 1 and 2 for each 
phenotype. Statistical analysis for each was by one-way ANOVA and multiple 
comparisons. 
Size and shape 
As long non-coding RNAs are known to act at all levels in eukaryotic cell 
behaviour, simple assessment of cell size and shape were performed to 
identify any major fundamental effects on cell structure.  




Figure 5-12: Cell area and perimeter 
No difference in mean (+SD) cell area or perimeter was observed when LINC01272 was 
knocked down with x2 different GapmeRs.N=3 biological replicates, 5 wells per condition, 
each well imaged in 9 independent sections. (mean (+SD), ANOVA and multiple 














• Lipid uptake 
• Reactive oxygen species production 
 
Apoptosis 
Apoptosis of macrophages and other cells is a major factor in the development 
of the unstable plaque. Apoptosing macrophages and the cellular debris they 
release are extremely pro-inflammatory and contribute largely to the 
expanding necrotic core, combined with a failure of efferocytosis (clearance of 
dead cells).  
Furthermore, if LINC01272 was an important factor in any basic cellular 
functions high levels of apoptosis could be seen at baseline.  
Apoptosis was not affected by LINC01272 knockdown either at baseline, or 









Figure 5-13: High content analysis - apoptosis at baseline 
The proportion of cells positive for annexin uptake (Y axis) was not significantly different 
after knockdown of LINC01272 with x2 different GapmeRs. (N=3 biological replicates, 5 
wells per condition, each well imaged in 9 independent sections, mean (+SD), ANOVA and 














The proportion of cells positive for annexin uptake (Y axis) was not significantly different 
after knockdown of LINC01272 with x2 different GapmeRs and after 24 hours of incubation 
with Staurosporine [300nM]. (N=3 biological replicates, 5 wells per condition, each well 
imaged in 9 independent sections, mean (+SD), ANOVA and multiple comparisons). 
 
 
Although overall levels of apoptosis were higher after Staurosporine incubation 
than at baseline, neither of the apoptosis assays demonstrated a significant 
difference under LINC 01272 knockdown conditions. 
 
Phagocytosis 
Phagocytosis is a critical macrophage function in the atherosclerotic plaque. 
Although the overall effect of phagocytosis on the plaque is nuanced and has 
been an area of debate, the mechanisms of phagocytosis are relatively well-
studied.  
Within the plaque, phagocytosing macrophages are known to ingest unwanted 
and dead cells including erythrocytes and platelets as well as cellular debris, 
and in-so-doing become more pro-inflammatory. They also ingest dead 
macrophages, in a process known as efferocytosis (284, 285). Further, 
phagocytosis is also the mechanism by which macrophages ingest oxidised 
lipids such as oxidised low-density lipoprotein (oxLDL) and become foam cells. 
This is largely via surface receptors including CD36, SRA, CD68 and LOX-1. 
Once overladen, the cells then undergo programmed cell death themselves 
and rupture their pro-inflammatory contents into the necrotic core, expanding 





This positive feedback loop continues to upregulate inflammation within the 
plaque, which can ultimately lead to instability and plaque rupture.  
Whether phagocytosis has a net positive or negative effect towards plaque 
instability depends largely on the particular stage of development the plaque 
is in. Early on the uptake of harmful debris may be considered helpful, but later 
the increasing effects on inflammation, necrotic core growth, and secretion of 
fibrous cap degrading proteins almost certainly push the burgeoning plaque 
towards greater levels of instability and increase its chances of rupture.  
The diagram below (Figure 5-15) adapted from Schrijvers at al (2007) 
summarises the pattern of macrophage surface receptors responsible for the 
phagocytosis of particles including LDL, platelets (PLT), red blood cells (RBCs) 
and apoptotic cell bodies.  
 
 
Figure 5-15: Phagocyte recognition of lipoproteins  
Adapted from Schrijvers et al, Cardio Res 2007 (285) 
Phagocyte recognition of lipoproteins (LDL), apoptotic cells (AC), red blood cells (RBC) and 
platelets (PLT). Several receptors on the phagocyte membrane are involved in the 
phagocytic process. They interact either directly with their ligands or via bridging molecules. 
CD14, lipopolysaccharide receptor; LOX-1, lectin-like oxidized low density lipoprotein 
receptor-1; CD36, thrombospondin receptor; CD68, macrosialin; SRA, scavenger receptor 
class A; FcR, Fc fragment of immunoglobulin G receptor; LRP, LDL receptor-related protein; 
SREC, scavenger receptor of endothelial cells; MARCO, macrophage receptor with 
collagenous structure; CD91, calreticulin; GAS-6, growth arrest-specific gene 6; β2-GPI, 
beta 2-glycoprotein 2; ABC-1, ATP-binding cassette-1; TSP, thrombospondin; PS, 
phosphatidylserine; PSR, PS receptor; αvβ3, vitronectin receptor. Copyright © 2006, 





Phagocytosis assays in cell culture models are a widely used method to 
assess the effects of modulating RNAs and proteins. Commercially available 
particles such as pHRodo beads are readily taken up by macrophages in vitro, 
and are labelled with fluorescent markers (286).  
When LINC01272 was knocked down the GapmeRs 1 and 2, both 






Figure 5-16:High content analysis – phagocytosis  
Phagocytosis of PHrodo beads was reduced in macrophages when LINC01272 expression 
was knocked down with x2 different GapmeRs, when compared to non-specific GapmeR 
controls. N=3 biological replicates, 5 wells per condition, each well imaged in 9 independent 
sections. (mean (+SD), ANOVA and multiple comparisons, p<0.05=*, p<0.01=**, 
p<0.001=***, p<0.0001=****).  
Lipid uptake 
The accumulation of lipoproteins in plaque macrophages is principally by 
phagocytosis and via the scavenger receptors CD36, SRA1, CD68 and LOX-
1 (285, 287). Within the subintimal space, modification of LDLs by oxidization, 
acetylation or aggregation allows the macrophage to accumulate excessive 
amounts, and avoid the negative feedback mechanism to stop (288). This 
leads to engulfment and classical foam cell formation. Although oxidized LDL 
(oxLDL), acetylated LDL (acLDL) and aggregated LDL (agLDL) are all 
characteristically scavenged by the plaque macrophage, oxLDL accounts for 
the majority (288-291).   
Monocyte-derived macrophages were fed with oxLDL (produced locally) 
labelled with Topfluor. Under LINC01272 knockdown conditions, there was a 
significant reduction in lipid accumulation (Figure 5-17).  
Given the close relationship between the lipid uptake and phagocytosis 
assays, this represents a scientifically consistent finding. A reduction of the 








Figure 5-17: High content analysis – lipid uptake  
Uptake of oxLDL in macrophages was reduced when LINC01272 expression was knocked 
down with x2 different GapmeRs, compared to a non-specific GapmeR control. 
N=3 biological replicates, 5 wells per condition, each well imaged in 9 independent sections. 
(Bars represent mean (+SD), ANOVA and multiple comparisons, p<0.05=*, p<0.01=**, 
p<0.001=***, p<0.0001=****).  
Reactive oxygen species 
Reactive oxygen species (ROS) are important molecules in the pathology of 
the unstable plaque, and regulation of ROS and their effects remains an area 
of ongoing study (292). Reactive oxygen species are produced by 
macrophages, endothelial cells, smooth muscle cells and stem cells within the 
plaque. They exist both intra- and extra-cellularly, and some level of oxidative 
stress is normal and necessary for normal cellular signalling. However, too 
much oxidative stress is atherogenic (293).  
When ROS production in monocyte-derived macrophages was measured at 
baseline there was no difference under LINC01272 knockdown conditions 
(Figure 5-18).  
 
Figure 5-18: High content analysis – Reactive oxygen species production at baseline 
ROS production was not reduced in macrophages with LINC01272 knockdown with x2 
different GapmeRs, compared with GapmeR control. N=3 biological replicates, 5 wells per 
condition, each well imaged in 9 independent sections. (Bars represent mean (+SD), 
ANOVA and multiple comparisons, p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=****).  
After stimulation with the radical stress generator menadione for 30 minutes, 




Figure 5-19: High content analysis – Reactive oxygen species production with 
menadione stimulation 
ROS production when stimulated with menadione [10µM] was significantly reduced in 
macrophages with LINC01272 knockdown with 2 different GapmeRs, when compared with 
GapmeR control. N=3 biological replicates, 5 wells per condition, each well imaged in 9 
independent sections. (ANOVA and multiple comparisons, p<0.05=*, p<0.01=**, 





5.3.8 Phenotype validation 
Findings of reduced lipid uptake and phagocytosis in LINC01272 knockdown 
are consistent and suggest an important functional role for LINC01272 in this 
critical macrophage process within the atherosclerotic plaque.  
To confirm and validate these data, further assays in phagocytosis and 
efferocytosis were undertaken separately, in Edinburgh.  
 
Phagocytosis validation 
A high content approach was again used, this time on an Operetta microscope 
and images analysed using Columbus software. Cells were identified by 
Hoechst nuclear staining, and their cytoplasm area defined by 
autofluorescence. Identified cells were then analysed for TRITC fluorescence 
within, which would only be present if containing pHRodo beads, through 
phagocytosis. Cells with TRITC fluorescence over the significance threshold 
















     A              B 
  
Figure 5-20:Columbus software analysis of phagocytosis high content analysis 
Columbus software identifies cells within each image by cytoplasmic autofluoresence and 
draws a cell membrane accordingly. If TRITC fluorescence from pHRodo beads is detected 
above the threshold for significance within the cell membrane the cell is pseudo-labelled by 
the software as positive, and those below it are marked as negative. Cells pseudo labelled 
as positive are represented in green, and negative cells red, Representative images 
demonstrate high (A) and low levels of phagocytosis (B), white scale bar 50µm.  
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Figure 5-21: Phagocytosis of PHrodo beads 
Representative images of high uptake (left) and low uptake (right). Macrophages (blue with 
pale nucleus) autofluoresce, and PHrodo beads exude TRITC fluorescence and are seen 








Consistent with previous findings, phagocytosis was reduced in the presence 
of LINC01272 knockdown (Figure 5-22).  
 
Figure 5-22:Phagocytosis validation in high content analysis 
Phagocytosis was significantly reduced in LINC01272 knockdown (One-way ANOVA with 
multiple comparisons). N=3 biological replicates for each condition, 4-5 wells per condition, 9 
images per well acquired for analysis with Columbus software (see Methods section 2.17). 






Efferocytosis is the process by which dead and apoptotic cells are removed 
from the plaque, and is a process which is carried out to a large extent by 
macrophages (294). It is closely related to phagocytosis, and refers specifically 
to apoptotic cell bodies that self-signal for removal.(295) In this assay, labelled 
apoptotic Jurkat cells (JCs) were fed to macrophages with LINC01272 
knockdown, and fluorescence-activated cell sorting (FACS) used to count the 









Figure 5-23: The effect of LINC01272 knockdown on efferocytosis.  
FACS histogram, to show the presence of Calcein labelled (FITC+) Jurkat cells within 
macrophages, shown as percentage labelled in macrophages. (A)  Unlabelled jurkat cells 
are used as a negative control. The percentage of FITC+ macrophages in (B) GapmeR 
control, and (C, D) LINC01272 knockdown. Each plot shows an overlay of 3 replicates 
(orange, blue, red lines). FITC+ =Fluorescein positive cells. (E) GapmeR knockdown of 
LINC01272 did not affect overall percentage of Jurkat cell uptake, mean, ANOVA and 






5.3.10 Correlation with CD36 
CD36 is key receptor in oxLDL uptake and phagocytosis (296), both of which 
were downregulated by LINC01272 knockdown (Chapter 5.3.6). To determine 
if CD36 could be involved in the mechanism of action of LINC01272, its 
expression in control and LINC01272 knockdown conditions was assessed.  
The expression of CD36 in LINC01272 knockdown macrophages was reduced 
by an average of 39% compared with controls (Figure 5-24).  
 
Figure 5-24: CD36 expression in LINC01272 knockdown monocyte-derived 
macrophages. 
CD36 was significantly reduced with both GapmeRs (N=5 biological replicates, mean (+SD), 








In Chapter 4 the RNA sequencing experiment which formed the basis for 
lncRNA discovery described how LINC01272 was upregulated in unstable 
plaque compared with stable. After describing CD36 as a potential mediator of 
the phagocytosis and lipid uptake phenotype, the same RNA nseq was again 
interrogated for correlation between CD36 and LINC01272. 
There was a very strong positive correlation (R2=0.9287, p=0.0001) between 
PELATON and CD36 (Figure 5-25).  
 
 
Figure 5-25:Correlation of LINC01272 and CD36 expression in stable vs unstable RNA 
sequencing  
Very good correlation between expression values was observed, R2 = 0.93 by Pearson’s 
correlation. 
 

















Using a wide variety of scientific techniques, LINC01272 has been 
characterised as a bonafide lncRNA with no protein coding potential, 
expressed highly in the monocyte and macrophage cell line. Within the human 
atherosclerotic plaque it co-localises with CD68 cells alongside the necrotic 
core and plaque shoulder regions, and fluorescent in situ hybridisation 
confirms nuclear expression within the cell. Upon knockdown, several 
important macrophage functions were reduced, including phagocytosis and 
oxLDL uptake, and ROS production. Basic mechanistic investigation revealed 
an interaction with CD36, a potential mechanism for the phenotypic changes 
observed. 
The vivid in vitro hybridisation images confirmed the findings of the previous 
cell panel PCR, that LINC01272 is highly enriched in macrophages within the 
plaque. Furthermore, the predominance for the transcript around the necrotic 
core and the shoulder regions is in keeping with the general pattern of 
macrophage infiltration (297). CD68 is a common marker of macrophages, and 
itself is a scavenger receptor with an affinity for oxLDL and apoptotic cell 
bodies. Whilst it is contained primarily in the endosomal / lysosomal 
compartment it can rapidly transfer to the cell’s surface (298).  The lack of 
correlation between LINC01272 and αSMA also further confirms that smooth 






As described previously, macrophages are responsible for more than just 
plaque progression, and likely have a role in plaque rupture. It is hence 
possible that LINC01272 has a role in the same. Macrophages are shown to 
directly induce this process by secretion of matrix metalloproteinases (MMPs) 
which actively degrade the collagenous extra-cellular matrix of the fibrous cap 
(299, 300). Whether LINC01272 is involved in this process would be an 
interesting future area of research.   
When expression of LINC01272 was compared in classical and alternatively 
stimulated macrophages (Figure 5.5), macrophages stimulated with IFNγ and 
LPS (M1), express LINC01272 significantly less than controls (M0 
macrophages) and the other phenotypes. This is somewhat against the 
prevailing hypothesis that LINC01272 is a pro-inflammatory lncRNA, a theory 
thus far supported by its upregulation in inflammation in existing literature, and 
in the earlier described RNA-seq data from stable and unstable plaque. One 
clear limitation of this assay is that simple stimulation by 1 or 2 cytokines 
significantly oversimplifies the plaque environment. Plaque macrophages are 
constantly stimulated by a plethora of signalling molecules, and within the 
constraints of the simple cell model used, it’s possible only to extrapolate the 
findings speculatively. Furthermore, given that the M2c and MoxLDL 
stimulated macrophages were not well polarised, the relative differences in 
expression between them could be misinterpreted. A larger sample size and a 
wider range of stimuli would be beneficial to further investigate this point. To 





macrophage phenotypes along the transcriptional spectrum an in vivo model 
would be preferred.  
This series of experiments hence relied heavily on the human derived 
monocyte-derived macrophage (hdMDM) cell model, which formed the basis 
for the majority of the assays. As LINC01272 is highly enriched in these cells, 
it is clear that a monocyte lineage would be suitable to perform the in vitro 
analyses. However, there are several alternatives, and the hdMDM system is 
not the simplest to culture and maintain. Unlike the immortalised THP-1 cell 
line, which was derived from childhood leukaemia cells, hdMDMs have a once 
only usage. For fresh cells, each culture requires a donation of blood from 
healthy volunteers or study subjects, which is then followed by a 7-day culture 
with expensive cytokines, and variable cell senescence. Despite this, they are 
likely a superior solution to THP1 cells which may be transcriptionally quite 
different from plaque monocytes and macrophages, and as with any 
immortalised cell line, less analogous to the inherent variability of human 
subjects (301, 302).  
Targeted GapmeR knockdown within the hdMDMs against a specific 
sequence common to all annotated isoforms of LINC01272 achieved a good 
level of transcript depletion (Figure 5-9). This knockdown model provided the 
basis for a well-controlled high content analysis experiment, which identified 
several important effects on macrophage function.  
Phagocytosis, oxLDL uptake and ROS production are all critical, and indeed 





are known to produce ROS, which in-turn oxidise lipids, which are then taken 
up into the macrophage by the mechanism of phagocytosis  (284, 285, 293).  
A reduction in phagocytosis, which was also replicated in different conditions, 
is entirely in-keeping with the observed reduction in oxLDL uptake and in ROS 
production. These hypothesis generating results suggest that LINC01272 has 
a role in these functions, and that normal or higher levels of the transcript would 
upregulate all 3 of these atherogenic and plaque de-stabilising mechanisms.  
Whilst efferocytosis is a similar and related process, it differs from 
phagocytosis.  The substrate for encapsulation is an apoptotic cell body, rather 
than a modified lipid, and it can be performed via a number of different cell 
receptors (Figure 5-15). Whilst LINC01272 is apparently an important 
molecule in several atherosclerosis processes, it is unlikely to regulate all that 
occurs in the pathology.  
To strengthen the hypotheses generated in the phenotypic experiments, an 
association with CD36 has been demonstrated both in LINC01272 
knockdown, and also in the original RNA sequencing experiment.  As a major 
cell receptor in phagocytosis, this is indeed a plausible interaction. Given that 
depletion of LINC01272 in cells resulted in a reduction in CD36 mRNA, it could 
be speculated that the lncRNA has a role in CD36 regulation. Long non-coding 
RNAs can regulate protein expression at the transcriptional and post-
transcriptionally by interaction with the apparatus of transcription and 
transcription factors, alternative splicing, micro-RNA regulation and several 





reduces the expression of CD36, it may be that LINC01272 is a promoter of 
CD36 and enacts its effects on phagocytosis via this pathway. Further study 
into this mechanism represents one of the important next steps in elucidating 
LINC01272’s mechanism. 
Finally, a plasmid cloning experiment was undertaken using an in vitro 
translation kit to confirm the non-coding nature of LINC01272. By combining a 
HA tag with the predicted ORF for the proposed protein within LINC01272, it 
would be possible to detect and anneal it in a Western Blot, and hence 
demonstrate its presence (or absence). The control sequence was taken from 
LINC00948 which contains an ORF coding for micro peptide myoregulin. 
Reassuringly, there was no protein translated from the LINC01272-HA mRNA 
(Figure 5-8), whilst the analogous control MLN clearly produced a protein of 
the expected size.  
Based on these data and the publication of the paper describing them (304), 
LINC01272 was renamed by the HUGO Gene Nomenclature Committee as 
‘plaque enriched lncRNA in atherosclerotic and inflammatory bowel 
macrophage regulation’ or PELATON.  
This name reflected the data demonstrating PELATON’s role in the 
atherosclerotic macrophage, as well as referring to its previous association 
with inflammatory bowel disease.  
In conclusion, the data presented in this chapter define LINC01272 as a 
lncRNA in macrophage phagocytosis and formed the basis to rename it as 
























6.1 General discussion 
As the global pandemic of ischaemic heart disease continues to grow, this 
thesis identifies the need for new understanding in the pathology, diagnosis, 
risk stratification and treatment of myocardial infarction.  In an analysis of the 
GRACE 2.0 score in type 2 MI, it is demonstrated that existing risk models 
perform reasonably well, but there is still work to be done in the classification 
of MI, which would allow the much-needed development of risk stratification 
tools, and novel approaches in this area. Further, in an exploratory programme 
of pre-clinical investigation, a novel long non-coding RNA involved in the 
regulation of macrophages in the atherosclerotic plaque is described. New 
discoveries about this previously uncharacterised long non-coding RNA 
demonstrate the extent to which atherosclerosis pathology remains poorly 
understood and adds to the small but growing body of evidence that non-
coding RNAs may be important players in future development of this area. 
 
GRACE 2.0 Score Performance in Type 2 Myocardial Infarction 
For the clinical aspect of the project, the predictive strength of the GRACE 2.0 
score was assessed in 2 large, European cohorts of patients with type 2 
myocardial infarction. The study found that GRACE 2.0 performed well in 
prediction of all-cause mortality at one year (AUC 0.73) but not as well as in 
type 1 myocardial infarction (AUC 0.83-85). Further study to refine the GRACE 
2.0 score for type 2 myocardial infarction or derive a new score altogether 





The Global Registry of Acute Coronary Events (GRACE) was originally 
conceived in 2000, designed to collate and analyse the data of ACS patients 
all around the world (305). Through characterising the acute coronary 
syndrome (ACS) population in more than 100,000 patients in 30 countries, the 
investigators derived a risk stratification tool to predict outcomes of death, MI 
and in-hospital mortality using just 8 data points readily available at the 
bedside (213-215).  Since then, newer iterations of the GRACE score have 
been added, and it has been validated as a clinical tool in the management of 
ACS many times over, as well as in other pathologies such as pulmonary 
embolism and contrast renal nephropathy (216, 306-308). Critically however, 
these studies do not differentiate the type of myocardial infarction as per the 
new ‘Fourth Universal Definition of Myocardial Infarction’ (74), and patients 
with type 2 myocardial infarction are likely under-represented.  
Our present study (309) was devised to assess the performance of the GRACE 
2.0 Score in patients with both type 1 and type 2 myocardial infarction. As 
expected, discrimination of death was better than death/MI, and performance 
was superior in type 1 myocardial infarction, the population in which the score 
was originally devised.  
The performance of any risk stratification tool is highly dependent on the 
reference population from which it was devised and the patients in which it is 
applied. Patients with type 2 myocardial infarction differ significantly from the 
cohort of patients that were included in the original GRACE registry. Modern 





injury, resulting in a shift in the characteristics of the population defined as 
having had myocardial infarction (222). Recent evidence suggests that 
implementing a high-sensitivity troponin in a population of patients with 
suspected acute coronary syndrome increases diagnosis of type 1 MI, type 2 
MI, and acute and chronic myocardial injury by 11%, 22%, 36% and 44% 
respectively (222). 
This relatively newly characterised population of patients with type 2 
myocardial infarction is demographically older and more female (223, 226), 
and clinical factors other than those related to the cardiovascular system such 
as frailty may be important in prediction of outcome (310). Further study to 
develop new risk prediction tools must include parameters like frailty which 
encompass non-cardiovascular risk factors and are easily measurable at the 
bedside.  
A limitation of the present study and of others which have attempted to devise 
risk scores for type 2 myocardial infarction is in the inherent heterogeneity of 
patients in this group (230, 231). Unfortunately, this is owed largely to what 
has become a slightly confusing classification system, whereby patients who 
have completely disparate pathologies can be given the same diagnosis of 
type 2 myocardial infarction. Although the Universal Definition of Myocardial 
Infarction was published in multiple iterations with the intention of unifying 
diagnosis, investigation and management of patients with MI, developments in 





magnitude troponin elevations are now commonly detected in the presence of 
relatively minor ischaemia, and evidence on optimal management is lacking.  
Clearly, a patient with type 2 myocardial infarction who sustains myocardial 
injury due to profound anaemia should not be treated in the same manner as 
a patient with type 1 MI due to atherothrombosis. However, neither should 
patients with type 2 MI due to other diverse pathologies, such as atrial 
fibrillation, or aortic stenosis. Although the same diagnosis should be applied 
to such patients (type 2 myocardial infarction), quite different underlying 
pathologies would require different investigational strategies, and of course 
different treatments.  
Whilst development of better risk stratification tools in type 2 myocardial 
infarction are scientifically within reach, it may be difficult to unify investigation 
and treatment strategies because even though patients could be grouped by 
risk, their underlying pathologies would be different. 
The DEMAND-MI study has now completed recruitment and aims to 
characterise a contemporary cohort of patients with type 2 myocardial 
infarction with respect to coronary artery disease prevalence, patterns of 
myocardial injury and cardiovascular outcome. These findings should clarify 
the distribution of myocardial injury mechanisms in this diverse group of 
patients and inform further randomised studies into how type 2 myocardial 
infarction patients should be optimally investigated and managed. Further, 
appropriate risk stratification parameters will be identified, to inform further 





Ultimately, it may become too difficult to generalise in patients with type 2 
myocardial infarction, and it may be necessary to change how myocardial 
injury is classified and managed altogether. Grouping patients with myocardial 
injury by more specific, individual characteristics would allow a more 
personalised approach to work towards improving patient outcomes.  
 
PELATON Discovery 
The mechanisms of long non-coding RNA in atherosclerosis were studied, to 
gain insight into new pathways for treatment of patients with myocardial 
infarction. Based on interrogation of existing RNA sequencing data in unstable 
human carotid endarterectomy samples, a novel long non-coding RNA in 
unstable atherosclerosis was discovered, characterised and renamed 
PELATON. Through its interaction with the membrane protein CD36, this 
important lncRNA represents a new target for unstable plaque detection and 
treatment.  
To explore new pathways and gain new insights into mechanisms 
underpinning myocardial infarction, it is important to consider translational 
applications of rapidly developing technologies, not least in the area of high 
throughput genetic screening, and high content analysis. Insight into 
undiscovered mechanisms can lead to novel diagnostic pathways, treatments, 
and risk prediction models. It is possible that new biomarkers could distinguish 
the mechanism of myocardial injury upstream in the diagnostic pathway, and 





Advances in understanding of non-coding RNA have recently uncovered a 
potentially rich new layer of complexity to almost all human pathologies, and 
multiple completely novel non-coding RNAs have now been shown to have 
critically important roles in vascular pathologies, including PELATON (304, 
311). 
The data presented above describe PELATON as a monocyte and 
macrophage enriched lncRNA, that regulates phagocytosis, lipid uptake and 
reactive oxygen species production (Chapter 5). Early indications suggest that 
the macrophage surface marker and scavenger receptor CD36 may mediate 
these effects (Chapter 5.3.9).  
Although PELATON had been predicted to encode a micro-peptide called 
SMIM25 part way into the study, robust in vitro translation data was able to 
disprove this (Chapter 5.3.10). This intervention was timely, as several 
contemporaneous publications had very recently described ‘bifunctional long 
non-coding RNAs’. These are transcripts which function both as non-coding 
RNA transcripts, but also contain functional open reading frames which 
encode micro-peptides (312). Anderson et al. reported an interesting micro-
peptide called Myoregulin (MLN), which is transcribed from LINC00948  (103), 
and was used to good effect as an experimental control in the in vitro 
translation experiment in Chapter 5 (Figure 5-23). Much like LINC00948, 
PELATON contains a possible open reading frame within it, but in the case of 
PELATON it is simply not transcribed, and PELATON will maintain its non-





lncRNA PNUTS which functions both as mRNA for PNUTS and as a lncRNA 
sponge for miR-205 (313); and the lncRNA steroid receptor RNA activator 
(SRA1), which also encodes protein whilst functioning as a hormone activating 
lncRNA (314). At the time of writing, no micro-peptide encoding lncRNAs have 
yet been described in atherosclerosis. 
Further to this, PELATON is quite highly expressed for a lncRNA, more in the 
range of a protein, as lncRNAs are usually much less abundant in cells. Raw 
CT values of 20 and 21 in macrophages and monocytes, respectively in RT 
qPCR with cDNA (produced using standard protocols) are low and indicate 
abundance (Figure 4-17). This is a factor which makes PELATON attractive 
as a substrate for study, but also as a therapeutic target. The cell-type 
enrichment of PELATON is typical for a lncRNA, and is an advantageous 
feature of lncRNAs that also make them good targets for novel therapies (315). 
However, whilst PELATON is reliably upregulated in unstable vs stable plaque, 
certain limitations acknowledged principally in Chapter 4 should be considered 
before accepting the explanation for this. Various issues in RNA-seq design 
could lend to a degree of variability in the proportion of monocytes and 
macrophages between stable and unstable samples, and there is a possibility 
that differences between groups exist because of a difference in cell number 
rather than levels of expression within the cells. If this is the case, it would not 
rule out an important role for PELATON, which was studied in more depth 
afterwards, but a more nuanced approach to understanding its expression in 





underline this, an unexpected reduction in PELATON expression in M1 
macrophages was observed in Chapter 5 when monocyte-derived 
macrophages were classically and alternatively stimulated (Figure 5-5). This 
experiment was limited by small sample size, and likely incomplete polarisation 
of all phenotypes, but again emphasises that a more complete picture of 
PELATON expression in immune cells with differing polarisation would be 
desirable. 
 
In the ensuing experiments however, LNA-GapmeR knockdown achieved 
adequate depletion of PELATON in macrophages, which was sufficient to 
reduce phagocytosis of pHRodo beads and oxidised LDL.  
A reduction in lipid uptake by PELATON knockdown, as a novel therapy, may 
possibly therefore reduce plaque progression to instability, as it would interfere 
with multiple atherogenic mechanisms within the plaque. Macrophage 
differentiation to foam cell is a key factor in almost all of the processes which 
result in plaque growth and instability(24, 268, 289). Attenuation of this process 
in the human vasculature could potentially slow the rate of atherosclerotic 
progress, and thereby reduce the risk of plaque rupture. No therapies are 
currently licensed for this specific indication, except statins (and more recently 
PCSK9 inhibitors (68, 316)) which were originally given really for their lipid 
lowering properties. Contemporary data has suggested however that the 





be ascribed to their pleiotropic effect of a reduction in inflammation rather than 
just a reduction in circulating LDL (317).  
Whilst macrophages are extremely well studied in atherosclerosis, no other 
study as yet reports a potential therapeutic agent to act on lipid uptake (318, 
319). Whilst statins significantly reduce circulating lipids and are well known to 
reduce cardiovascular risk more generally, they have no effect on lipid uptake 
within the plaque. Other recent evidence of lncRNA modulation of macrophage 
behaviour relates to regulation of apoptosis (320-322) rather than lipid 
regulation, and none have yet progressed as far as phase 2 studies in human.  
Translation of these in vitro and animal model findings is fundamentally 
possible, and necessary, but relatively few have progressed to clinical use. 
Just as in the majority of experimental science in this field, the basic diametric 
options are to either over-express or deplete the target in the pathologically 
relevant cell or tissue. Earlier attempts at over-expression have seen limited 
success using viral vectors, but off-target effects remain a problem (323, 324). 
Depletion using silencing RNAs (siRNAs) and antisense oligonucleotides such 
as GapmeRs hold promise and have been more successful on an 
experimental level. Both methods manipulate endogenous RNA transcription 
machinery to knock-down expression of target genes by different mechanisms. 
SiRNAs are delivered as a double-stranded RNA molecule which binds with 
RISC, allowing the passenger strand to dissociate and anneal their target to 
be degraded. GapmeRs and other anti-sense nucleotides bind directly to 





One notable example of a siRNA in atherosclerosis which has been clinically 
proven and is about to be introduced is a drug called Inclisiran (327, 328). 
Inclisiran targets the mRNA of PCSK9, depletion of which has already been 
shown in RCTs to significantly reduce circulating LDL levels, and translates to 
a reduction in cardiovascular endpoints (68, 69, 316). 
Evidence thus far suggests strongly that PELATON is highly enriched in the 
monocyte / macrophage cell line in the plaque, but more evidence is needed 
to understand other sources of expression including other immune cells, and 
other important roles in human physiology and pathology. Given the previously 
cited evidence of upregulation in gastric cancer and in inflammatory bowel 
disease it is quite evident that PELATON exists outside of the atherosclerotic 
plaque. However, exactly which cell types express it in these conditions is not 
demonstrated, and it may well be the same cell lines, which are in fact 
implicated in both pathologies. Assuming that PELATON is expressed more 
widely in the body than in the vasculature, it is likely that depletion would have 
some off-target effects. This unquantified risk of off-target side effects may be 
difficult to avoid when therapies are delivered systemically, particularly when 
the target cell line is ubiquitous to multiple different tissues around the body, 
and represents a significant limitation of the approach. Whilst the siRNA or 
ASO might reliably penetrate the target cells and deplete the lncRNA within, 
further study would be necessary to develop methods to avoid unwanted 
action on cells in other organs or territories. In the case of PELATON, given 





process in innate immunity, careful study in animal models would be a 
necessary next step to understand how the immune system would be affected.  
One peculiarity of coronary artery disease compared to other pathologies is 
that there is already a therapy which facilitates extremely precise, localised 
delivery of drugs, and is already in routine clinical practice. Percutaneous 
coronary intervention with stents is performed as a class 1a treatment for 
angina and acute coronary syndromes in all developed healthcare systems 
and is extremely mature in terms of technology and operator experience. 
Modern drug eluting stents are impregnated with immunosuppressant 
compounds such as everolimus and sirolimus, designed to prevent endothelial 
overgrowth known as in-stent restenosis. As this technology already exists, 
there is logically already a vehicle to target an ASO to the culprit vessel, and 
increase the chance of avoiding off target, systemic effects.  
A barrier to this approach is that primary prevention of plaque rupture with 
“prophylactic” implantation of stents for vulnerable plaque has never been 
shown to be beneficial. Stent implantation carries a risk of re-stenosis of 
approximately 1% per year, and immediate complications such as coronary 
dissection, peri-procedural myocardial infarction, stroke and even death affect 
around 1% of patients. The risk of stenting may well exceed the risk of 
myocardial infarction, especially in primary prevention. If PELATON is capable 
of causing plaque regression, which is of course unknown, the risk-benefit 





setting. Here the culprit plaque would be already identified, and the benefits of 
PCI to culprit lesions is well established.  
Another potential mode of delivery which avoids the complication of early stent 
thrombosis and later re-stenosis is the bioresorbable stent. Bioresorbable 
stents or scaffolds were once thought to be advantageous over tradition bare 
metal and drug-eluting stents, as they are physically resorbed over time, 
leaving no physical remnant, and also facilitate delivery of local immune-
suppressant drugs. Studies are still ongoing in this field, as clinical benefit was 
not shown in earlier studies, and the technology is still in a relatively early 
phase.  
 
6.2 Concluding remarks 
 
The data presented above confirm that myocardial infarction remains one of 
the world’s major health problems. Despite the advances of contemporary 
science and medicine, patients with type 1 and type 2 myocardial infarction 
still have a 10-25% risk of death at 1 year. Analysis of the GRACE 2.0 score 
in risk stratification of patients with type 2 MI demonstrates that although 
existing models of care perform reasonably well, the complexity of this 
condition is still unfolding, and much is still to be learned about type 2 
myocardial infarction.  
In an exploratory study of long non-coding RNAs in unstable atherosclerosis, 





in the atherosclerotic plaque. Further study is now needed to understand if 
PELATON depletion in vivo is clinically beneficial, and safe to perform. 
6.3 Future perspectives 
Type 2 myocardial infarction is a burgeoning area of research, and several 
groups internationally continue to generate data in this area. As the Universal 
Definition of Myocardial Infarction (UDMI) has evolved over years, and the 
diagnosis of type 2 MI becomes ever more common, the magnitude of the 
clinical problem continues to expand.  
There are several domains within type 2 myocardial infarction where evidence 
is desperately needed to improve not only patient outcomes, but first the 
scientific understanding of this condition needs to improve. 
Currently, the grouping of such diverse pathologies within the umbrella 
terminology of type 2 myocardial infarction renders generalisation of 
investigation and management strategies impossible. Whilst all patients have 
features of myocardial injury and ischaemia in common, the mechanisms 
underlying are diverse.  Further work into a more suitable classification system 
is urgently needed to facilitate good quality research into the optimum 
management of each individual patient who falls into this awkward category.  
As previously discussed, the DEMAND-MI study for which the author is a lead 
investigator should hopefully produce valuable data on the profile of type 2 MI 
patients and form the basis for RCTs of optimum investigation and 
management. It is likely that the presence or absence of coronary artery 
disease in this population is an important and useful discriminator, which would 





statins. How best to diagnose this anatomically, whether invasive or non-
invasive is another research question, which we intend to address.  
For the patients with coronary disease, PELATON represents an interesting 
new possible target with the potential to regress atherosclerosis and reduce 
plaque instability.  
Whilst a phenotype has been well-identified, further work is now needed to 
understand the mechanism by which PELATON interacts with CD36, and by 
what pathway macrophage functions are regulated. This understanding is not 
absolutely necessary to bring a new drug to market, but mechanistic insights 
allow better prediction of clinical effects, both intended and unintended. 
Furthermore, a fuller appreciation of the multiple molecular interactions in this 
pathway, which are inevitable, widens the scope for therapeutic interventions.  
Investigation into PELATON is very early stage, and several key milestones 
need to be achieved before it could be considered for phase 2 studies. In 
parallel, mechanistic and in vivo studies should be carried out. Both systemic 
and local delivery should be performed in animal models, and effects on 
vasculature, and more generally the immune system investigated.  
Murine genetic knockout models are often considered at this stage but are 
frequently hampered by significant unintended harm to the organism, and in 
fact full gene knockout is quite likely to be deleterious in an important and 





If proven safe and efficacious in animal models, studies into the optimum 
delivery method, including bioresorbable stents would be an attractive 









7.1 GRACE supplementary material  
Table 7-1: Performance of the GRACE 2.0 score for death and death or myocardial 
infarction in the Scottish cohort with and without multiple imputation. 
 
             Scottish cohort 
 Type 1 MI Type 2 MI 


























Death or MI 560 (22%) 1,075 (22%) 166 (26%) 297 (27%) 
AUC for 










AUC: area under the receiver-operator-curve; HL: Hosmer-Lemeshow test.  
 
 
As we used electronic records and enrolled consecutive patients into the High-
STEACS trial, some variables required for the calculation of the GRACE score 
were missing from our dataset. This was most commonly due to the omission 
of routine observations which was assumed to be at random. To maximise the 
available dataset and to minimise bias from excluding participants, we applied 
multiple imputation using chained equations with five imputations of the 
dataset, using the mice package in R. For imputation we applied Bayesian 
linear regression for continuous data (creatinine, heart rate, systolic blood 
pressure), multinomial logistic regression for ordinal data (Killip class) and 





the following variables (n,%) ; creatinine (64, 1%), cardiac arrest status (460, 
7.5%), ECG ischaemia (718, 11.8%), Killip class (1,079, 17.7%), heart rate 





Table 7-2: Performance of the GRACE 2.0 score for all-cause death and all-cause 
death or myocardial infarction at one year in the Scottish and Swedish cohorts  
AUC: area under the receiver-operator-curve; CI = confidence interval, HL: Hosmer-
Lemeshow test. The principle of the Hosmer-Lemeshow test is to compare the concordance 
between predicted and actual event rates. Based on the predicted probability, the data is 
divided into ten groups. In each of these groups the predicted and actual are calculated, and 
a χ2 statistic is calculated to compare the differences between predicted and actual event 
rates (sum of [actual-expected]2/expended). Small χ2 values with a p-value close to 1 
indicates a good calibration 
 
 













All-cause death 720 (15%) 112 (10%) 258 (23%) 57 (23%) 
AUC  
 























P-value for DeLong 
test  
Reference Reference <0.001 0.008 
























P-value for DeLong 
test  







Table 7-3: Performance of the GRACE 2.0 score for all cause death and death or myocardial infarction by sex 
 
 
 Type 1 myocardial infarction Type 2 myocardial infarction 











































P-value for DeLong test  
(Men versus Women) 
0.04 0.70  0.86  0.77 



























 Low Risk GRACE (<3%) Intermediate Risk GRACE (≥3 and ≤8%) High Risk GRACE (>8%) 
 Type 1 MI Type 2 MI Type 1 MI Type 2 MI Type 1 MI Type 2 MI 
No. of participants (%) 1,826 (37) 131 (12) 1,511 (30) 305 (27) 1,644 (33) 685 (61) 
Age (years), mean (SD)   55 (9)  51 (12)   70 (9)  68 (10)   80 (10)  81 (9) 
Men, n (%) 1281 (70)   54 (41)   861 (57)  156 (51)   853 (52)  291 (42)  
Past medical history       
  Myocardial infarction, n (%)  194 (11)    6 (5)   188 (12)   45 (15)   285 (17)  112 (16)  
  Ischemic heart disease, n (%)  335 (18)   12 (9)   485 (32)  111 (36)   699 (43)  331 (48)  
  Cerebrovascular disease, n (%)   49 (3)    5 (4)    97 (6)   23 (8)   222 (14)  107 (16)  
  Diabetes mellitus, n (%)  205 (11)    6 (5)   264 (17)   35 (11)   333 (20)  106 (15)  
  Heart failure hospitalisation, n (%)   89 (5)    6 (5)   207 (14)   61 (20)   496 (30)  225 (33)  
New medication        
  Aspirin, n (%) 1217 (67)   33 (25)   635 (42)   40 (13)   388 (24)   44 (6)  
  DAPT, n (%) 1409 (77)   20 (15)   928 (61)   35 (11)   632 (38)   61 (9)  
  Statin, n (%) 1020 (56)   15 (11)   501 (33)   27 (9)   243 (15)   26 (4)  
  ACE inhibitor or ARB, n (%)  886 (49)   20 (15)   473 (31)   33 (11)   218 (13)   51 (7)  
  Beta-blocker, n (%)  961 (53)   39 (30)   560 (37)   74 (24)   357 (22)  106 (15)  
  Oral anti-coagulant, n (%)‡   18 (1)   23 (18)    55 (4)   62 (20)    56 (3)  124 (18)  
Electrocardiogram§       
  Myocardial ischemia  671 (37)   35 (27)   551 (36)  103 (34)   650 (40)  245 (36)  
Physiological parameters§       
  Heart rate, beats per minute   74 (16)  93 (36)   77 (19) 108 (40)   86 (21) 105 (32) 
  Systolic blood pressure, mmHg  149 (25) 148 (26)  142 (26) 140 (29)  134 (30) 126 (29) 
Hematology and clinical chemistry       





Table 7-4: Characteristics of Scottish cohort stratified by low, intermediate and high GRACE risk categories. 
 
  eGFR, ml/min   59 (7)  56 (12)   54 (12)  54 (11)   43 (15)  42 (15) 
  Peak hs-cTn, ng/L  808 [132, 6255] 111 [44, 513]  787 [92, 5437] 128 [45, 672] 1063 [93, 8626] 124 [51, 609] 





Table 7-5: Performance of GRACE 2.0 for the prediction of in-hospital death in the 
Scottish and the Swedish cohorts 
 




 Type 1 MI  
(n=4,981) 
Type 2 MI  
(n=1,121) 
Type 1 MI  
(n=1,080) 
Type 2 MI  
(n=247) 
In-hospital death  
n (%) 
74 (1.5) 25 (2.2) 27 (2.5) 14 (5.7) 
AUC (95% CI) 0.85 (0.81-0.89) 0.67 (0.57-0.78) 0.85 (0.78-0.93) 0.82 (0.70-0.94) 
















Table 7-6: Performance of high-sensitivity cardiac troponin assays alone for the 
prediction of death at one year 
 




 Type 1 MI  
(n=4,981) 
Type 2 MI  
(n=1,121) 
Type 1 MI  
(n=1,080) 
Type 2 MI  
(n=247) 
Death at one year          
AUC (95% CI) 
0.58 (0.56-0.61) 0.62 (0.58-0.65) 0.64 (0.58-0.69) 0.72 (0.65-0.80) 












Figure 7-1: Observed versus predicted all-cause mortality or myocardial infarction events in type 1 and type 2 myocardial infarction 
according to the GRACE 2.0 algorithm in the Scottish and Swedish cohorts.   
7.2 LINC01094 Data 
 
 
Figure 7-2: Intracellular localisation of LINC01094 in monocytes. 
Fractionation by PARIS kit and RTqPCR demonstrates intra cellular localisation of 










Fractionation by PARIS kit and RTqPCR demonstrates intra cellular localisation of 
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